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“If you want to build a ship, 
don't drum up the men to gather wood, 
divide the work and give orders. 
Instead, teach them to yearn for the vast and endless sea.” 
 
Antoine de Saint-Exupéry (1900 - 1944) 
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1. Approaches to the total synthesis of biological active 
guaianolides with a trans-annulated lactone moiety 
 
1.1 Introduction 
Guaianolides, consisting of a tricyclic 5,7,5-ring system represent a large subgroup of 
naturally occurring sesquiterpene lactones exhibiting significant biological activity.[1,2] Plants 
containing such compounds as the active principles have been used in traditional medicine 
throughout history for treating conditions ranging from rheumatic pains, increase of bile 
production to pulmonary disorders. 
 
 
Figure 1. Skeletal relationships. 
 
As the name itself indicates, the core structure of the guaianolides is derived from Guaiane, a 
natural product with a cis-fused 5,7-bicyclic hydroazulene ring-system (Figure 1). With only a 
few exceptions the hydroazulene core is also cis-fused in the 5,7,5-tricyclic carbon skeleton, 
while the γ-butyrolactone ring is trans-annulated in approximately 85% of all known 
guaianolides.[3] 
This interesting class of natural products shows a broad range of biological activity (Figure 2) 
stimulating the development of research towards their total synthesis. Although several 
strategies especially towards monocyclic γ-butyrolactones are reported to date,[4-10] only a few 
groups succeeded in the total synthesis of guaianolides.[10-14] 
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Figure 2. Some guaianolides, representing the structural diversity of this class of compounds.  
 
The structure-activity relationship (SAR) of α-methylene sesquiterpene lactones was 
intensively studied.[15-20] It was shown that these compounds can react by conjugate addition 
of various biological nucleophiles such as cystein or thiol-containing enzymes (E-SH) 
(Scheme 1). Consequently, α-methylene sesquiterpene lactones are good alkylation agents 
manifesting their biological activity but also their cytotoxicity. 
 
 
Scheme 1. Michael addition on α-methylene sesquiterpene lactones. 
 
There is further evidence, that compounds of this type inhibit cellular enzyme activity and do 
not show DNA-alkylating properties.[18,21-26] Furthermore it is assumed that the residual 
substitution pattern of the guaianolides determines the specificity and the resulting biological 
activity.[11] 
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1.2 Biosynthesis of guaianolides 
1.2.1 The mevalonate pathway 
Since ancient times various oils with intensive and mostly delightful fragrances were 
extracted from numerous plants. In the beginning direct distillation and later on steam 
distillation were common techniques to afford the essential oils, which mainly consisted of 
terpenes. Until now more than 30,000 terpenes from all sources have been identified, making 
them a large and structurally highly diverse family of natural products. It was early 
recognized that terpenes are formally derived from C5-isoprene units (7), but that isoprene (8) 
itself, a metabolite produced naturally, is not involved in their formation (Figure 3). 
 
 
Figure 3. Comparsion of C5-units. 
 
The biochemically active isoprene units are isopentenyl-pyrophosphate (IPP, 9) and 
γ,γ-dimethylallyl-pyrophosphate (DMAPP, 10). These important precursors are formed via 
certain biochemical pathways that have been extensively studied over the last 50 years leading 
to the generally accepted mevalonate (MVA) biosynthesis pathway of terpenes in 
organisms.[27-30] More recently a second biosynthetic route was discovered in plants also 
leading to IPP (9) and DMAPP (10) as the final products.[30-32] This so called mevalonate 
independent pathway or methylerythritol-phosphate pathway (MEP) is only found in a few 
plants and microorganisms. It was also recognized that the MVA-pathway is located in the 
cytosol and the MEP-pathway takes place in the plastids (chloroplasts, leukoplasts, etc.). 
Furthermore, in organisms equipped with both pathways, a limited exchange of intermediates 
between MVA and MEP also appears. This may explain why the MEP pathway was 
completely overlooked until labeling experiments revealed its existence.[33-36] 
The biosynthesis in the cytosol starts with the assembly of three molecules of activated acetic 
acid (acetyl-CoA) (11) by an initial Claisen-condensation and a subsequent aldol reaction to 
give β-hydroxy-β-methyl-glutaryl-CoA (13) (Scheme 2). 
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Scheme 2. MVA pathway for the biosynthesis of IPP (9) and DMAPP (10). 
  
Reduction with NADPH+H+ releases mevalonic acid (Mevalonate, MVA, 14), which is then 
activated by means of ATP to the pyrophosphomevalonate (15). Decarboxylation and 
elimination leads to isopentenyl-pyrophosphate (IPP, 9), further isomerization of the double 
bond to dimethylallylpyrophosphate (DMAPP, 10). 
To construct the basic backbones of terpenes, prenyltransferases connect IPP (9) and its 
isomer DMAPP (10) in a head to tail fashion (Scheme 3). In a first step DMAPP (10) is 
therefore ionized to an allylic cation 16, to which the double bond of IPP (9) can add resulting 
in a tertiary cation 17. Subsequent stereoselective loss of a proton introduces selectively a new 
trans substituted double bond and releases geranylpyrophosphate (GPP, 18), a fundamental 
precursor for the biosynthesis of monoterpenes (e.g. menthol). 
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Scheme 3. Biosynthesis of GPP (18) and FPP (19). 
 
For the biosynthesis of sesquiterpenes the C10-skeleton of GPP (18) has to be extended by 
addition of a further C5-IPP (9) unit according to the isoprene rule[37-39] ((C5)n, n = 3 for 
sesquiterpenes) which was first discovered by Otto Wallach in 1887 but largely ignored until 
Leopold Ruzicka recognized its general significance. Repeating the electrophilic addition of 
IPP (9) and stereospecific elimination (Scheme 3) gives rise to farnesylpyrophosphate 
(FPP, 19), the precursor for linear and cyclic sesquiterpenes and sesquiterpene lactones. 
 
1.2.2 Biosynthesis of guaianolides 
The further assembly of guaianolides used in nature has been intensively investigated by 
de Kraker et al. based on the biosynthetic route of sesquiterpene lactones in chicory which is 
reasonable to assume to be also valid for other plant species (Scheme 4).[40-43] According to 
these studies, cyclization of FPP (19) yields (+)-Germacrene A (20). Because of the double 
bond configuration in FPP (19) two (E)-substituted double bonds are incorporated within the 
10-membered ring system of 20. 
Oxidation of the isopropenyl side chain by (+)-Germacrene A hydroxylase to the primary 
alcohol 21 and further oxidations by NAD(P)+-dependent dehydrogenases afford 
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Germacrene acid (23). It was further demonstrated that hydroxylation on the C6-position and 
subsequent lactonization yields (+)-Costunolide (25). 
This intermediate is seen as a branching point in the biosynthesis of sesquiterpene lactones, 
because here the pathways for the formation of guaianolides, eudesmanolides and 
germacranolides are considered to divide. 
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Scheme 4. Biosynthesis of (+)-Costunolide (25). 
 
Quite a number of stereospecific biomimetic transformations of germacranolides and their 
derivatives into eudesmanolides and guaianolides have been reported in literature.[44-52] Based 
upon these studies it is postulated that the second cyclization of germacranolides towards the 
guaianolide skeleton is directed by epoxidations or hydroxylations of the costunolide 
skeleton 25. Enzymatic epoxidation on C4-C5 position directly affords Parthenolide (26) 
(Scheme 5). This interesting germacranolide is a highly active antimigraine agent isolated 
from feverfew and magnolia and also shows anti-inflammatory and anti-tumor activities.[53-55] 
Trans-annular cyclization of the strained ring system in 26 and subsequent elimination 
completes the guaianolide skeleton 27.[56] 
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Scheme 5. Guaianolides (27) via cyclizations starting from (+)-Costunolide (25). 
 
In addition to the above described route also an alternative pathway is proposed: Enzymatic 
introduction of a hydroxy group at C3-position in (+)-Costunolide (25) affords 28. 
Subsequent dehydration and cyclization also leads to the guaianolide skeleton 27.[43] 
 
Further oxidation steps on the 5,7,5-membered ringsystem of 27 introduce many different 
functionalities: Epoxides (e.g. found in Arglabin (1) or Estafiatin (4)) or the introduction of 
hydroxy groups (see Thapsigargins (6)) on various positions contributes to the diversity and 
complexity of this interesting and biologically important class of natural products. 
Esterification or glycosylation[57] of the later also broadens the structural variety of the 
guaianolides. 
In summary, nature has proven a tremendous creativity in the construction of the guaianolides 
with respect to their structures and biological functions. For an organic chemist now the 
question arises how to find synthetic entries towards these natural products. Even with 
modern state of the art techniques in organic synthesis at hand, the complexity of the core-
structure and the high substitution pattern still makes the class of the guaianolides a 
challenging and exciting target. 
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1.3 Racemic approaches towards guaianolides 
1.3.1 Total synthesis of (±)-Compressanolide and (±)-Estafiatin 
Although there are some reports in literature dealing with the synthesis of pseudo-
guaianolides[1] or of guaianolide related compounds,[58-61] to the best of our knowledge the 
first total synthesis of a guaianolide with a trans-annulated lactone moiety was reported by 
Vandewalle et al.[62-64] in 1982. On the basis of a novel, flexible and convergent route towards 
substituted hydroazulenes the total synthesis of various sesquiterpene lactones has been 
achieved.[65] 
As the starting point the photochemical addition of 1,2-bis[trimethylsiloxy]-cyclopentene (29) 
to cyclopentenone (30) affords the 5,4,5-membered ring system (±)-31 as a single 
diastereomer, in which the five-membered rings are anti-oriented to each other (Scheme 6). 
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Scheme 6. Synthesis of key intermediate (±)-34. 
 
Subsequent Wittig-reaction and TMS-deprotection set the stage for ring expansion by 
oxidative cleavage of the diol (±)-32, giving rise to (±)-33 in which the exo-methylene double 
bond had concurrently migrated in conjugation to the carbonyl group. Acid catalyzed 
acetalization chemoselectively protected the more reactive carbonyl group on C-10 to afford 
the racemic key intermediate (±)-34, which allowed access to a number of different 
sesquiterpene lactones. 
With the substituted hydroazulene (±)-34 in hands the group of Vandewalle started out for the 
total synthesis of (±)-Compressanolide (44),[62] a guaianolide first isolated from Michelia 
compressa.[66] Furthermore a small variation of this route allowed the synthesis of 
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(±)-Estafiatin (4),[62,64] a natural product first isolated by Romo and co-workers from 
Artemisia mexicana (Willd).[67] 
The opening step entails the epoxidation of the double bond in the 5-membered ring of (±)-34 
(Scheme 7, top). Controlled by steric hindrance (shielding of the β-face by the bulky ketal 
protecting group) the bulkiest reagent gave the best selectivity of 6:1 for the desired 
α-epoxide (±)-35. 
In contrast, epoxidation of the key intermediate (±)-34 using H2O2 afforded the epoxide in 
better yield and a 1:9 ratio, this time approaching from the β-face (Scheme 7, bottom) forming 
the now desired trans-fused 5,7-membered ring system (±)-36. 
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Scheme 7. Stereoselective epoxidation and alkylation. 
 
The next key step in the synthesis is the selective introduction of the prenyl-sidechain at the 
C7-position which is later on used for the formation of the lactone moiety. Attempts to 
introduce this arm by kinetic controlled deprotonation/alkylation already in the key 
intermediate (±)-34 failed, but alkylation of epoxide (±)-35 afforded the desired product 
(±)-37 in a 2:1 ratio (β:α). Base induced equilibration of the undesired epimer led again to an 
approx. 1:1 ratio, providing the possibility to recycle the unwanted epimer. Alkylation of 
(±)-36 on C-7 also introduced the prenyl-sidechain and afforded (±)-38 in a 4:1 ratio. 
The selective reductive opening of the epoxide in (±)-37 is the next crucial reaction, installing 
three stereocenters present in (±)-Compressanolide (44) within one step. This complex 
sequence starts with a reductive cleavage of the epoxide present in (±)-37 and a fast 
protonation of the resulting enolate (±)-39 (Scheme 8). 
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Scheme 8. Stereoselective reduction sequence. 
 
Intramolecular tautomerization to ketone (±)-40 by intramolecular proton transfer from the 
near by hydroxy group leads to a less strained cis-annulated hydroazulene ring system. 
Subsequent in situ reduction gives rise to the more stable equatorial alcohol (±)-41, trans to 
the vicinal prenyl-sidechain at the C7-position. 
The trans-lactone moiety in (±)-42 is obtained by ozonolysis and Jones-oxidation of the 
prenyl-side chain completing the guaianolide skeleton (Scheme 9). Acid deprotects the 
masked ketone and a Wittig-reaction introduces the exo-methylenic double bond at the 
C10-position of (±)-43, a very common structural feature of sesquiterpene lactones. 
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Scheme 9. Final steps towards (±)-Compressanolide (44). 
 
The resulting tertiary alcohol was protected, before α-methylation unfortunately afforded a 
mixture of 1:4 for the undesired isomer of (±)-44. Equilibration by kinetic protonation of the 
enolate improved the ratio only slightly to 1:3 towards (±)-Compressanolide (44). 
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Applying the stereoselective reduction on (±)-38 as described above (Scheme 8) and sub-
sequent oxidation gave rise to the all-trans substituted 5,7,5-ring system (±)-45 (Scheme 10). 
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Scheme 10. Finals steps in the synthesis of (±)-Estafiatin (4). 
 
The regioselective elimination of the tertiary alcohol present in (±)-45 proved to be difficult: 
As classical methods for the dehydration failed, only the application of Burgess-reagent 
resulted in a 3:1 endo:exo elimination towards (±)-46. Acidic deprotection of the ketal also is 
accompanied with an equilibration of the resulting ketone to 3:1 for the desired more stable 
cis-connected endocyclic alkene (±)-47. Subsequent Wittig-olefination and α-methylenation 
followed by epoxidation of the more reactive trisubstituted endocyclic double bond finally 
afforded (±)-Estafiatin (4) in 4.3% overall yield. 
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1.3.2 Total synthesis of (±)-Dehydrocostus Lactone and (±)-Grosshemin 
Four years later Rigby et al.[68,69] reported the racemic synthesis of three further guaianolides 
((±)-Dehydrocostus Lactone (2) (IC50 = 14 µM, CTL cells[70]), (±)-Estafiatin (4) and 
(±)-Grosshemin (62) starting from commercially available 2,4,6-cycloheptatrienone 
(Tropone) (48). Similar to the Vandewalle-approach described above, the first target was also 
the construction of the hydroazulene core. Utilizing the 7-membered ringsystem already 
present in Tropone (48), 1,8-addition of appropriate nucleophiles afforded the alkylated 
products 49 and 50, which were further converted into the aldehyde 51 and the 
diazocompound 52, respectively (Scheme 11). 
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Scheme 11. Functionalization of Tropone (48) by Rigby et al. 
 
The required cis-fused hydroazulene ring system is then formed via a Lewis-acid mediated 
cyclization on 51 and subsequent reductive opening of the resulting epoxide (±)-53 releasing 
the next key-intermediate (±)-54 in the synthesis of (±)-Estafiatin (4) (Scheme 12, top). 
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Scheme 12. Formation of cis-fused hydroazulene systems. 
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Alternatively an intramolecular cyclopropanation in 52 gives rise to the tricyclic system 
(±)-55 which is then opened by a Lewis-acid mediated homoconjugate addition reaction 
releasing the intermediate (±)-56 for the synthesis of (±)-Grosshemin (62) (Scheme 12, 
bottom). 
To introduce the trans-fused lactone moiety, the double bond in (±)-54 was first selectively 
epoxidized (approach of peracid from the less hindered upper face) and then the epoxide was 
opened with the appropriate lithium-organyle closing the ring to lactone (±)-57 (Scheme 13). 
Functional group transformation leads in 4 steps to the diene (±)-58.  
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Scheme 13. Final steps towards (±)-Dehydrocostus Lactone (2) and (±)-Estafiatin (4). 
  
The still missing α-exo-methylenic group is introduced via a Mannich-type reaction to yield 
(±)-Dehydrocostus Lactone (2) in 1.0% overall yield. The structural closely related 
(±)-Estafiatin (4) was then obtained in 0.3% overall yield by selective isomerization of the 
double bond present in (±)-2 towards the more stable tetrasubstitution and subsequent regio- 
and stereoselective epoxidation. 
 
Using the hydroazulene key intermediate (±)-56 Rigby and coworkers started out for the 
synthesis of (±)-Grosshemin (62), first isolated by Rybalko et al. from Grossheimia 
macrocephala.[71] The methyl group present in (±)-Grosshemin (62) was selectively 
introduced via alkylation by methyliodid approaching over the less hindered upper face of 
(±)-56 (Scheme 14). 
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Scheme 14. Final steps towards (±)-Grosshemin (62). 
 
Further six steps including functional group transformation and Wittig olefination lead to 
allylalcohol (±)-60. The trans-fused lactone ring is introduced by directed epoxidation via the 
allylic alcohol and subsequent epoxide opening as shown in (±)-61. Again a Mannich-type 
reaction introduced the α-exo-methylene group at the lactone ring and finalized the synthesis 
of (±)-Grosshemin (62) in 8.6% overall yield. 
 
 
1.4 Stereoselective total synthesis of guaianolides 
1.4.1 Total synthesis of (+)-Cladantholide and (-)-Estafiatin 
A very elegant stereoselective approach towards two members of the guaianolide family via a 
radical cyclization cascade was reported by Lee and co-workers,[72] who succeeded in the total 
synthesis of (+)-Cladantholide (3) (isolated from Cladanthus arabicus (L.) Cass.)[73] and 
(-)-Estafiatin (4) starting from (R)-Carvone (63). 
In three steps the chlorohydrin derivative 64 was synthesized, which was subjected to a 
stereoselective Favorskii-rearrangement to afford the highly substituted cyclopentane-
carboxylate 65 (Scheme 15). Three more steps were necessary to obtain the bromoacetal 66, 
which was set up for a radical cyclization being initiated by AIBN/Bu3SnH under standard 
high-dilution conditions. 67 was obtained in quantitative yield and perfect diastereoselectivity 
with respect to the newly created stereocenters at the C7- and the C10-position. 
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Scheme 15. Favorskii-rearrangement and radical cyclization. 
 
The stereochemical outcome of this highly selective and efficient cascade can be explained by 
conformational analysis of the substrate (Scheme 16): The most stable conformation of the 
cyclopentane ring in 68 is represented with three substituents in equatorial positions, and the 
attached sidechains are oriented chairlike.  
 
 
Scheme 16. Conformational analysis of 68 and radical cyclization. 
 
Consequently 5-exo-cyclization of the primary radical onto the opposite double bond forms 
the trans cyclic acetal 69 setting the correct stereochemistry on C7. Subsequent 7-endo 
cyclization affords the tertiary radical 70, while the alternative kinetically favored 6-exo 
pathway was not observed. Final hydrogen addition setting the correct stereocenter at C10 
must have occurred from the α-face, which is presumable sterically less hindered. 
The high preference for the 7-membered ring formation by radical cyclization was also 
observed by Reiser and co-workers during their investigations on model systems towards the 
synthesis of bi- and tricyclic sesquiterpene lactones of the xanthanolide and guaianolide 
family (Scheme 17).[74] 
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Scheme 17. 7-endo cyclization by Reiser et al. 
 
To finalize the synthesis of (+)-Clandantholide (3) Lee et al. had to transform 67 to the 
ketoacetal 73, in which the introduction of a hydroxy group adjacent to the ketogroup yields 
α-hydroxyketone 74 (Scheme 18). 
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Scheme 18. Synthesis of (+)-Cladantholide (3). 
 
Applying the Shapiro-protocol to 74 resulted in the regioselective introduction of the C=C-
double bond to give the allylalcohol 76. It was argued, that the reaction proceeds through an 
intermediate 75, in which the lithium coordinates with the first nitrogen of the hydrazone and 
the adjacent hydroxy group. Consequently, excess base can only deprotonate next to the 
methyl group, affording the trisubstituted double bond in 76. Finally, oxidation and 
stereoselective α-methylation completed the synthesis of (+)-Cladantholide (3). 
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Scheme 19. Synthesis of (-)-Estafiatin (4). 
 
65 has also been the starting point for the synthesis of (-)-Estafiatin (4) (Scheme 19), for 
which again a radical cascade cyclization has been the key step. In difference to the reductive 
conditions employed for the transformation of 66 to 67, the cyclization of 77 to 78 was carried 
out under oxidative conditions, being initiated by hydrogen rather than halogen abstraction of 
the α-halo-carbonyl functionality. Reductive dechlorination and dehydration proceeded 
uneventfully to 79 and subsequent α-methylenation using Eschenmoser´s salt and selective 
epoxidation of the endo double bond afforded (-)-Estafiatin (4). 
 
1.4.2 Synthesis of the Thapsigargins by Ley et al. 
A powerful demonstration of modern organic synthesis was shown by Ley and co-workers 
with their total synthesis of the Thapsigargins (6).[75-77] Although extracts from the root of 
Thapsia garganica L. were used for a long time as treatment for rheumatic pains and 
pulmonary disorders, the identification and characterization of the active principles was not 
reported until 1980.[78,79] The potent biological activities reach from histamine liberation[80] to 
selective Ca2+-modulating properties[81-83] on subnanomolar concentrations. 
The outstanding activity and the complex molecular structure consisting of a polyoxygenated 
5,7,5-core structure which is further functionalized with eight stereogenic centers and up to 
four different ester groups, makes this class of guaianolides to an especially challenging target 
for total synthesis. 
The overall strategy towards the Thapsigargins (6) was again to construct the hydroazulene 
core first and subsequently functionalize it towards the target. 
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Therefore Ley and co-workers started from (S)-Carvone (63) following a similar route as 
described above for Lee et al.[72] Within five steps 80 was reached and further eight high 
yielding steps lead to aldehyde 81 with already one allyl sidearm installed (Scheme 20). 
 
 
Scheme 20. Ring closing metathesis as an essential key step. 
 
The second arm for the ring closing metathesis key step was introduced using the lithium 
anion of ethylvinylether. Following strictly the Felkin-Anh model diene 82 was generated as a 
single diastereomer. The bicyclic hydroazulene ringsystem was then constructed by ring 
closing metathesis affording 83 in high yield. 
The convex half space of the double bond present in 83 is shielded by the bulky TES 
protecting group and so osmylation results in good selectivity (16:1) for the concave attack 
releasing 84 (Scheme 21). 
 
 
Scheme 21. Facial selective osmylation. 
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Esterification of the resulting alcohol and subsequent intramolecular Horner-Wadsworth-
Emmons reaction provided the butenolide 85 which was within 3 steps transformed into 86. 
Further functionalization of 86 towards the highly oxygenated core system of the targets was 
performed by selective dihydroxylation of the side chain to yield 87 (Scheme 22). The desired 
trans-annulated lactone 88 was formed after selective oxidation of the primary alcohol. 
 
 
Scheme 22. Dihydroxylation and completion of the tricyclic framework. 
 
Until this point already 23 steps were necessary, but this process required five 
chromatographic steps only, providing a nice possibility to assemble material in 11% overall 
yield to this point in multiple gram quantities. After MOM deprotection the acetonide 89 was 
formed stabilizing the already complex system. 
The next target was the modification of the cyclopentane ring. Kinetic enolisation of 89 
followed by oxidation from the less hindered concave face provided α-siloxy-ketone 91 
(Scheme 23). 
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Scheme 23. Synthesis of conjugated ketone by selenium elimination. 
 
Again, enolisation, this time to the opposite side, afforded highly functionalized 92, the 
starting point for a complex unanticipated catalytic selenium reaction. The opening step in 
this sequence is supposed to be a selenation of the TMS protected secondary alcohol 92, 
because this seems to be the least hindered position. Subsequent 2,3-sigmatropic 
rearrangement affords a selenoxide 94 which is able to undergo syn-elimination in direction 
towards the 7-memberd ringsystem. Hydrolysis of the resulting enolether 95 releases the 
conjugated ketone 96.  
 
To complete the synthesis Ley and co-workers still had to set the last stereocenter in the 
cyclopentane ring of 96 by stereoselective reduction (4:1 selectivity, again by steric controlled 
attack from the concave face). Esterification with angelic acid of the resulting alcohol and 
removal of the TMS protecting groups afforded the diol 97 (Scheme 24). Selective acetyl 
protection of the more reactive hydroxy group via a polymer supported reagent installed the 
second ester group in 98. 
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Scheme 24. Final synthetic steps towards the Thapsigargins. 
 
Removal of the acetal protection provided the triol 98. Esterification of the more reactive 
secondary alcohol on the C-4 position finally afforded three members of the Thapsigargin 
family.  
 
 
1.5 Hemi-Synthesis starting from Santonin 
First isolated by Kahler et al. in 1830 [84,85] it was a long and exciting way to elucidate the full 
structure of (-)-α-Santonin (100).[85-90] Commercially available by extraction,[91] this 
eudesmanolide provides a perfect starting point for the synthesis of various sesquiterpene 
lactones (Scheme 25). Abe et al.[92-94] and Marshall et al.[95] also succeeded in the total 
synthesis starting from a hexahydronaphtalene skeleton or 3-methyl-benzoic acid, 
respectively. 
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Scheme 25. Structure and rearrangement of (-)-α-Santonin (100). 
  
Despite its own biological activity, the most important feature of (-)-α-Santonin (100) is the 
possibility to rearrange the 6,6,5-eudesmanolide skeleton to a hydroazulene carbon backbone 
(Scheme 25). The light induced rearrangement of 100 is one of the longest known 
photochemical organic reactions.[96] The cross conjugated dienone rearranges upon irradiation 
in the presence of acetic acid towards acetyl-isophotosantonic lactone 101 and serves as a 
classic example for photochemical rearrangements, although it was a long way to completely 
understand this reaction.[85,96-99] Furthermore was found that solvolysis of methanesulfonates 
102 also provides an entry to the 5,7,5-ringsystem of the guaianolides. 
 
1.5.1 Syntheses by Ando et al. 
Ando et al. were able to synthesize more than ten guaianolides starting from (-)-α-Santonin 
(100). Preparing suitable derivatives of this available natural product and subsequent 
solvolytic rearrangement offers a very interesting and efficient entry towards the guaianolides. 
 
1.5.2 Synthesis of (+)-Arborescin 
(+)-Arborescin (107) was first isolated by Meisels and Weizmann from Artemisia arboresces 
(Compositae), a plant used for contraceptive purpose by the ancient Greeks and Arabs.[100] 
The proposed structure by Herout et al.[101] was later on confirmed by X-ray analysis.[102] 
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In an opening step Ando et al.[103] transformed (-)-α-Santonin (100) into the eudesmanolide 
103 (Scheme 26). Protecting group transformation and reduction afforded the alcohol 104. 
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Scheme 26. Synthesis of (+)-Arborescin (107). 
 
Mesylation and solvolytic rearrangement resulted in a mixture of olefins 105, which was 
rectified by selective epoxidation of the tetrasubstituted double bond of the endo-isomer. The 
approach of the epoxidizing agent from the sterically less hindered down face sets the right 
stereochemistry for the epoxide. Subsequent deprotection and elimination afforded 
(+)-Arborescin (107) with a trans annulation of the cyclopentane ring. 
 
 
1.5.3 Synthesis of Zaluzanines 
A similar approach was used for the synthesis of different Zaluzanines (111).[104,105] These 
guaianolides were originally isolated from Zaluzania augusta and Zaluzania triloba[106,107] 
and show high biological activities for example in tumor inhibition.[108] 
The rearrangement of the (-)-α-Santonin (100) derivative 108 to the guaianolide skeleton 109 
resulted again in a mixture of double bond isomers which was rectified by selective 
epoxidation of the endo-isomer (Scheme 27). 
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Scheme 27. Synthesis of (+)-Zaluzanin C/D (111). 
 
Subsequent Mitsunobu-inversion of the secondary alcohol in 109 sets the right 
stereochemistry of the hydroxygroup in the cyclopentane ring of 110 and afforded after 
introduction of the exo-methylenic bond (+)-Zaluzanin C and D (111). 
 
 
1.5.4 Mokko lactone, Dehydocostus Lactone and Eremanthin 
Mokko Lactone (114) and Dehydrocostus Lactone (2) (both isolated from costus root 
(mokko)[109,110]) and Eremanthin (5) (isolated from the hartwood oils of Eremanthus 
elaeagnus and Vanillosmopsis erytrhoppa)[111-113] are also accessible via this route. A 
common feature of these three natural products is the lacking of the hydroxy functionality in 
the cyclopentane ring. 
Starting again from (-)-α-Santonin (100) Ando and co-workers synthesized 112 (Scheme 28). 
After deprotection of the ketal and double bond isomerization the resulting ketone was 
reduced to the secondary alcohol 113, which is needed for subsequent mesylation. Solvolysis 
directly affords Mokko Lacone (114) accompanied with its double bond isomers 115 and 116. 
Desaturation of 114 and 115 releases Dehydrocostus Lactone (2) and Eremanthin (5), 
respectively 
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Scheme 28. Further Guaianolides starting from (-)-Santonin (98). 
 
This strategy allowed Ando et al. to succeed in the total synthesis of over ten different 
guaianolides (Figure 4).[114] 
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Figure 4. Some guaianolides prepared by Ando and co-worker. 
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Inspired by this route Pedro et al. were also able to present stereoselective hemi-syntheses for 
(+)-11βH,13-Dihydroestafiatin, (+)-11βH,13-Dihydroludartin, (-)-Compressanolide (44), and 
(-)-11βH,13-Dihydro-micheliolide starting from (-)-α-Santonin (100).[115] 
 
 
1.5.5 Biomimetic synthesis of Absinthin 
Several short biomimetic syntheses of several guaianolides starting from suitable modified 
natural germacranolides have also been reported in literature.[47,49,51,52] The main problems 
within these approaches are the insufficient availability of the staring materials or the 
frequently observed complex mixtures during the cyclization reactions in combination with 
poor yields. For example Gallicin (117) a germacranolide isolated from Artemisia maritima 
gallica ssp Willd can be mesylated and subsequent cyclization affords the guaianolide 
skeleton which can be further converted into Compressanolide (44) (Scheme 29). 
 
 
Scheme 29. Biomimetic cyclization of germacranolides. 
 
 
Isolated in 1953 by Herout et al.[116-118] as a main dimeric guaianolide from Artemisia 
absinthium L. the complex structure of (+)-Absinthin (122) was not determined before the 
1980s.[119-122] The challenging structure and the biological activity of this compound inspired 
Zhang and co-workers to search for a synthetic approach towards this compound.[123]  
Photochemical rearrangement of (-)-α-Santonin (100) provided access to the guaianolide 
skeleton and reduction yielded the alcohol 118 (Scheme 30). Subsequent Mitsunobu-
arylselenation followed by oxidative elimination afforded the precursor diene 119. 
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Scheme 30. Biomimetic dimerisation via [4+2] Cycloaddition. 
 
The biomimetic dimerisation of the two identical Diels-Alder partners proceeded highly 
regio- and stereospecific towards 120. This can be explained by minimizing the steric 
interactions during the approach of the reaction partners via the less hindered face (for the 
cyclopentadiene moieties). A head to head orientation (for the lactone moieties) also 
minimizes steric interactions between the 7-membered ring systems (inset box in Scheme 30). 
After basic cleavage of the acetyl-protecting groups the stereocenters of the resulting tertiary 
alcohol 120 had to be inverted. This was achieved by initial elimination and subsequent 
oxidative cleavage of the resulting exo-cyclic double bond to release diketone 121. To 
complete this biomimetic total synthesis of (+)-Absinthin (122), stereoselective methylation 
of the carbonyl groups afforded the target compound in 18.6% overall yield. 
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1.6 Conclusions 
The search for new synthetic ways towards the guaianolides did not only result in new total 
synthesis of complex and biological active natural products, but also contributed to the 
development of a wide range of new and modern chemistry. The fundamental and 
methodological aspects of natural product synthesis have always proven to be of great 
importance beside the straight forward synthetic pathway towards the target structures. As 
there are more and more members of the guaianolide family discovered and extracted from 
different plants, the full evaluation of their biological activity is still of current interest. 
Therefore total synthesis has to find new, efficient and flexible ways to make these 
compounds and their derivatives available. 
Aim of this work 
 
36
2. Aim of this work 
This work seeks to explore a new synthetic strategy towards the total synthesis of two 
interesting members of the guaianolide family, namely Cynaropicrin (123) and Ixerin Y 
(126). A highly promising biological activity in combination with their complex structure 
makes these compounds challenging targets for total synthesis.  
 
2.1 Cynaropicrin - the herb principle of artichoke 
The artichoke (Cynara scolymus L.) was elected as the medical plant of the year 2003.[124] 
This 1.5-2 m tall perennial thistle is originated in southern Europe especially around 
Mediterranean (Figure 5).[125-129] 
 
     
Figure 5. Pictures of Cynara scolymus L. and structure of Cynaropicrin (123). 
 
Dried or fresh leaves and stems of Cynara are used as a choleretic (to increase bile 
production) and to treat gallstones. Furthermore, drugs are prepared from the extracts for the 
treatment of dyslipidemias, arteriosclerosis and inflammatory bowel disorders.[130] 
Responsible for the bitter taste of this vegetable is the guaianolide Cynaropicrin (123),[131,132] 
also identified as the active principle, which shows a broad variety of biological activities: 
Significant cytotoxicity against human tumor cell lines (ED50 = 0.23-1.72 µg/ml) was found 
by Choi and co-worker.[133] Further reports are provided in literature on the pro-apoptotic 
activity of Cynaropicrin (123) on leukocyte cancer cell lines[134] in combination with activity 
in acute and chronic inflammatory processes.[135-137] In addition to this, antibacterial effects 
are seen by irreversible inhibition of MurA, an enzyme responsible for the first step in 
cytoplasmatic biosynthesis of peptidoglycan precursors.[138] This enzyme is of certain interest 
for drug development projects, since the MurA-dependent metabolites are of vital importance 
for bacteria.[139-141] 
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2.2 Ixerin Y - a guaianolide sesquiterpene lactone glucoside 
Various interesting natural products have been isolated from Ixeris plants (Figure 6), and 
sesquiterpene lactones as the Ixerins A-Z have been characterized (Figure 7).[142-146]  
 
   
Figure 6. Pictures of Ixeris denticulata f. pinnatiparita. 
 
A wide spectrum of biological activities, such as cytotoxicity[147] as well as having ant 
repellent[148] and antifeedant[149] properties is reported for some members of the Ixerin family. 
In addition to this, Ixerin Y (126) shows a promising inhibitory effect against the growth of 
human breast cancer cell lines (MCF7: IC50 = 6.36 µg/ml, MDA468: IC50 = 11.87 µg/ml).[57] 
Prominent members of the Ixerin guaianolide family are given in Figure 7.  
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Figure 7. Prominent members of the Ixerin guaianolide family. 
 
A common feature of the mentioned members of the Ixerins is the glycosidic linkage of a 
glucose moiety found at different positions on the hydroazulene core skeleton. Ixerin X (125) 
and Y (126) differ only in the configuration of the hydroxy functionality at the C4-position 
which is absent in Ixerin D (124) and Z (127).  
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Table 1. Sources of members of the Ixerin family. 
Entry Guaianolide isolated from Ref. 
1 Ixerin D (124) Ixeris tamagawaensis [143] 
2 Ixerin X (125) Ixeris Denticulata f. pinnatipartita and 
Ixeris sonchifolia resp. 
[57,150,151] 
3 Ixerin Y (126) Ixeris Denticulata f. pinnatipartita and 
Ixeris sonchifolia resp. 
[57,150] 
4 Ixerin Z (127) Ixeris Denticulata f. pinnatipartita and 
Ixeris sonchifolia resp. 
[150,152] 
5 Ixerinoside (128) Ixeris sonchifolia [153] 
  
The complex structure in combination with their broad spectrum of biological activity makes 
all these compounds to challenging targets for total synthesis. 
 
 
 
2.3 Retrosynthetic analysis of the target compounds 
All total synthetic approaches described so far (see introduction) find their first target in the 
construction of the guaiane core system. Once this skeleton is assembled, the trans-annulated 
lactone moiety is introduced in the synthesis. The stereochemistry is mostly substrate 
controlled via the hydroazulene core system and the target structures are finally reached by 
functional group transformations. 
In contrast to this, the synthetic approach towards the two guaianolides described above seeks 
for a different route: The lactone moiety and its trans-substitution pattern is constructed first 
as seen in lactone aldehyde 129, and the guaianolide skeleton is finalized by closing the 
hydroazulene substructure (Figure 8). 
Although Cynaropicrin (123) and Ixerin Y (126) have been isolated from very different 
sources, there seems to exist quite an interesting structural relationship between these 
compounds: The basic framework of 123 and 126 differs only in the position of the double 
bonds within the guaiane skeleton as well as in the position of the hydroxy group on the 
allylic moiety in the cyclopentane ring. 
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Figure 8. Retrosynthesis of Cynaropicrin (123) and Ixerin Y (126). 
 
Because of this, a stereoselective synthesis of both natural products is envisioned to the 
common precursor 129 using either a radical cyclization or ring closing metathesis approach 
to form the central seven membered ring. 
The lactone aldehyde intermediate 129 having already incorporated five stereocenters with 
respect to the target structures, was envisaged to be assembled from the cyclopropyl-
carbaldehyde (-)-130, accesible from furan 131, and the disubstituted allylsilane 132. The 
construction of the latter is acchieved starting from the enantiomerically pure protected 
cyclopentenon 133. 
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3. Synthesis of chiral allylsilanes 
Allylsilanes have proven to be versatile tools in organic chemistry, especially for the mild and 
highly selective Hosomi-Sakurai allylation.[154-158] To construct the southern cyclopentane 
ring of the guaianolides, two chiral allylsilanes with all the desired substituents in place were 
prepared. Compounds 134 and 135 are envisioned as important key intermediates with three 
major features (Figure 9): 
i)  the allylsilane moiety allows the smooth addition onto the cyclopropylcarbaldehyde. 
ii)  the protected alcohol already possesses the right stereochemistry (with respect to 
Cynaropicrin (123)) and can be further functionalized. 
iii)  the bulky silyl group in the sidechain acts as a directing group during the addition 
reaction and can be transformed into a free hydroxy functionality later on. 
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Figure 9. Retrosynthesis of chiral allylsilanes 134 and 135, respectively. 
 
To be able to introduce all of these features, the synthesis of the allylsilanes 134 and 135 is 
referred to the chiral protected cyclopentenone 133, which is readily accessible in 
enantiomeric pure form, starting from inexpensive commercially available furfuryl 
alcohol (136). 
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3.1 Synthesis of the enantiomeric pure cyclopentenone 
There are quite a number of methods known for the synthesis of optically active cis-2-
cyclopenten-1,4-diol derivatives,[159-168] but many of these show certain inconveniences 
(e.g. cracking of dimer when starting from cyclopentadiene, instability of intermediates, loss 
of stereoselectivity during the synthesis).[169] To avoid these problems it was decided to 
follow a well established route reported by Curran et al. for large quantity preparation of 
optically active cis-2-cyclopenten-1,4-diols.[169,170] 
First, furfuryl alcohol (136) was rearranged to 4-hydroxycyclopent-2-enone (±)-137 in 
moderate yield (Scheme 31). 
 
 
Scheme 31. Synthesis of precursor for enzymatic resolution: a) KH2PO4, pH = 4.1, H2O, reflux, 2 d, 40%; b) 
TBDMSCl (1.15 eq.), NEt3 (1.50 eq.), DMAP (5 mol%), THF, 0 °C - rt, 89%; c) LiAlH4 (0.70 eq.), LiI (0.50 
eq.), toluene/TBME, -30 °C, 3 h, 85% (cis/trans 92:8). 
 
The following TBDMS-protection of the free hydroxy group introduces a bulky substituent in 
(±)-138, which directs the subsequent reduction towards the cis-substituted (±)-139 in good 
yield and selectivity.  
The racemate of (±)-139 was subjected to kinetic enzymatic resolution using porcine pancreas 
lipase (PPLE).[171] (-)-139 and (+)-140 were separated afterwards by simple chromatography 
on silica gel, and both compounds can be used in the further synthesis providing the important 
feature not to loose material within this early stage (Scheme 32). 
 
 
Scheme 32. Enzymatic resolution: a) porcine pancreas lipase PPLE, vinylacetate (4.50 eq.), NEt3 (0.68 eq.), 
TBME, rt, 48 h, (-)-139 (95%, 92% ee), (+)-140 (80%, >99% ee). 
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The progress in the enzymatic resolution can easily be monitored via chiral GC analysis by 
determination of the ee-value for the starting material (-)-139 (Figure 10).  
 
 
Figure 10. Kinetic resolution of (-)-139 monitored by chiral GC. 
 
In the first 12 h the reaction velocity was high, illustrated in the steep slope of the curve at the 
beginning (Figure 10). The maximum ee of 92% for (-)-139 was reached after 48 h. A change 
of the high ee-value of >99% for the acetylated product (+)-140 was not observed during this 
reaction. All attempts to recycle the used enzyme for further resolution reactions were not 
successful and only very low conversion was seen. 
For the further synthesis, the acetyl-protection of (+)-140 was removed by saponification 
using LiOH (Scheme 33). 
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Scheme 33. a) LiOH (1.20 eq.) THF:MeOH:H2O (3:1:1), rt, 2 h, 96%; b) NaH (1.25 eq.), NaI (1.00 eq.), 
p-methoxybenzylbromide (1.30 eq.), THF, rt, 5 h, 86%; c) TBAF (1.00 eq.), NEt3 (0.10 eq.), THF, rt, 24 h, 85%. 
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Because TBDMS- and benzyl-protection approaches already failed in previous attempts 
within similar syntheses of guaianolides carried out in our group,[172] the strategy within this 
work was changed to the protecting group p-methoxybenzyl (PMB) which is stable to all 
conditions needed in the further synthesis and is readily removed under mild oxidative 
conditions (preferably DDQ). Protection of (+)-139 by p-methoxybenzylbromide afforded 
PMB-protected (+)-141 in 86% yield and standard TBDMS removal by TBAF led to (-)-142. 
 
(-)-142 is also accessible by protecting group transformation starting from (-)-139. Reacting 
the free hydroxy functionality in (-)-139 with acetic anhydride in pyridine afforded the fully 
protected compound (-)-140 in excellent yield (Scheme 34). 
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Scheme 34. a) pyridine (15.0 eq.), Ac2O (4.5 eq.), rt, 6 h, 97%; b) TBAF (1.0 eq), NEt3 (0.1 eq.), THF, rt, 2 h, 
95%; c) p-methoxybenzyltrichloroacetimidate (1.67 eq.), Cu(OTf)2 (5 mol%), CH2Cl2, 0 °C - rt, 24 h, 83%; d) 
LiOH (1.2 eq.), THF/MeOH/H2O (3:1:1), rt, 2 h, 92%. 
 
The removal of the TBDMS protection under standard conditions smoothly provided (+)-143 
as a colorless solid, which can be easily recrystallized from diethylether. 
The introduction of the required PMB protecting group proved to be difficult on this 
substrate. First attempts using PMB-Br (similar to the synthesis of (+)-141, Scheme 33) failed 
due to racemization under these conditions. However, applying the trichloroacetimidate 
protocol under Cu(OTf)2 catalysis as described by Basu et al.[173] afforded (+)-144 in good 
yield and purity. Removal of the acetyl protection by standard saponification also provided 
(-)-142 in 92% yield. 
Altogether, both compounds resulting from the enzymatic resolution can be transformed into 
the same intermediate (-)-142, providing the important possibility to assemble large quantities 
of this material on this early stage of synthesis. 
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Final oxidation of (-)-142 using PCC yielded the PMB-protected cyclopentenone (-)-145 
(Scheme 35). 
 
 
Scheme 35. Oxidation of (-)-142 to key intermediate (-)-145: a) PCC (1.2 eq.), 4 Å MS, CH2Cl2, rt, 24 h, 86%. 
 
With this synthesis the key intermediate (-)-145 was accessible in 8-9 steps starting from 
commercially available furfuryl alcohol (136). Each step in the described sequence was a spot 
to spot reaction and could easily be monitored by TLC or GC. After optimization of the 
reaction conditions, up-scaling to 18 g batches in the enzymatic resolution was possible 
without loosing the enantiomeric purity of the resulting products. 
 
3.2 Synthesis of the chiral allylsilanes 
The PMB-protected cyclopentenone (-)-145 was subjected to a highly selective 1,4-addition 
with appropriate cuprate reagents to introduce the functionalized carbon side chain at 
C3-position. 
The desired hydroxy functionality is introduced in this step, masked as a bulky silyl group, 
offering certain advantages (Scheme 36): The desired cuprate reagents 147 with an n-electron 
donor atom (here oxygen) attached to the metalated carbon are not readily accessible from the 
corresponding halides 146 by usual procedures[174] and often involve multiple steps in their 
preparation (e.g. using tin-containing intermediates).[174,175]  
 
 
Scheme 36. Metal organyls used for 1,4-addition: a) Mg (3.0 eq.), THF, rt, 2 h. 
Main Part 
 
45
Additionally, the introduction of a further hydroxy protecting group at this early stage of the 
synthesis was thought to be problematic in terms of restrictions in transformations and in 
protecting group differentiation. 
To avoid these problems, commercially available chloromethylsilanes 148 (R = OiPr, Ph) 
were used for standard Grignard formation. In situ conversion to the appropriate cuprates 
provided the reagents for the 1,4-addition onto cyclopentenone (-)-145. The use of different 
substituents at the silicon atom (R = OiPr, Ph) opens the possibility to investigate different 
conversion protocols for the transformation of the masked hydroxy group into the 
corresponding free alcohol. 
Because the bulky PMB-protecting group in (-)-145 shields the lower half space, the cuprate 
addition proceeds highly diastereoselectively from the upper face resulting in the desired anti-
substitution on the cyclopentane ring. The resulting enolates were trapped in the presence of 
TMS-Cl as the corresponding silylenolethers 150 and 151 (Scheme 37). These materials are 
very sensitive to heat and traces of acid.[176] Therefore, purification by distillation or 
chromatography was not possible, however, after extensive extraction the products possessed 
sufficient purity to carry on with the next steps. 
 
OPMB
O
SiMe2
R
TMS
OPMB
SiMe2
R
TMS
a b
(-)-145
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151 R = OiPr
152 R = Ph
153 R = OiPr  
Scheme 37. Synthesis of chiral allylsilanes: a) LiCl (0.3 eq.), CuI (0.15 eq.), TMSCl (4.0 eq.), R = Ph: 
PhMe2SiCH2MgCl (1N in THF) (1.25 eq.), THF, -78 °C, 3 h, 99%, dr >99:1; R = OiPr: iPrOMe2SiCH2MgCl 
(1 N in THF) (1.15 eq.), THF, -78 °C, 3 h, 90%, dr >99:1; b) Ni(acac)2 (0.1-1.0 eq.) Me3SiCH2MgCl (1 N in 
Et2O) (1.5-2.0 eq.), Et2O, rt, 5 d, R = Ph: 40%, R = OiPr: 34%. 
 
For the final transformation of the silylenolethers into the corresponding allylsilanes 152 and 
153 a modified procedure reported by Kumada et al. was used.[177] Ni(acac)2 catalyzes the 
coupling of silylenolethers with the appropriate Grignard reagent to afford the desired 
allylsilanes 152-153 only in moderate yields (34-40%). This might be due to the highly 
substituted cyclopentane ring and the resulting steric strain preventing the cross coupling to 
the allylsilanes. Attempts to improve this reaction by gentle warming, elongated reaction 
times or increasing the catalyst loading as well as reagent excess did not lead to better results. 
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From the Ni(acac)2 coupling reaction compounds 154 and 155 were also isolated as 
decomposition products of the corresponding silylenolether (Scheme 38).  
 
 
Scheme 38. Possible use of by-products. 
 
These trans-substituted cyclopentenones 154 and 155 are very interesting structures 
themselves, since sugar-like trisubstituted cyclopentanes 157 and 158 could become 
accessible within a short sequence, including Tamao-Fleming oxidation of the side chain and 
reduction of the resulting ketone 156. These pseudo-anomeric structures have already proven 
to be important compounds as sugar mimics for pharmaceutical or biochemical purposes.[178] 
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4. Synthesis of the cyclopropylcarbaldehyde 
Both enantiomers of the highly functionalized 1,2,3-trisubstituted cyclopropylcarbaldehyde 
130 are readily accessible in enantiomeric pure form via a well established two step sequence 
starting from methyl-2-furoate (131).[6,74,179,180] 
The stereochemical outcome of the sequence of cyclopropanation, ozonolysis to the 
cyclopropylcarbaldehyde 130 and subsequent allylation/retroaldol-lactonization depends on 
the stereochemistry of the bis(oxazoline)-ligand (BOX) 159 initially used (Figure 11 and 
Scheme 39). 
 
 
Figure 11. iPr-BOX-ligands (+)/(-)-159 used for asymmetric cyclopropanation. 
 
 
Scheme 39. Stereochemical relationships of iPr-BOX-ligands and stereochemistry of lactone aldehydes. 
 
The (R,R)-iPr-BOX ligand (+)-159 derived from D-valine leads to the desired substitution 
pattern on the lactone aldehyde 161 as found in the natural products, and subsequently the 
(S,S)-iPr-BOX ligand (-)-159, prepared from the less expensive natural L-valine, gives rise to 
the enantiomeric compound 162. 
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Both enantiomers of the chiral BOX-ligands 159 were prepared starting from D- or L-valinol 
164, derived from the corresponding amino acids by reduction with sodiumborohydride and 
iodine. Coupling of 2,2-dimethylpropane-dioyl-dichloride 163 and valinol 164 proceeded 
successfully to diamide 165 (Scheme 40). Subsequent tosylation and cyclization gives rise to 
the corresponding enantiomeric pure ligand (+)-159.[181] 
 
 
Scheme 40. Synthesis of bis(4-isopropyloxazoline) ligand: a) valinol (2.0 eq.), NEt3 (2.5 eq.), CH2Cl2, 0-rt °C, 
70 min, 84%; b) DMAP (10 mol%), NEt3 (4.0 eq.), TsCl (2.0 eq.), CH2Cl2, rt, 27 h, 83%. 
 
BOX-ligand (+)-159 was applied in a Cu(I)-mediated asymmetric regio- and 
diastereoselective cyclopropanation of methyl-2-furoate (131), resulting in (+)-160 with high 
enantioselectivity of 85-90% ee, which was improved to >99% ee after recrystallization 
(Scheme 41). 
 
 
Scheme 41. Cyclopropanation and ozonolysis: a) (i) ethyl diazoacetate (2.67 eq.), Cu(OTf)2 (0.66 mol%), 
(+)-159 (0.84 mol%), PhNHNH2 (0.70 mol%), CH2Cl2, 0 °C, 54%, 85-90% ee; (ii) recrystallization (CH2Cl2, 
pentane), >99% ee, 37%; b) (i) O3, CH2Cl2, -78 °C; (ii) DMS (4.00 eq.), 22 h, -78 °C - rt, 90%. 
  
The stereochemical outcome of this reaction can be explained applying the models suggested 
by Pfaltz[182] and Andersson[183] for the asymmetric cyclopropanation of alkenes: 
The reactive complex 166 in this reaction is shown in Figure 12 (left). An approach of 131 
(substituent CO2Me oriented away from 166 to minimize steric interactions) from the right 
side is expected to be favored, since an attack from the left side shows strong repulsive steric 
interaction of the approaching olefin 131 and the iPr group of the ligand (+)-159 (Figure 12, 
right). An attack from the right side will also lead to a flipping of the ester group E in 166 to 
the left (counterclockwise), resulting in only small interactions with the hydrogen 
substituent Ha. 
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Figure 12. Reactive complex and model for asymmetric cyclopropanation. 
 
In the subsequent cyclopropanation the less substituted and presumably more electron rich 
double bond of 131 is attacked. 
The formation of the corresponding endo-diastereomer was not observed and after 
optimization of the reaction conditions a scale-up to 50-100 g was possible, still affording 
high enantioselectivity, so that both enantiomers of 160 can be prepared in optical pure form 
and multigram quantities. 
To access the cyclopropylcarbaldehyde, the double bond present in (+)-160 was cleaved by 
ozonolysis followed by reductive work-up leading to (+)-130 in 90% yield (Scheme 41). This 
material rendered solid upon treatment with diethylether and was stable for months while 
stored under a nitrogen atmosphere at -35 °C. 
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5. Formation of the anti-substituted lactone aldehyde 
The next step was the addition of the chiral allylsilanes to the cyclopropylcarbaldehyde. In 
general, the stereocontrol of additions onto a cyclopropyl-substituted carbonyl compound 167 
can be explained by analyzing the conformational preferences and applying the Felkin-Anh-
model[184] in combination with the Curtin-Hammett-principle.[185] 
The cyclopropane ring shows in analogy to an alkene double bond strong π-donating 
properties. These are only effective in the two bisected conformations, which are very similar 
to the Felkin-Anh conformations s-cis-167 and s-trans-167 of the cyclopropyl-substituted 
carbonyl compounds (Scheme 42). 
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Scheme 42. Nucleophilic attack on cyclopropyl-substituted carbonyl compounds. 
 
From these possible conformations the latter is energetically more favored because the steric 
interactions of the aldehyde and the space demanding cyclopropane ring are minimized. A 
nucleophile attacking the more stable s-trans-167 conformation would consequently have to 
approach over a bulky substituent leading to the anti-Felkin-Anh-168 product. The 
experimentally observed Felkin-Anh-168 product results from the s-cis-167 conformation 
which is attacked by the nucleophile coming over a less hindered half space. 
If the activation energies of the selectivity determining step are higher than the rotation barrier 
between the different conformers, the Curtin-Hammet principle can be applied. For this case 
not the preferred conformation of the substrate (here s-trans-167) is responsible for the 
product distribution, but the activation energy of the transition state determines the 
stereochemical outcome. 
In the case described here, the rotation barrier for the transformation of s-cis to s-trans must 
be smaller than the activation barrier for the selective addition step and so the attack of bulky 
nucleophiles will occur on the less hindered path over the smaller substituent leading to the 
experimentally observed Felkin-Anh-168 product. 
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The synthesized chiral silylenolethers 150/151 and allylsilanes 152/153 were now combined 
in a Lewis acid mediated Mukaiyama-aldol reaction or a Hosomi-Sakurai allylation with the 
cyclopropylcarbaldehyde (+)-130, respectively. 
All attempts to add the silylenolether 151 and allylsilane 153 with the OiPr- substituent at the 
silicon atom in the side chain failed due to decomposition of the silyl precursor. 
In contrast, the reactions using the Ph-substituted compounds 150 and 152 proceeded 
smoothly to the highly substituted intermediates 170 and 171 which were obtained as single 
diastereomers (Scheme 43). The Mukaiyama-aldol reaction of 150 (X = O) did not afford a 
clean product 170, as the silylenolether could not be purified and therefore had to be used as a 
crude material. 
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Scheme 43. Addition of chiral silylenolethers and allylsilanes to the cyclopropylcarbaldehyde: a) BF3⋅OEt2 
(1.1 eq.), CH2Cl2, -78 °C, 16 h, 170: X = O: 95%, dr >99:1; 171: X = CH2: 95%, dr >99:1. 
 
These highly functionalized materials can not be purified easily by distillation due to their 
high molecular mass or chromatography because they tend to decompose on silica gel. Simple 
extraction afforded the products in sufficient purity to proceed with the next step in the 
synthesis. 
The stereochemical outcome of this reaction can be explained by the proposed transition state 
169 (Scheme 43). In this case, the nucleophile attacks the s-cis-conformation of the carbonyl 
group in anti-orientation to its bulky substituent (CH2SiMe2Ph) leading to the trans-Felkin-
Anh-products 170 and 171 (see discussion above).  
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In an attempt to combine 152 and (-)-130 in the mismatched case, only a complex mixture of 
at least four compounds was observed in a very low yield, which indicates the importance of 
the double stereochemical differentiation with the chiral allylsilanes. 
Upon treatment with Ba(OH)2 in methanol only the Hosomi-Sakurai allylation product 171 
(X = CH2) rearranged to the lactone aldehyde 175 in 72% yield (Scheme 44). Attempts to use 
triethylamine or LiOH as base for this transformation failed. The reaction proceeds by 
saponification of the more labile oxalic ester, upon which a ring opening of the now 
unmasked donor-acceptor substituted cyclopropane 172 is triggered, followed by 
lactonization of 173 to give 175 as a single stereoisomer. 
 
 
Scheme 44. Retroaldol-lactonization: a) Ba(OH)2⋅8H2O (0.55 eq.), MeOH, rt, 2 h, 72%, dr >99:1; b) i) O3, 
CH2Cl2, -78 °C, 15 min; ii) DMS (4.0 eq.), -78 °C - rt, 24 h. 
 
In contrast, the addition product 170 which resulted from the Mukaiyama-aldol reaction failed 
to rearrange into the ketone-aldehyde 176. Therefore, an attempt was made to subject lactone 
aldehyde 175 to ozonolysis conditions to access the ketoaldehyde 176, but only 
decomposition of the starting material was observed. 
The lactone aldehyde 175 is an important key-intermediate in further investigations towards 
the total synthesis of guaianolide sesquiterpene lactones: The trans-stereochemistry at the 
lactone ring is already set and the cyclopentane ring is highly functionalized also having the 
stereochemistry at the connection point to the lactone ring and the protected hydroxy group 
set in the right way. The aldehyde group and the double bond present in the molecule are 
versatile functionalities, which allow many further transformations to construct the framework 
of the guaianolides and related natural products via certain ring closing reactions. 
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6. Investigations towards 5,6,5-ring systems 
In addition to oxidative derivatisation, nature has also the possibility to rearrange the complex 
5,7,5-carbon skeleton of the guaianolides. Probably by a Wagner-Meerwein-type 
rearrangement a 5,6,5-ring system is formed, as for example found in Lasiolaenolide (178) 
and its derivatives, isolated from various plants, such as Lasiolaena santosii (Scheme 45).[186] 
 
 
Scheme 45. Ring closing reactions to form rearranged guaianolides. 
 
The lactone-aldehyde 175 should be a suitable precursor to construct the core 177 of this 
family of natural products. Connecting the carbonyl-carbon with the opposite double bond 
would lead to a 5,6,5-ring system. Although, the methyl group at the C5-position is lacking 
this transformation would provide a direct and interesting route to this skeleton. 
 
6.1 Intramolecular carbonyl-ene reaction 
The first approach to perform this ring closure was the utilization of an intramolecular 
carbonyl-ene reaction on aldehyde 175 which should directly lead to the 5,6,5-membered ring 
system 179 (Scheme 46).  
 
 
Scheme 46. Intramolecular carbonyl-en-reaction: a) see Table 2. 
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Although intramolecular carbonyl-ene reactions on less functionalized precursors have been 
reported,[187] treating lactone aldehyde 175 with different Lewis acids at different 
temperatures did not lead to the desired tricyclic structure 179 (Table 2). At low temperatures 
(-78 °C) no reaction was observed and at higher temperature (0 °C or rt) only decomposition 
of the starting material occurred. 
 
Table 2. Intramolecular carbonyl-ene-reaction conditions. 
Entry Lewis Acid Reaction conditions Yield 
1 BF3⋅OEt2 (2.0 eq.) -78 °C, 4 h no reaction 
2 BF3⋅OEt2 (2.0 eq.) rt, 4 h decomposition 
3 BF3⋅OEt2 (2.0 eq.) 0 °C, 1 h decomposition 
4 TiCl4 (2.0 eq.) 0 °C, 1 h decomposition 
5 SnCl4 (2.0 eq.) 0 °C, 1 h decomposition 
 
The difficulties encountered in this transformation might be due to the high functionalization 
of 175 and moreover, the PMB protecting group might not be stable under these Lewis acidic 
conditions.  
 
 
Scheme 47. PMB deprotection of 175: a) DDQ (1.14 eq.), CH2Cl2/H2O, rt, 2 h. 
 
To remove the PMB protecting group, 175 was treated with DDQ (Scheme 47). This resulted 
in an inseparable mixture of unknown products and did not afford the desired free 
alcohol 180. 
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6.2 SmI2-promoted radical cyclization 
Another potential reaction for the construction of the skeleton of type 177 is the SmI2 
promoted intramolecular radical cyclization of aldehydes into C=C-double bonds which 
already has found many applications in the total synthesis of various natural products.[188]  
SmI2 is a one-electron-transfer reagent, which should transform the lactone aldehyde 175 into 
the radical intermediate 181 (Scheme 48). Subsequent cyclization by incorporating the 
exo-double bond would led to the 5,6,5-membered ring system 182. The 6-endo product 
should form with preference rather than the 5-exo product, since the trans-configuration at the 
lactone moiety introduces strain into the system. This should lead to the formation of the 
larger ring which is presumably thermodynamically more stable. Moreover, upon the 5-exo 
ring closure a primary radical rather than a tertiary radical as for the 6-endo ring closure 
would be formed. 
 
 
Scheme 48. SmI2-promoted radical cyclization: a) SmI2 (2.0 eq.), THF, 0 °C, 2 h. 
 
Unfortunately, applying the standard SmI2 cyclization conditions on lactone aldehyde 175 did 
not afford the expected tricyclic structure and resulted in an inseparable mixture of 
undefinable products. 
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7. Investigations towards the guaianolide core skeleton 
Since all previous attempts (carbonyl-ene reaction and SmI2-radical cyclization) to build a 
tricyclic framework failed, the strategy was changed, focusing on the construction of the 
5,7,5-membered ring system of the guaianolides. Different approaches to close the central 
7-membered ring were explored including radical cyclization and ring closing metathesis. 
 
7.1 Radical cyclization approach 
We were already able to show the transformation of simplified precursors 71 into bi- and 
tricyclic sesquiterpene lactone skeletons 72 via radical cyclizations (Scheme 49).[74]  
 
 
Scheme 49. Synthesis of unsubstituted bi- and tricyclic sesquiterpene lactone scaffolds by radical cyclization. 
 
This promising sequence was investigated on lactone aldehyde 175. Alkenylation by a 
modified Horner-Wadsworth-Emmons (HWE) reaction gave rise to 183 in 72% yield and in 
an expected preference for the Z-isomer (E/Z = 17:83). Here it has to be noted that it proved 
to be more convenient and higher yielding to generate the 2-bromo-phosphonoacetate in situ 
to prevent the formation of unhalogenated HWE-product. 
 
 
Scheme 50. Radical cyclizations towards the guaianolide skeleton: a) (i) NaH (1.05 eq.), triethylphosphono-
acetate (1.05 eq.), Br2 (1.11 eq.), THF, 0 °C, 1 h; (ii) NaH (1.05 eq.), 175, THF, 0 °C to rt, 1 h, 72%, E/Z = 
17:83; b) AIBN (0.2 eq.), Bu3SnH (1.5 eq.), benzene, reflux, 2 h, 89%, dr = 87:13; c) DDQ (1.3 eq.), CH2Cl2, 
pH 7 buffer, rt, 4 h, 89%. 
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Under diluted radical generating conditions (AIBN, Bu3SnH) an E/Z-mixture of 183 (17:83) 
reacted to the tricyclic guaianolide scaffold 184. While comparing the remarkably high yield 
(89%) of this radical cyclization with the E/Z-ratio of the precursor it is clear, that both 
isomers can be cyclized.  
 
Deprotection of the PMB-group on the finalized core skeleton under standard conditions 
using DDQ gave rise to 185 in 89% yield (Scheme 50), which can be subjected to further 
functionalization (e.g. oxidation, esterification, glycosylation). 
 
Stork et al. have shown the synthetic value of vinyl radicals.[189,190] Based on this work it was 
recognized, that a fast inversion of the radical species between E- and the corresponding 
Z-isomer takes place. An explanation for this behavior is found in the analysis of the involved 
orbitals (Scheme 51). 
 
 
Scheme 51. Orbital inversion of vinyl radicals. 
 
The orbital hybridization of 186 and 188 with a bent structure is best described as sp2-hybrids: 
The unpaired electron is therefore found in a sp2-orbital and an angle of approximately 60 ° 
against the elongated C-C bond is included. 
The transition state of the radical inversion is best represented with the linear structure 187 
having a sp-hybridization and the unpaired electron located in a p-orbital perpendicular to the 
π-bond. The geometry of the radical center is highly influenced by the π-(C=C)-double bond 
and the σ-(C-R3)-single bond and a nearly linear assembly is assumed. Indeed, this 
assumption was proven by EPR-spectroscopy (especially for R3 = CO2H or Ph)[191] and a low 
inversion barrier for the interconversion of Z- and E-isomers is seen, resulting in a fast 
inversion of the vinyl radical.[192,193] Therefore, both isomers can take part in the cyclization 
reaction to give rise to the observed high yield of 89% in this transformation. 
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The mechanism for the cyclization reaction of 183 to 184 appears obvious, but there are two 
pathways possible, both leading to the same final product (Scheme 52): 
After initial radical formation, a reaction can take place directly with the opposite double 
bond present in 189 to form the observed product 184 via a 7-endo-trig cyclization. 
Also, an initial 6-exo-trig cyclization of 189 towards 190 is conceivable, providing a primary 
radical which can subsequently form the cyclopropinylcarbinyl radical 191. Rearrangement of 
this highly strained structure leads also to the isolated 7-endo-product 184. 
Although, radical trapping experiments in the presence of ethylacrylate as a possible 
scavenger were tried, the exact reaction mechanism remains unknown. 
 
 
Scheme 52. Possible radical cyclization mechanisms towards 184. 
 
The stereochemistry of the final product 184 was then determined by NOE-experiments 
where a clear coupling between 6a-3a, 6a-9a and 6a-CH2Si-protons is seen only for the major 
isomer. This is only possible in the cis-fused case, where these protons are found on the same 
side of the molecule. This preference (87:13) can be explained by a lower allover strain within 
the guaianolide core by a cis-fused cyclopentane ring system, where the final H-addition 
occurs from the top face of the molecule. 
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7.2 Ring closing metathesis approach 
Ring closing metathesis (RCM) is a versatile tool in organic chemistry and has already proven 
to be suitable for the formation of also unusual ring sizes. Its application in the total synthesis 
of guaianolides was shown by Ley et al. in their investigations on the Thapsigargins 
(see Scheme 20).[75,77] 
 
7.2.1 Hosomi-Sakurai allylation 
For the application of RCM, a diene system is needed, which is constructed in the next step 
by an Hosomi-Sakurai allylation of the lactone aldehyde 175.[155-158] This transformation is 
accompanied with the introduction of a new stereocenter in the northern sidechain, which is 
found in the final targets Cynaropicrin (123) and Ixerin X/Y (125/126) at the C4-position in 
the molecules (Figure 13).  
 
 
Figure 13. Stereochemistry of the natural products at the C4-position. 
 
While Ixerin X (125) and Ixerin Y (126) differ only in the stereochemistry at this position, 
many guaianolides show only α-configuration for this hydroxy functionality. A control of this 
stereocenter is therefore essential and is achieved by substrate controlled Hosomi-Sakurai 
allylation of lactone aldehyde 175 with different acyclic allylsilanes 192-194 (Scheme 53). 
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Scheme 53. Hosomi-Sakurai allylation of 175: a) Allylsilane (1.2-2.0 eq.), BF3⋅OEt2 (1.1 eq.), CH2Cl2, -78 °C, 
24 h, see Table 3. 
 
The allylated products were isolated in good yields, except for 197, which might be due to the 
fact that an instable bromo substituted silane 194 was used. For the allylsilanes that carry a 
substituent at C2-position (X = CH3, Br) a preference (up to 80:20) for the desired stereo-
chemistry (Table 3, entry 2-3) with respect to Cynaropicrin (123) and Ixerin Y (126) is 
observed. In contrast, the unsubstituted allylsilane 192 (R = H) gave only a 50:50 mixture of 
diastereomers (Table 3, entry 1). 
 
Table 3. Hosomi-Sakurai allylation. 
Entry Product R Yield [%] dr a 
1 195 H 73 50:50 
2 196 CH3 72 80:20 
3 197 Br   35 b 78:22 
a determined by 1H NMR; b 10 h, -78 °C, 41% aldehyde 175 
recovered. 
 
As we have learned from our earlier experiments on similar unsubstituted structures,[194] the 
new free hydroxy functionality is known to disturb the subsequent ring closing metathesis. 
To overcome this known problem, different protecting groups were installed in the next step 
to afford the RCM precursor dienes 198 (Scheme 54 and Table 4). 
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Scheme 54. Protection of the free hydroxy group to form RCM precursors 198a-d: a) see Table 4. 
 
Although being quite bulky, the TES-protection on this position led to good results in 
previous investigations on less substituted substrates.[194] Therefore it was assumed that this 
silyl protection might be suitable for 196 as well, which was achieved using TES-Cl in 68% 
yield (Table 4, entry 1). 
As a key step in the further synthesis the Tamao-Fleming oxidation of the silyl side chain was 
planned for which acidic conditions (HOAc, HBF4) will be needed (Scheme 64). Therefore, 
the necessity for an acid and fluorine stable protection arises. Acetyl-protection is known to 
be suitable for these conditions. Treatment of 195-197 with acetic anhydride yielded the 
corresponding protected RCM precursors in 80-99% yield. (Table 4, entry 2,3,4). 
A separation of the formed diastereomers is not possible at this stage of the synthesis and the 
mixture was used for the subsequent RCM reaction. 
 
Table 4. Protection of RCM precursors. 
Entry Product R Pg Reaction conditions Yield [%] a dr b 
1 198a CH3 SiEt3 TESCl (1.5 eq.), NEt3 (2.0 eq.), 
CH2Cl2, rt, 48 h 
68 80:20 
2 198b H Ac Ac2O (1.5 eq.), DMAP (0.1 eq.), 
NEt3 (1.5 eq.), CH2Cl2, rt, 24 h 
80 50:50 
3 198c CH3 Ac Ac2O (1.5 eq.), DMAP (0.1 eq.), 
NEt3 (1.5 eq.), CH2Cl2, rt, 24 h 
99 80:20 
4 198d Br Ac Ac2O (2.0 eq.), DMAP (0.1 eq.), 
NEt3 (2.0 eq.), CH2Cl2, rt, 16 h 
86 75:25 
a isolated yield; b determined by 1H NMR. 
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7.2.2 Ring closing metathesis 
With the protected dienes in hand, the guaianolide ring system was formed in the next step 
(Scheme 55). The formation of a highly substituted double bond in combination with the 
formation of a trans-annulated 7-membered ring system is still a challenging task. Therefore 
different catalysts (Figure 14) were screened while applying the already established inert gas 
sparging technique to remove the evolving ethylene from the reaction mixture.[194]  
 
OO
H
H
H
OPMB
SiMe2Ph
PgO
R
OO
H
H
H
OPMB
SiMe2Ph
PgO
R
a
198 4S-199
4S
ring closing
metathesis
 
Scheme 55. Ring closing metathesis: a) catalyst (3x5 mol% every 2 h), abs. toluene, inert gas (Ar or N2) 
sparging, 95 °C, 6 h. 
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Figure 14. Ring closing metathesis catalysts. 
 
The results of the RCM experiments are summarized in Table 5. Comparing the isolated 
yields, it becomes clear that Grubbs 1st gen catalyst 200 and Hoveyda-Grubbs 2nd gen catalyst 
202 are not suitable for this ring closing reaction. In contrast, Grubbs 2nd gen 201 and 
catMETium®[195] 203 completed the guaianolide skeleton in very good yield (77-94%) while a 
change in the diastereomeric ratio during the reaction is not observed. 
15 mol% of catalyst had to be employed to achieve good conversions, attempts to decrease 
the catalyst loading were not successful. 
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The RCM product 199c (R = CH3, Pg = TES, Table 5, entry 6) could not be separated from 
still remaining starting material 198a. Therefore, the sily-protecting group was removed by 
TBAF in situ after the reaction to afford the free alcohol as a more polar final product, which 
was now separable by chromatography. 
 
Table 5. Ring closing metathesis. 
Entry R Pg Product Catalyst Yield a 
1 H Ac 199a Grubbs 2nd gen 201 82% (75% 4S, 90% 4R) 
2 CH3 Ac 199b Grubbs 1st gen 200 7%b 
3 CH3 Ac 199b Grubbs 2nd gen 201 94% (93% 4S) 
4 CH3 Ac 199b Hoveyda-Grubbs 2nd gen 202 43% c 
5 CH3 Ac 199b catMETium® 203 78% (82% 4S)  
6 CH3 TES 199c Grubbs 2nd gen 201 77% d 
a isolated yield, dr did not change during reaction; b 87% starting material isolated; c 57% starting material 
isolated; d isolated yield of free alcohol after TBAF deprotection, dr = 80:20. 
 
A big advantage of the acetyl-protection is found in the fact that the RCM reaction can easily 
be monitored by TLC as the precursors 198b/c and the corresponding products 199a/b show 
different Rf-values. A further important feature of the acetyl protected RCM products is the 
possibility to separate the diastereomers, resulting from the initial Hosomi-Sakurai allylation 
(Scheme 53). This provides access to diastereomeric pure materials which is essential for the 
further synthesis. 
Compound 199a, lacking the methyl group at the C6-position could provide a direct entry 
towards the Cynaropicrin skeleton 207 (Scheme 56). Hydroboration of the trisubstituted 
double bond should introduce a hydroxy group on the less substituted C6-position in 204, 
which could be further oxidized to the corresponding ketone 205. 
 
 
Scheme 56. Proposed strategy towards the Cynaropicrin skeleton 207. 
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A Wittig reaction as reported in the Vanderwalle synthesis of (±)-Compressanolide (44) 
(Scheme 9)[3,62] or in Rigby´s synthesis of (±)-Estafiatin (4) (Scheme 13)[69] would introduce 
the exo-methylenic double bond in 206 at the C6-position and further transformations in the 
cyclopentane ring could afford the Cynaropicrin skeleton 207. This promising synthetic 
sequence remains to be explored. 
 
The bromo-substituted precursor diene 198d opens the possibility to generate the guaianolide 
skeleton 199d via RCM reaction (Scheme 57, top). The incorporated vinylbromide at the 
7-membered ring system would allow further transformations and functionalization 
(e.g. palladium coupling) at this position. 
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H
H
OPMB
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SiMe2Ph
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H
H
OPMB
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PhMe2Si
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H
H
H
OPMB
SiMe2Ph
AcO
Br
radical cyclization
or intramolecular
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a
b or c
RCM
198d
199d
208  
Scheme 57. Ring closing attempts on 198d: a) Grubbs 2nd gen 201 (3x5 mol%), abs. toluene, N2-sparging, 
95 °C, 6 h; b) Bu3SnH (1.5 eq.), AIBN, toluene, reflux, 1 h; c) Pd(PPh3)4 (20 mol%), K2CO3 (5.0 eq.), CH3CN, 
reflux, 18 h. 
 
In contrast to the good results obtained above (Table 5), all attempts to successfully achieve a 
RCM reaction on the bromo-substituted diene precursor 198d failed, and only starting 
material was recovered. 
Because of the vinylic-bromide present in 198d, this compound is suitable for other ring 
closing strategies (Scheme 57, bottom): Unfortunately, intramolecular radical cyclization 
using the standard Bu3SnH/AIBN protocol, as well as the application of standard 
intramolecular Heck-reaction conditions resulted only in decomposition or dehalogenation of 
the starting material and no ring closing to tricyclic systems like 208 was observed. 
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7.3 Synthesis of a 3x3 scaffold library 
To explore the scope and limitations of this approach towards the skeleton of the 
guaianolides, a small combinatorial library around the backbone motif 209 was constructed 
(Figure 15). Utilizing a short five step sequence, a set of interesting scaffolds found in several 
classes of natural products is accessible starting from cyclopropylcarbaldehyde (-)-130 and 
various allylsilanes 211. Also hybrid structures, which combine typical structural features of 
guaianolides and their derivatives within the same molecule, are accessible and provide a 
highly diverse oriented synthesis of natural product related core structures. 
 
 
Figure 15. Design and retrosynthesis of a scaffold library. 
 
The allylsilanes used for the allylation reactions are given in Figure 16: If not commercially 
available, the reactants are accessible within one or two steps. 
 
 
Figure 16. Allylsilanes 211 used for synthesis. 
 
Reaction of linear and cyclic allylsilanes 211a-c with cyclopropylcarbaldehyde (-)-130 
resulted in the allylated products 212a-c (Scheme 58) with high diastereoselectivity. These 
materials proved to be sensitive to heat and traces of acid. Therefore, it was not possible to 
purify these compounds by chromatography or distillation, but nevertheless, after simple 
extraction the material was sufficiently pure for the lactonization step without further 
purification. 
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Scheme 58. Synthesis of lactone aldehydes 210: a) allylsilane (1.1 eq.), BF3⋅OEt2 (1.1 eq.), CH2Cl2, -78 °C, 
18 h; b) Ba(OH)2⋅8H2O (0.55 eq.), MeOH, 0 °C, 5 h. 
 
Base induced retro-aldol lactonization gave directly rise to the lactone aldehydes 210a-c in 
moderate yields, but with excellent selectivity (Scheme 58, Table 6). The stereoselectivity in 
the nucleophilic additions to cyclopropyl substituted aldehydes and the lactone aldehydes has 
been discussed in detail before (see Scheme 42). 
 
Table 6. Synthesis of lactone aldehydes. 
Entry Allylsilane Product Yield [%] a dr b 
1 211a 51 95:5 
2 211b 
210b
OO
CHO
H
H
50 96:4 
3 211c 
OO
CHO
H
H
H
210c
45 95:5:0:0 
a isolated yield over 2 steps; b determined by 1H NMR. 
 
On the lactone aldehydes 210a-c the same allylsilanes 211a-c (Figure 16) were used in a 
second Hosomi-Sakurai allylation (Scheme 59). Subsequent acetyl-protection of the crude 
products afforded the protected precursor dienes 213a-i for the ring closing metathesis key 
step (Table 7). The allylation introduces new stereocenters in the northern sidearm and a 
separation of the resulting diastereomers was not possible at this stage of the synthesis. 
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Scheme 59. Completion of the library: a) (i) allylsilane (1.50 eq.), BF3⋅OEt2 (1.15 eq.), CH2Cl2, -78 °C, 18 h; (ii) 
Ac2O (1.50 eq.), DMAP (10 mol%), NEt3 (1.75 eq.), CH2Cl2, rt, 18 h; b) 3x5 mol% Grubbs 2nd gen catalyst 201, 
toluene, N2-sparging, 95 °C, 6 h. 
 
The central 7-membered ring was constructed by applying ring closing metathesis. Since 
Grubbs 2nd generation catalyst 201 already proved to be most efficient for this kind of 
transformation,[187] 3x5 mol% were used in the optimized procedure in combination with the 
N2-sparging technique.[194] The results for the RCM reaction are summarized in Table 8.  
 
Table 7. Synthesis of precursors 213a-i for ring closing metathesis. 
Entry Aldehyde Allylsilane Product a Yield [%] b  dr c 
1 210a 211a 
OO H
H
AcO
213a  
67 73:27 
2 210a 211b 
OO H
H
AcO
213b  
49 67:33 
3 210a 211c 53 82:18:0:0
continued 
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Table 7. continued. 
Entry Aldehyde Allylsilane Product a Yield [%] b  dr c 
4 210b 211a 
OO H
H
AcO
213d  
73 77:23 
5 210b 211b 
OO H
H
AcO
213e  
57 70:30 
6 210b 211c 
OO H
H
AcO
213f
H
59 79:21:0:0 
7 210c 211a 
OO H
H
AcO
H
213g  
57 80:20 
8 210c 211b 
 
47 70:30 
9 210c 211c 
OO H
H
AcO
H
213i
H
 
53 >99:1:0:0 
a major isomer shown; b isolated yield over two steps; c determined by 1H NMR. 
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All precursors 213 cyclized to the desired RCM-products 209 except 213a, leading to an 
inseparable mixture of unknown, partially polymeric products during the course of the 
reaction. In this case, the only disubstituted double bond would be formed within this set of 
compounds, resulting in a reactive alkene 209a, which might be able to undergo further 
metathesis steps such as ring opening polymerization (ROMP). In all successful cases, the 
diastereomeric ratio before and after cyclization remained the same. Only for 213f the major 
diastereomer seems to react with high preference, since only one isomer of 209f was isolated 
from the reaction mixture. 
 
Table 8. Results of ring closing metathesis. 
Entry Product a Yield [%] (dr) b Entry Product a Yield [%] (dr) b 
1 
OO H
H
AcO
209a  
- (-) 6 
OO H
H
AcO H
209f  
78 (>99:1) 
2 
OO H
H
AcO
209b  
96 (68:32) 7 
OO H
H
AcO
H
209g  
87 (79:21) 
3 
 
76 (84:16) 8 
OO H
H
AcO
H
209h  
96 (72:28) 
4 
OO H
H
AcO
209d  
93 (80:20) 9 
 
48 (>99:1) 
5 
 
91 (75:25) 
   
a major isomer shown; b isolated yield, dr determined by 1H NMR. 
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The yield of the ring closing reaction is constantly high (76-96%), with the exception of 209i, 
which was isolated in a yield of only 48% probably due to steric reasons. Compound 209i is 
of special interest, since it can be seen as a hybrid structure, combining the northern and the 
southern cyclopentane ring present in various guaianolides within one molecule (Figure 20). 
Investigating the stereochemistry of 209c, 209f and 209i at the 4a-position at the northern 
cyclopentane ring proved to be difficult: The NOE experiments did not allow a clear 
interpretation, because the complex multiplet structures of the protons 3a (chosen as point of 
reference) and 4a (Figure 17) are found to be very close in their chemical shift and their 
NMR-signals overlap with other complex multiplets of diastereotropic protons. 
 
 
Figure 17. Unsuccessful NOE experiments to determine the stereochemistry at the 4a-position. 
 
The RCM-products 209f and 209i were isolated as single diastereomers (Table 8) and both 
crystallized from diethylether in colorless needles which were suitable for X-ray experiments. 
 
   
Figure 18. X-ray structure of 209f. 
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The X-ray structures of 209f (Figure 18) and 209i (Figure 19) clearly show the all trans-
configuration of the central 7-membered ring system and prove the stereochemistry at the 4a-
positions. Unfortunately, 209c did not render crystalline, but because of the very close 
structural relation, it can be assumed that here the same configuration at the 4a-position is 
present as the major product. 
 
  
OO H
H
AcO
H
H
209i  
Figure 19. X-ray structure of 209i. 
 
The bicyclic structures 209b,d,e represent very interesting derivatives of the xanthanolide 
backbone. Xanthatin (214) (Figure 20) is a very prominent member of this class of natural 
products and shows promising antibacterial activity against methicillin-resistant 
Staphylococcus aureus (MRSA)-strains.[196] The more linear 5,7,5-ring systems of 209c,f is 
envisioned to be a skeleton similar to pseudo-guaianolides as for example Britanin (215), a 
compound isolated from Inula britannica wild[197] and Inula caspica.[198] The tricyclic 
structures 209g,h display interesting derivatives of the guaianolide scaffold, providing the 
possibility for the synthesis of further natural product analogues. 
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Figure 20. Biological active xanthanolides and pseudoguaianolides. 
 
In summary, a small library consisting of eight new core structures was synthesized, including 
interesting structural motifs of various γ-butyrolactone containing natural products. 
The allylation with commercially available or easily accessible allylsilanes introduces 
diversity at two points during this synthesis: 
• allylation of the cyclopropylcarbaldehyde 130 results in the possibility of controlling 
the ring size and/or substitution pattern in the southern part of the molecules. 
• allylation of the lactone aldehyde provides the chance to control also the ring size 
and/or substitution of the northern part. 
Finally, a third point of diversity can be introduced by acylation of the hydroxy group at the 
C4-position: It is known, that different ester groups (e.g. derived from angelic acid, butyric 
acid, (S)-2-methylbutyric acid, senecioic acid) are present at this particular position in many 
natural products of the guaianolide family.[75,77] 
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8. Towards Cynaropicrin and Ixerin Y  
The ring closing metathesis reaction finalized the synthesis of the guaianolide skeleton and 
afforded already highly functionalized compounds that seem to be suitable for further 
conversion towards the target molecules. 
 
8.1 Inversion of the C4-stereocenter 
Since the Hosomi-Sakurai allylation of the lactone aldehyde 175 (Scheme 53) proceeded only 
in moderate selectivity (80:20), it is of great interest to find a way to transform the minor 
diastereomer into an intermediate that is useful for the further synthesis of Cynaropicrin (123) 
or Ixerin Y (126). This can be achieved by an inversion of the stereocenter on the C-4 position 
of the minor isomer 4R-199 resulting from the RCM reaction. 
 
8.1.1 Mitsunobu reaction 
A standard procedure for this inversion is the Mitsunobu reaction, providing a powerful tool 
for the transformation of stereogenic centers in natural product synthesis. 
In a first step, the acetyl-protection in the minor isomer 4R-199 was removed to release the 
free secondary alcohol 4R-216 in 75% yield (Scheme 60). Following the standard protocol for 
the inversion of secondary alcohols, 4R-216 was treated with excess diethylazodicarboxylate 
(DEAD), triphenylphosphine and various acids (Table 9). 
 
OO
H
H
H
OPMB
SiMe2Ph
RO
OO
H
H
H
OPMB
SiMe2Ph
O
O
R
b
Mitsunobu reaction
4R-199: R = Ac
4R-216: R = H
4S-199a
4R 4S
 
Scheme 60. Mitsunobu reaction to invert the C4-stereocenter: a) K2CO3 (0.55 eq.), MeOH, 0 °C-rt, 24 h, 75%; 
b) R-CO2H (4.4 eq.), DEAD (5.0 eq.), PPh3 (5.0 eq.), THF, rt, 24 h.  
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Table 9. Mitsunobu reaction. 
Entry acid pKa Yield [%] 
1 acetic acid 4.75 - a 
2 benzoic acid 4.20 - a 
3 p-nitro-benzoic acid 3.44 - a 
a no conversion. 
 
First, acetic acid was used in the Mitsunobu reaction, since this could directly afford the major 
acetyl protected isomer 4S-199 (R = CH3) isolated from the RCM reaction (Scheme 55). 
Since this attempt failed, stronger acids were used, but here also only starting material was 
recovered after work-up (Table 9). 
 
8.1.2 Oxidation/Reduction approach 
Because the Mitsunobu approach failed, an attempt was made to achieve the inversion on the 
C4-position by an oxidation/reduction sequence (Scheme 61). The free hydroxy group in 
4R-216 was oxidized by PCC to the ketone 217 in 75% yield. 
 
 
Scheme 61. Oxidation/Reduction approach: a) PCC (1.5 eq.), 4 Å MS, CH2Cl2, rt, 5 h, 75%; b) CeCl3 (1.3 eq.), 
NaBH4 (1.3 eq.), MeOH, -5 °C, 30 min, 82%. 
 
The subsequent Luche-reduction[199] using NaBH4/CeCl3 was predicted to be substrate 
controlled by an attack from the less hindered face of the molecule. Indeed, only one 
diastereomer was isolated in 82% yield from this reaction, unfortunately showing the same 
configuration at C4-position as the starting material 4R-216. Therefore, an inversion is also 
not possible via this route. 
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8.2 Investigations on epoxidations 
In some guaianolides such as Arglabin (1) or the closely related Arborescin (107), an epoxide 
at the 7-membered ring junction at 6-6a-position is present showing α-configuration leading 
to a trans-annulation of the cyclopentane ring system (Figure 21). 
 
 
Figure 21. Epoxides in various guaianolides and proposed directing effect in 218. 
 
In earlier studies on similar structures, it was recognized that there is a preference for 
epoxidation from the undesired β-face of the molecule.[172,200] To overcome this problem, a 
homoallylic alcohol substituent as shown in 218 (Figure 21) is envisioned to direct the 
epoxidizing agent (such as mCPBA) to approach from the α-face.[201] Furthermore, the bulky 
SiMe2Ph-group pointing to the top face of the molecule can presumable shield the upper half 
space allowing the attack only from the less hindered down face as seen in Ando´s synthesis 
of (+)-Arborescin (107), Scheme 26). 
To generate the desired homoallylic alcohol moiety, the PMB protection in 4S-199 was 
removed in 90% yield, using DDQ in order to release the free hydroxy group at the 
C8-position in 218 (Scheme 62). 
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Scheme 62. Deprotection and epoxidation: a) DDQ (1.2 eq), CH2Cl2/H2O, rt, 2 h, 90%; b) mCPBA (1.7 eq), 
CH2Cl2, 0 °C-rt, 24 h, 96%, α-219:β-219 = 20:80. 
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Reaction of 218 with mCPBA at ambient temperature afforded an inseparable mixture of 
α-219 and β-219 epoxide in a ratio of 1:4, respectively. The stereochemistry of the resulting 
products was determined by NOE-experiments and a clear crosspeak between the protons of 
the CH3-group on the C6- and the proton on C4-position of the major isomer β-219 is 
detected (Scheme 62, right). This indicates the close distance of these protons, which is only 
possible for the undesired β-219. The high preference for the cis-fused ringsystem is 
indicating that there is no directing effect based on the homoallylic alcohol system or the 
shielding by the SiMe2Ph. 
An alternative epoxidizing agent known to be suitable for acyclic homoallylic alcohols is 
provided with V(O)(acac)2/tert-butylhydroperoxide systems, but remains to be tested on this 
substrate.[202] 
 
8.3 Tamao-Fleming oxidation 
In addition to retro-aldol lactonization and ring closing metathesis, a further essential key step 
in the projected syntheses of Cynaropicrin (123) and Ixerin Y (126) is the transformation of 
the silyl side chain into a primary alcohol. Procedures for this conversion of high synthetic 
value were developed in parallel by the groups of K. Tamao[203,204] and I. Fleming.[205,206] 
 
 
Figure 22. Comparison of the Tamao and Fleming system. 
 
The difference in their systems is found in the substitution pattern at the silicon atom: Tamao 
and his co-workers used a silyl group that already carries a nucleofugal group such as a 
halogen, oxygen or nitrogen substituent (Figure 22, left). Considering the fact that these 
groups are already reactive functionalities, they are usually not suitable to be carried through 
many steps within the synthesis and have to be converted immediately after their 
introduction.[207] In contrast to this, the group of Fleming used silyl groups, fully substituted 
Main Part 
 
77
by carbon ligands, which are much more robust and can be converted into the corresponding 
alcohols by oxidation at any appropriate stage (Figure 22, right).[205,208]  
This can turn for example the phenyldimethylsilyl group into a masked alcohol, marking the 
position of a future hydroxy functionality. The PhMe2Si-group is sterically bulky and 
relatively unreactive under most conditions commonly used in organic synthesis. It possesses 
no lone pairs to coordinate with Lewis acids and with four tetrahedrally arranged substituents 
it shows a very low dipole moment without having the possibility of hydrogen bond 
formation.  
To conclude, the Fleming system, utilizing a PhMe2Si group, behaves chemicaly opposite to a 
free or protected OH-group (small, electronegative, Lewis base and/or a Brønsted acid, 
contributes a substantial dipole moment to the polarity, forms strong H-bonds). Furthermore, 
its electronic influence on adjacent groups is rather electron donating than electron 
withdrawing. 
The PhMe2Si group is easily introduced into a molecule either as an electrophile 
(phenyldimethylsilylchloride (PhMe2SiCl)) or as a nucleophilic reagents (e.g. bis(phenyl-
dimethylsilyl)cuprate (Cu(PhMe2Si)2), PhMe2SiCH2MgCl). Due to its robustness and the 
different ways of introduction, the phenyldimethylsilyl-group has already found several 
applications in synthetic work.[209-212] 
The mechanism of the Fleming oxidation is illustrated in Scheme 63: In a first step the phenyl 
substitutent in 220 has to be exchanged by aromatic electrophilic substitution using 
electrophiles such as a proton, mercuric ion or bromine to form the more reactive intermediate 
221, comparable to the Tamao system (see Figure 22, left). 
 
 
Scheme 63. Fleming oxidation of phenyldimethylsilyl group. 
 
After displacement by peracid, the peroxocompound 222 rearranges to 223 and subsequent 
protic work-up releases the desired alcohol 224 with retention of configuration. 
Many different protocols for the Fleming oxidation are reported in literature, but performing 
the whole sequence as a one-pot reaction[213] is most desirable and even procedures catalytic 
in mercury are reported.[205] 
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The first attempts to apply the standard Fleming conditions (HBF4, mCPBA or KBr/peracetic 
acid) on substrate 4S-199 failed to afford the free alcohol and only decomposition of the 
starting material was observed, which might be due to the strong acidic conditions needed 
(Scheme 64, Table 10, entry 1-2). 
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Scheme 64. Fleming oxidation of 4S-199: a) see Table 10. 
 
Using an acetic anhydride/H2SO4/H2O2 mixture yielded 225 in moderate yield along with 
some acetyl protected material 226. This might be due to the excess of acetic anhydride used. 
The best results for this transformation were obtained by the application of 
Hg(OAc)2/peracetic acid as an oxidizing system (Table 10, entry 4). 
 
Table 10. Results of the Fleming oxidation of 4S-199. 
Entry Reaction conditions Yield [%]a 
1 HBF4, mCPBA - 
2 KBr, HO2Ac, NaOAc, HOAc - 
3 Ac2O, H2SO4, H2O2, HOAc, Hg(OAc)2 (1.6 eq.) 46b 
4 HO2Ac, Hg(OAc)2 (1.25 eq.) 70 
5 HO2Ac, Hg(OAc)2 (0.3 eq.), Pd(OAc)2 (0.1 eq.) -c 
a isolated yield, b additionaly acetyl-protected product 226 isolated in 10% yield, c 
product 225 was formed initially, but decomposed over time. 
 
The use of stoichiometric mercury is necessary, since the protodemercuration of arylmercuric 
salts, which is important for the regeneration of the mercury ions, is slower than the 
protodesilylation of arylsilanes.[214] Furthermore, arylmercuric salts are known to be 
unreactive towards oxidizing agents and can therefore not be recovered by oxidation.[215] 
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An environmental and economical goal is to find suitable conditions to render this process 
catalytic in mercury: Pd(OAc)2 is known to help to recover Hg(OAc)2 from the corresponding 
arylmercury compounds[216] and the resulting arylpalladium species are readily oxidized by 
peracids.[217] For this reason, Fleming et al. developed a catalytic one-pot procedure,[205] and 
the proposed catalytic cycle is illustrated in Figure 23. 
 
 
Figure 23. Catalytic cycle for mercurydesilylation. 
 
Mercurydesilylation of RSiMe2Ph substitutes the phenyl ring at the silicon by acetate, which 
is then oxidized and rearranged to the desired free alcohol. Within this process Hg(OAc)2 is 
transformed into the corresponding arylmercury compound PhHgOAc, from which the phenyl 
ring is then transmetalated into the palladium acetate. This recovers the Hg(OAc)2, which 
enters the catalytic cycle again. Subsequent oxidation to Pd(OAc)2 by peracetic acid releases 
PhOAc and finishes the catalytic cycle. 
 
These reaction conditions catalytic in mercury and palladium were applied onto 4S-199 and 
resulted in an initial formation of the desired product 225 as determined by TLC on 
comparison with an authentic sample of 225. After complete consumption of the starting 
material, the product started to decompose and no material could be isolated from this 
reaction (Table 10, entry 5). 
As mentioned before (Scheme 62) the double bond present in 199 can be epoxidized, and 
during the Fleming oxidation also an epoxidation at the 6-6a-positions is observed. The 
stereochemistry of the resulting epoxide was determined by NOE-experiments and a clear 
cross signal for the CH3 group on C6- and the proton at C4-position was detected, which is 
only possible if both are located on the same side of the molecule (Scheme 64). 
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Scheme 65. Protecting group transformation: a) Ac2O (2.0 eq.), NEt3 (2.0 eq.), DMAP (10 mol%), CH2Cl2, rt, 
16 h, 99%; b) DDQ (1.5 eq.), CH2Cl2/H2O, rt, 5 h, 90%. 
 
The proof for all stereocenters present was obtained with the X-ray structure of 227 (Figure 
24), which was accessible by acetyl-protection of the free primary alcohol 225 and subsequent 
PMB deprotection following the standard DDQ protocol to afford the free secondary alcohol 
227 in 90% yield (Scheme 65). 
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Figure 24. X-ray structure of 227. 
 
The crystal structure of 227 reveals the all-trans-configuration along the hydroazulene core 
skeleton as found in the final natural products. The acetoxy-substituent on C-4 is oriented to 
the same side as the proton on the 3a-position. Also the stereochemistry of the epoxide on the 
6-6a-position is shown to be β-oriented, resulting in a cis-fused cyclopentane ring system. 
4 
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The additional epoxidation reaction observed during the Fleming oxidation does not have to 
be seen as a disadvantage, although no such functionality is found at this position in 
Cynaropicrin (123) and Ixerin Y (126): This epoxide might act as a protecting group for the 
double bond during the elimination reactions investigated later on (Figure 26).  
 
8.4 Oxidation at the C8-position 
A common feature often found in various guaianolides is a keto-functionality at the 
C8-position in the molecule as for example seen in the structures of the Chinensiolides A-C 
228-230 (Figure 25). These compounds were isolated from Ixeris chinensis Nakai 
(Compositae),[218-220] also known as Siyekucai, a plant which is used in Chinese folk medicine 
for the treatment of bronchitis, pneumonia, pharyngitis, dysentery and poisonous indigestions. 
 
 
Figure 25. Guaianolides isolated from siyekucai (Ixeris chinensis). 
 
A possible way to introduce this keto-functionality at this position is the oxidation of the 
secondary alcohol present in 227. The application of the standard PCC protocol oxidized the 
hydroxy group to the desired keto-functionality in 231 (Scheme 66). 
 
 
Scheme 66. Oxidation of the secondary alcohol: a) PCC (1.3 eq.), 4 Å MS, CH2Cl2, 5 h, rt, 80%. 
 
This reaction is accompanied by the opening of the epoxide, generating the tertiary allyl 
alcohol 231 in 80% yield. The stereochemistry at the C6-position is defined by the starting 
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epoxide and is in the same configuration as found in the natural products 228-230. The 
resulting material is only barely soluble in most organic solvents, except acetonitrile. 
Hydrogenation of the now introduced double bond in 231 and elimination within the still 
acetyl-protected side chain can set the stage for the synthesis of interesting members of the 
chinensiolide family. Since nearly all stereocenters are already set in 231 with respect to the 
natural products, functional group transformation in the cyclopentane ring and subsequent 
α-methylenation could lead to the final natural products. 
 
8.5 Elimination reactions 
The next essential step towards the target molecules Cynaropicrin (123) and Ixerin Y (126) is 
the introduction of a double bond at the cyclopentane ring. With the various hydroxy 
functionalities set in place regioselective elimination should introduce the desired C=C-
double bonds at the appropriate positions. 
 
8.5.1 Elimination reactions towards Cynaropicrin 
An exo-methylene double bond is found in the Cynaropicrin core skeleton 123 at the 
C9-position. To introduce this functionality the primary hydroxy group in the side chain of 
225 was transformed into a suitable leaving group (Scheme 67).  
 
 
Scheme 67. Elimination towards Cynaropicrin: a) Tf2O (1.2 eq.), pyridine (4.0 eq.), CH2Cl2, 0 °C, 24 h; 
b) MesCl (3.0 eq.), NEt3 (4.0 eq.), CH2Cl2, 0 °C, 2 h, 92%; c) TsCl (4.0 eq.), pyridine (8.0 eq.), CH2Cl2, rt, 24 h, 
66%; d) NaI (2.0 eq.), DBU (4.0 eq.), 35-100 °C, 5 h, 55%. 
 
Attempts to achieve elimination by using the Tf2O/pyridine system to generate the triflate 232 
failed and resulted in complete decomposition. To investigate milder reaction conditions, the 
mesylate 233 was formed successfully in a yield of 92%. 
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In contrast to this, tosylation resulted only in a moderate yield (66%) of 234, which might be 
due to steric reasons. The application of standard elimination conditions (NaI, DBU) on both 
compounds 233 and 234, respectively, transformed only the tosylated precursor into the 
corresponding exo-methylenic compound 235. 
The chemical shifts (1H and 13C NMR) of the so introduced C=C-double bond were compared 
with these of a sample of originally isolated Cynaropicrin (123)[221] and matched the reported 
values exactly. 
What remains to be tested is the selective epoxide opening in 235 to introduce the second exo-
methylenic group at the C6-position, which is needed for the final natural product 123. 
 
 
Scheme 68. Epoxide opening on substrates similar to 235: a) Lithium dicyclohexylamide, cyclohexylmagnesium 
bromide, DME, 237: 23%, 238: 74%. 
 
There are quite a number of methods reported in literature to selectively perform this 
transformation on very similar substrates with high regioselectivity. An example for the 
regioselective opening of epoxide 236 is given in Scheme 68, where a high preference for the 
desired structure 238 is found.[222,223] 
Final desoxygenation following the Barton-McCombie protocol, which is also known to be 
suitable for tertiary alcohols,[224-229] would remove the hydroxy group. Due to ring strain the 
desired thermodynamically more stable cis-fused cyclopentane ring system as found in 123 
should form. This assumption is also confirmed by the results obtained for the radical 
cyclizations (Scheme 52) where also a high preference for the cis-annulation is observed. 
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8.5.2 Elimination reactions towards Ixerin Y 
The elimination towards Cynaropicrin (123) can only result in one regioisomer (elimination 
of a primary alcohol, Scheme 67). In contrast to this is the elimination of a secondary alcohol 
239 towards Ixerin Y (126) accompanied by two problems (see Figure 26):  
i) unfavoured syn-elimination due to the trans-substitution pattern in the cyclopentane 
ring affording the Ixerin Y (126) scaffold. 
ii) preference for a formation of a conjugated system with already present C=C-double 
bond towards 240. 
 
 
Figure 26. Problems within the elimination towards Ixerin Y (126). 
 
As mentioned before (Scheme 64), the problem of forming a conjugated system with the 
C=C-double bond at the 6-6a-position disappears when this functionality is “protected” as an 
epoxide. 
The first attempt to introduce the desired double bond in the cyclopentane ring was made on a 
20:80 mixture of α-/β-219 (Scheme 69). The Tf2O/pyridine system, known to undergo cis-
elimination, has proven to be suitable for this transformation on similar substrates and should 
afford preferentially 242 rather than 241.[172] 
 
OO
H
H
H
OH
SiMe2Ph
AcO
OO
H
H
H
SiMe2Ph
AcO
OO
H
H
H
SiMe2Ph
AcO
+a
219
O O O
243 242
OO
H
H
H
SiMe2Ph
AcO
O
HH
: = 20:80
241
found: expected, but not found:
+
 
Scheme 69. Elimination on 219 (α:β = 20:80): a) Tf2O (2.0 eq), pyridine (6.0 eq), CH2Cl2, 0 °C-rt, 24 h, 13%. 
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Treating 219 with Tf2O and pyridine at 0 °C afforded a mixture of various products. The 
cyclopropanated product 243 was isolated as the only characterizable compound and was set 
for crystallization. This afforded a single crystal that was suitable for X-ray crystallography 
(Figure 27). 
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Figure 27. X-ray structure of 243. 
 
As seen in the X-ray structure of 243 (Figure 27) no elimination has taken place, but instead a 
1´-silyl-cyclopropane ring has formed pointing to the β-face of the molecule. Furthermore, the 
structure shows the bulky phenyldimethylsilyl-group being positioned on the sterically more 
favored exo-position which is oriented away from the rest of the molecule. 
Similar reactions are reported by Schaumann et al., who used appropriate tosylates and strong 
bases for the formation of 1-silyl-substituted cyclopropanes.[230] A possible mechanism for 
this reaction is proposed in Scheme 70: 
 
 
Scheme 70. Proposed mechanism for the formation of 243. 
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The secondary alcohol 219 reacts with Tf2O to form the corresponding triflate 244. Excess of 
pyridine deprotonates in α-position to the silicon atom (α-effect of Si) and an attack of the 
corresponding anion 245 from the top face substitutes the triflate to generate 243. 
 
A further attempt on the elimination reactions towards Ixerin Y (126) was made on substrates, 
where the phenyldimethylsilyl-group was converted to the corresponding alcohol. 
The primary alcohol in the sidechain of 225 was acetyl- or TBDMS-protected and the PMB 
protection was removed by DDQ to afford the free secondary alcohols 227 and 247 in good 
overall yield (Scheme 71). 
 
 
Scheme 71. Protecting group transformations: a) TBDMSCl (3.0 eq), NEt3 (3.5 eq.), DMAP (10 mol%), CH2Cl2 
rt, 24 h, 80%; b) R = Ac: DDQ (1.5 eq.), CH2Cl2/H2O, rt, 5 h, 90%; R = TBDMS: DDQ (1.25 eq.), CH2Cl2/pH7 
buffer, rt, 3 h, 88%; c) MesCl (3.0 eq.), NEt3 (4.0 eq.), CH2Cl2, 0 °C, 1 h, 94%; d) NaI (2.0 eq.), DBU (4.0 eq.), 
100 °C, 5 h. 
 
On the acetyl protected 227 the free hydroxy group was transformed into the corresponding 
mesylate 248 to generate a good leaving group, but the application of elimination conditions 
(NaI/DBU) did not lead to the eliminated products 249 or 250. 
Changing the strategy, 227 and 247 were subjected to the Tf2O/pyridine elimination protocol, 
but for the acetyl protected precursor 227 only decomposition was observed (Scheme 72). 
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Scheme 72. Elimination towards Ixerin Y (126): a) Tf2O (2.0 eq.), pyridine (5.0 eq.), CH2Cl2, -10 °C-rt, 16 h. 
 
The same elimination conditions applied on the TBDMS protected precursor 247 afforded a 
highly unstable material (presumably the corresponding triflate 251), which decomposed upon 
concentration during isolation, but did not release the products 252 or 253, respectively, even 
on elevated temperatures. 
Although similar elimination reactions on related structures proofed successful, an analogues 
transformation on the substrates described here was not achieved. 
Alternatives to perform this syn-elimination is seen in the application of the Chugaev-
conditions,[231,232] were the free hydroxy group in 227 or 247 is transformed into the 
corresponding xanthogenates 254 (Scheme 73, top), to undergo subsequent elimination. Also 
Burgess reagent[233] (see Estafiatin (4) synthesis by Vandewalle (Scheme 10)) should 
transform 227/247 under mild conditions into 255 (Scheme 73, bottom). Selective syn-
elimination should than also lead to the desired products. These reactions remain to be tested 
on these substrates. 
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Scheme 73. Chugaev-reaction and application of Burgess-reagent. 
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9. Stereoselective Synthesis of small molecule HAT 
Inhibitors 
The complex of DNA and certain proteins is called chromatin and is basically organized in 
three levels: DNA wrapping around nucleosomes (“beads on a string structure”), 30 nm 
condensed chromatin fiber (consisting of nucleosome array in their most compact form) and 
higher level DNA packing into the metaphase chromosome (Figure 28). 
 
          
Figure 28. DNA packing and nucleosome structure. 
 
Although other chromosomal proteins have important roles too, the fundamental building 
blocks of eukaryotic chromatin are the histone proteins and the nucleosomes they form with 
DNA. The core of the nucleosomes consists of highly conserved histone proteins (two copies 
of H2A, H2B, H3 and H4) forming a disc shaped molecule. The H1 protein is bound to the 
outside, closing the complex and interacting with other nucleosomes. 
The basic histone-proteins consist of a DNA-interacting globular region and approximately 
20-40 more flexible termini, which extend from the globular domains. The N-termini show 
positively charged lysine groups, important for interaction with charged phosphates in DNA 
or neighboring nucleosomes. Furthermore, the chromatin is subject to a vast array of 
posttranslational modifications, where especially the lysine-residues are known to undergo 
reversible acetylation, thereby regulating access to the underlying DNA. These modifications 
contribute to the so called “Histone-Code”-hypothesis, referring to the assumption that the 
modification of the histone tails creates a substitution pattern, which is recognizable for 
certain regulatory proteins.[234] These can create a connection between histone modification 
and cellular processes like activation or repression of transcription.[234-237] 
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A control of histon-acetyltransferases (HATs) and histon-deacetylases (HDACs) is thus of 
great importance for investigations of the „Histon-Code“ but offers also interesting novel 
targets for pharmaceutical industry.[238-241] 
 
In their ongoing investigations on histon-modifying enzymes Giannis et al.[242] reported the 
design, synthesis and biological evaluation of a selective small-molecule inhibitor (±)-256 for 
the histone acetyltransferase Gcn5.  
Based on the assumption that acetyl-CoA has to bind to Gcn5 first to make the binding pocket 
accessible, a ternary complex consisting of HAT-enzyme, acetyl-CoA and the histone protein 
is formed (Figure 29, A).[243-245] 
 
 
Figure 29. Comparison of binding of natural substrate and small-molecule inhibitor (±)-256.[242] 
 
The highly conserved glutamic acid Glu-173 is assumed to activate the lysine side chain of 
the approaching histone protein and facilitates the attack of the neighboring thioester of 
acetyl-CoA (Figure 29, A). A hydrogen bond to the backbone amide of Cys-177 stabilizes the 
corresponding intermediate and decomposition releases Glu-173, acetylated histone and 
CoASH. 
 
Based on this mechanism, Giannis and co-worker envisioned the γ-butyrolactone (±)-256 as a 
promising HAT inhibitor (Figure 29, B). Their short, but racemic synthesis towards (±)-256 
started from itaconic anhydride 257 (Scheme 74).[242] 
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Scheme 74. Racemic synthesis of γ-butyrolactones (±)-256 by Giannis and co-workers: a) p-methoxybenzyl-
alcohol, hexane, toluene, 60 °C, 36 h, 88%; b) LiHMDS, THF, -78 °C, 1 h; c) RCHO, THF, -78 °C, 12 h; d) 
CHCl3, EtOH, rt, 72 h 42-47% over 3 steps; e) phenol, HOAc, 60 °C, 3 h, 90-96%.[242] 
 
Regioselective ring opening of 257 at the non-conjugated side by p-methoxybenzylalcohol 
gave rise to PMB protected 258. Subsequent aldol reaction with various aliphatic aldehydes 
afforded racemic (±)-259, which closed the trans-substituted γ-butyrolactone ring to form 
(±)-260. PMB deprotection with acetic acid in liquid phenol afforded the final products 
(±)-256a-e in good yields, although in racemic form.  
Giannis et al. tested these butyrolactones in an in vitro HAT assay against Gcn5 and CBP 
where (±)-256c-e showed inhibition of CBP ((±)-256c: 0.5 mM, (±)-256d and (±)-256e: 1.7-
2 mM). In contrast to this, only (±)-256c inhibited the HAT Gcn5 with an IC50 = 100 mM. 
Because the binding of histone H3 by Gcn5 (or PCAF) in presents of acetyl-CoA is 
approximately 100 mM, compound (±)-256c showed comparable affinity to Gcn5 as the 
natural substrate H3. 
These results make compound (±)-256c a promising starting point for further investigations 
on these structures towards the evaluation of the “Histone-Code” while targeting Gcn5. 
In addition to this, also other groups are interested in these compounds: The γ-butyrolactone 
(+)-256c was isolated by Matsuura et al.[246] as a toxin produced by Lasiodiplodia 
theobromae, one of the main pathogens responsible for fruit decay, which provides serious 
economical impact on the agricultural industry. The relative stereochemistry of the five-
membered lactones of type 256 was investigated by Thiele et al.[247] It was shown that 
residual dipolar couplings (RDCs) in NMR can be used for the determination of the relative 
configuration even when conventional approaches (e.g. NOE, angular restraints from 
3J-coupling constants, cross-correlated relaxation) fail due to high substitution or distance of 
the stereogenic centers. 
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For further investigations on the inhibition of HATs it is essential to determine the biological 
active enantiomer of (±)-256c. 
Therefore, a highly stereoselective synthesis of these compounds has to be developed, not 
only to control relative, but also absolute stereochemistry of the lactone ring. In a 
retrosynthetic view the butyrolactone 256c was referred to the lactone aldehydes (+)- and 
(-)-210a with both stereocenters already set (Figure 30). 
 
 
Figure 30. Retrosynthesis of (+)- and (-)-256c. 
 
Allylation of the cyclopropylcarbaldehyde (-)-130 with commercially available trimethyl-
allylsilane 211a (Figure 16) and subsequent retroaldol-lactonization afforded the lactone 
aldehyde (-)-210a in moderate yield of 51%, but highly selective (for discussion see Scheme 
39 and Scheme 42). Following this route, both enantiomers of aldehyde 210a were 
synthesized (Scheme 75). 
 
 
Scheme 75. Stereoselective synthesis of lactone aldehyde 210a: a) 211a (1.1 eq.), BF3⋅OEt2 (1.1 eq.), CH2Cl2, 
-78 °C, 18 h; b) Ba(OH)2⋅8H2O (0.55 eq.), MeOH, 0 °C, 5 h, 51%, dr = 95:5. 
 
Since hydrogenation of the double bond in (-)-210a failed, the aldehyde was first oxidized to 
the corresponding carboxylic acid (-)-261 and subsequent hydrogenation afforded the 
aliphatic sidechain of (-)-262 in 96-98% yield (Scheme 76). 
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Scheme 76. Stereoselective synthesis of (-)-256c: a) KH2PO4 (0.6 eq.), NaClO2 (1.6 eq.), H2O2 (1.6 eq.), 0 °C-rt, 
CH3CN 16 h, 79-81%; b) Pd/C (1.0 mol%), ethylacetate, H2, rt, 24 h, 96-98%; c) (i) methoxymagnesium-
methylcarbonate (2 N in DMF, 37.5 eq.), 135 °C, 3 d; ii) HCHO, N-methylaniline, acetic acid, rt, 3.5 h, 53-63%. 
 
The lacking exo-methylene group was introduced in a two step sequence following a slightly 
modified procedure described by Greene et al.:[248] First Stiles´s-reagent (methoxy-
magnesiummethylcarbonate) was used to carboxylate (-)-261 and (-)-262. A Mannich-type 
reaction under decarboxylation was then triggered and afforded in moderate yields the desired 
exo-methylene products (-)-263 and (-)-256c. 
 
Following this route, four compounds in both enantiomeric forms have been prepared. All 
spectroscopic data of (-)-256c and (+)-256c perfectly matched the literature values as reported 
by Giannis et al.[242] The optical purity of 256c and 263 was determined by chiral HPLC 
(Figure 31) indicating the high stereoselectivity of this synthesis.  
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Figure 31. Chiral HPLC analysis for synthesized lactones.  
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Although, a complete baseline separation of the racemate was not possible (Figure 31, top), 
the chiral HPLC report of 256c and 263 proves the enantiomerical purity of the synthesized 
compounds. 
First attempts to evaluate the biological activity of all prepared compounds as described by 
Giannis et al. did not show the reported results, but further investigations in this field are 
being continued. 
The described synthetic route can be extended towards the scaffold 264, which offers certain 
points for derivatization (Figure 32). The initial use of various allylsilanes (such as seen in 
Figure 16) allows the control of ring size and substitution pattern of the southern sidearm. 
Elongation of the northern carboxylic acid sidechain (e.g. by Arndt-Eistert elongation) may 
also be of certain interest to generate derivatives. 
 
 
Figure 32. Possible derivatization on skeleton 264. 
 
In summary, a flexible and divers oriented stereoselective synthesis towards the scaffold 264 
was shown. The design and synthesis of a library for the screening on HAT-enzymes is 
possible, since there are many points for derivatisation present. The construction of a small 
molecule library and its biological evaluation could afford important results, which contribute 
knowledge in the field of the “Histone-Code”-hypothesis. 
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10. Summary 
Natural products have long presented chemists with golden opportunities for discovery. The 
synthesis of various members of the guaianolide family was reviewed to introduce this class 
of compounds as sources of inspiration for the development of unique synthetic strategies. 
The aim of this work was to seek for the first synthetic route towards Cynaropicrin (123) and 
Ixerin Y (126), two prominent guaianolides with promising widespread biological activity 
(Figure 33). 
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Figure 33. Structure of Cynaropicrin (123) and Ixerin Y (126). 
 
Within 8-9 steps starting from furfuryl alcohol (136) the enantiomerical pure PMB-protected 
cyclopentenone (-)-145 was prepared utilizing kinetic enzymatic resolution as a key step 
(Scheme 77). 
 
 
Scheme 77. Synthesis of the chiral allylsilane 151 and the lactone aldehyde 175 as central key intermediates. 
 
Two additional steps provided the chiral allylsilane 151 which was further transformed into 
the lactone aldehyde 175, a key intermediate of the further synthesis with many stereocenters 
set in right configuration. 
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175 was subjected to a modified HWE reaction releasing the brominated precursor 183 which 
afforded the guaianolide skeleton 184 by radical cyclization (Scheme 78, top). 
 
 
Scheme 78. Completion of the guaianolide skeletons. 
 
Stereoselective allylation of 175 and subsequent protection afforded dienes 198. Ring closing 
metathesis completed the 5,7,5-skeleton 199 and provided a powerful and flexible entry 
towards the core of the guaianolides (Scheme 78, bottom). 
Further transformations on the skeleton 199 were demonstrated (Figure 34): Epoxidation of 
the double bond in the 7-membered ring, as well as deprotection and oxidation of various 
hydroxy groups was shown. Tamao-Fleming oxidation of the silyl-side chain released a 
primary alcohol, which was subjected to elimination reactions to introduce a C=C-double 
bonds at this position. 
 
 
Figure 34. Functional group transformations on 199. 
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To investigate the scope and limitations of this synthetic strategy a small library consisting of 
eight natural product-like scaffolds was synthesized (Scheme 79). 
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Scheme 79. Synthesis of a 3x3 scaffold library. 
 
In addition to this, a second library of potential small molecule histone acetyl transferase 
inhibitors was synthesized (Scheme 80). Starting from enantiomeric pure lactone aldehyde 
intermediate 210a a set of eight compounds around the scaffold 256c was prepared in high 
stereoselectivity. 
 
 
Scheme 80. Stereoselective synthesis of small molecule HAT inhibitors. 
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11. Experimental Part 
11.1 General 
1H NMR-Spectra were recorded on Bruker Avance 300, Bruker Avance 400, Bruker Avance 
600, Varian Inova 600, Bruker DRX-400 with a H/C/P/F QNP gradient probe and Bruker 
Avance 500 with a dual carbon/proton CPDUL cryoprobe. The chemical shift δ is given in 
[ppm], calibration was set on chloroform-d1 (7.26 ppm) or tetramethylsilane (0.00 ppm) as 
internal standard. The spectra were evaluated in 1st order and the coupling constants are given 
in Hertz [Hz]. The following abbreviations for the spin multiplicity were used: s = singlet, d = 
doublet, t = triplet, q = quartet, qt = quintet, m = multiplet, dt = doublet of a triplet, dd = 
double doublet, ddd = doublet of a double doublet, sept = septet. The used deuterated solvents 
are given separately.  
13C NMR-Spectra were recorded on Bruker Avance 300, Bruker Avance 400, Bruker 
Avance 600, Varian Inova, Bruker DRX-400 with a H/C/P/F QNP gradient probe and Bruker 
Avance 500 with a dual carbon/proton CPDUL cryoprobe. The chemical shift δ is given in 
[ppm], calibration was set on chloroform-d1 (77.16 ppm), or tetramethylsilane (0.00 ppm) as 
internal standard. The multiplicity of the signals were detected by DEPT 135 and 90 (DEPT = 
distortionless enhancement by polarization transfer) and are given as: + = primary und tertiary 
C-atom (positive DEPT 135 signal; tertiary C-atom: DEPT 90 signal), - = secondary C-atom 
(negative DEPT 135 signal), Cq = quaternary C-atom (DEPT-signal intensity zero).  
Melting points were measured on a Büchi SMP 20 in a silicon oil bath. The melting points 
are uncorrected. 
Infrared-Spectra were recorded on a Bio-Rad Excalibur Series or Mattson Genesis Series 
FT-IR. Solid compounds were measured in KBr, liquid compounds as a neat film between 
NaCl-plates. The wave numbers are given in [cm-1]. 
Masspectrometry was performed on Varian MAT 311A, Finnigan MAT 95, Thermoquest 
Finnigan TSQ 7000, Nermag quadrupoles, VG ZAB high-resolution double-focusing and VG 
Autospec-Q tandem hybrid with EBEqQ configuration. The percentage set in brackets gives 
the peak intensity related to the basic peak (I = 100%). High resolution mass spectrometry 
(HRMS): The molecular formula was proven by the calculated precise mass. 
Elemental analysis was prepared by the micro analytic section of the University of 
Regensburg using a Vario EL III or Mikro-Rapid CHN (Heraeus). 
Optical rotation was measured at rt on a 241 MC Perkin-Elmer polarimeter at a wavelength 
of 589 nm (Na-D) in a 1 dm or 0.1 dm cell. The concentration is given in [g/100 ml]. 
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X-ray analysis was performed by the crystallography laboratory of the University of 
Regensburg (STOE-IPDS, Stoe & Cie GmbH) and the crystallography laboratory of the 
University of Kansas. 
Chiral HPLC was performed in the analytic department of the University of Regensburg or 
on a Kontron Instruments 325 System (HPLC 335 UV detector, λ = 254 nm, Chiracel 
OD/OD-H column (50x4.6 mm, 10 µm, flow rate: 1 mL/min, 20 °C, n-heptane/ethanol 99:1). 
Gaschromatography (GC) was measured in the analytic department of the University of 
Regensburg or on Fisons Instruments GC 8000 series (Data Jet Integrator, CP-chiralsil-DEX-
CP column). 
Thin layer chromatography (TLC) was prepared on TLC-aluminium sheets (Merck, silica 
gel 60 F254, 0.2 mm). Detection in UV-light λ = 254 nm, staining with I2, mostain, 
molybdatophosphoric-acid (5% in ethanol), KMnO4 solution or vanillin-sulfuric acid. 
Column chromatography was performed in glass columns (G2 or G3). As a stationary phase 
silica gel Merck-Geduran 60 (0.063-0.200 mm) or flash silica gel Merck 60 (0.040-
0.063 mm) was used. 
Microwave: Microwave experiments were performed in a Prolabo Synthewave S 402 
(2.45 GHz, focused, max. 300 W) or on CEM Discover System. 
Ozone-Generator: For ozone generation a Fischer process technology ozone generator OZ 
500 MM was used, supplied by an oxygen tank. 
Solvents: Abs. solvents were prepared according to usual lab procedures or taken from the 
MB-SPS solvent purification system. Ethylacetate, hexanes (40-60 °C) and dichloromethane 
were purified by distillation before use. Further solvents and reagents were of p.a. quality. 
Reactions with oxygen- and moisture sensitive reactants were performed in oven dried and in 
vacuo heated reaction flasks under a pre-dried inert gas (nitrogen or argon) atmosphere. For 
cooling to temperatures < -40 °C a cryostat Haake EK 90 or dry ice/iso-propanol mixture was 
used. 
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11.2 Abbreviations 
 
abs absolute 
AIBN azo-isobutyronitrile 
Bu n-butyl 
BuLi n-butyl lithium 
cat catalytic 
CI chemical ionization 
dr diastereomeric ratio 
DBU 1,8-Diazabicyclo[4.4.0] 
 undec-7-ene 
DEAD diethylazodicarboxylate 
DMAP N,N-dimethylamino pyridine 
DMF dimethyl formamide 
DMS dimethyl sulfide 
ee enantiomeric excess 
eq equivalents 
EI electronic ionization 
Et ethyl 
Glc glucose 
h hour 
HAT histone-acetyl-transferase 
HPLC high pressure liquid  
 chromatography 
HRMS high resolution mass  
 spectrometry 
HWE Horner-Wadsworth-Emmons 
iPr iso-propyl 
IR infra red 
LAH lithium aluminium hydride 
M metal 
mCPBA m-chloroperbenzoic acid 
Me methyl 
MeCN acetonitril 
Mes mesyl 
min minute 
MS molecular sieve 
NMR nuclear magnetic resonance 
NMO N-methylmorpholin-N-oxid 
NOE nuclear Overhauser effect 
Nu nucleophile 
PCC pyridinium chlorochromate 
Pg protecting group 
Ph phenyl 
PMB p-methoxy-benzyl 
PPLE porcine pancreas lipase enzyme 
pyr pyridine 
RCM ring closing metathesis 
rt room temperature 
SAR structure-activity 
 relationship 
TBME tert-butyl-methyl-ether 
TBDMS tert-butyldimethylsily 
TBAF tetrabutylammonium fluoride 
TPAP tetrapropylammonium 
 perruthenate 
tBu tert-butyl 
TES triethylsilyl 
THF tetrahydrofuran 
TMS trimethylsilyl 
Tf trifluormethanesulfonate 
Ts tosyl 
quant quantitative 
 
 
Indication of relative and absolute stereochemistry: 
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11.3 Synthesis of chiral allylsilanes 
 
p-methoxybenzylbromid[249] 
 
HBr (47% in H2O, 19.19 g, 12.8 ml, 111 mmol, 1.75 eq.) was added to p-methoxy-
benzylalcohol (8.80 g, 7.93 ml, 63.7 mmol, 1.0 eq.) at rt. The reaction mixture was stirred for 
24 h. Et2O (100 ml) was added and the layers were separated. The aqueous layer was again 
extracted with Et2O (2x50 ml). The combined org. layers were carefully washed with sat. 
NaHCO3 (2x15 ml), dried (Na2SO4) and concentrated in vacuo. 11.38 g (56.6 mmol, 89%) of 
the crude product was obtained and was used without further purification. 
 
1H NMR (300 MHz, CDCl3): δ = 3.85 (s, 3H, OMe), 4.52 (s, 2H, CH2), 6.80-6.90 (m, 2H, 
o-H), 7.30-7.40 (m, 2H, m-H). 
 
 
p-methoxybenzyl-2,2,2-trichloroacetimidate[250] 
 
Under a N2-atmosphere a solution of p-methoxybenzylalcohol (5.20 g, 4.68 ml, 37.6 mmol, 
1.0 eq.) in abs. Et2O (25 ml) was added to a suspension of NaH (60% in paraffin oil, 151 mg, 
3.76 mmol, 0.1 eq.) in abs. Et2O (25 ml). After stirring for 30 min at rt, the reaction mixture 
was cooled to 0 °C and CCl3CN (5.43 g, 3.77 ml, 37.6 mmol, 1.0 eq.) was added slowly. The 
reaction mixture was allowed to warm to rt and stirred for 4 h. The mixture was concentrated 
in vacuo without heating and hexanes (50 ml + 160 µl MeOH) was added. The resulting 
mixture was filtered over celite and the solution was concentrated to afford 9.44 g (33.4 
mmol, 89%) product as a yellowish oil. The crude product was stored under a N2-atmosphere 
in the fridge and was used without further purification. 
 
1H NMR (300 MHz, CDCl3): δ = 3.85 (s, 3H, OMe), 5.25 (s, 2H, CH2), 6.90-6.97 (m, 2H, o-
H), 7.35-7.45 (m, 2H, m-H), 8.35 (bs, 1H, NH). 
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(±)-4-hydroxycyclopent-2-enone ((±)-137) 
 
Furfuryl alcohol 136 (62 g, 632 mmol, 1.0 eq.) was dissolved in H2O (1.5 l). K2HPO4 (3.15 g) 
was added and the pH was adjusted to 4.1 using H3PO4 (0.25 N). The reaction mixture was 
refluxed for 40 h and than cooled to rt. The liquid was decanted from the brown slurry and the 
aqueous layer was extracted with toluene (3x200 ml). The aqueous layer was than 
concentrated to 100 ml and extracted with ethylacetate (5x150 ml). The combined organic 
layers were dried (Na2SO4), filtered and concentrated affording 24.6 g (251 mmol, 40%) 
crude product as a slightly brown oil, which was used without further purification. 
 
1H NMR (300 MHz, CDCl3): δ = 2.26 (dd, J = 18.5, 6.0 Hz, 1H, 5-H), 2.75 (dd, J = 18.5, 3.2 
Hz, 1H, 5-H), 3.6 (bs, 1H, OH), 5.0 (m, 1H, 4-H), 6.20 (d, J = 5.6 Hz, 1H, 2-H), 7.61 (dd, J = 
5.6, 4.8 Hz, 1H, 3-H). 
 
 
(±)-4-(tert-butyldimethylsilyloxy)cyclopent-2-enone ((±)-138) 
 
Under a nitrogen atmosphere (±)-4-hydroxycyclopent-2-enone (±)-137 (21.96 g, 224.0 mmol, 
1.0 eq.) was dissolved in abs. THF (75 ml). NEt3 (34.00 g, 47.2 ml, 336 mmol, 1.50 eq.) and 
DMAP (1.37 g, 11.2 mmol, 5 mol%) were added and the mixture cooled to 0 °C. TBDMSCl 
(38.8 g, 257 mmol, 1.15 eq. dissolved in 50 ml abs. THF) was added over 20 min and the 
mixture was allowed to warm to rt over night. After cooling to 0 °C the reaction mixture was 
diluted with Et2O (50 ml) and slowly H2O (100 ml) was added. The layers were separated and 
the aqueous layer was extracted with Et2O (2x100 ml). The combined organic layers were 
washed with brine (100 ml) and H2O (100 ml), dried (Na2SO4) and concentrated in vacuo. 
Chromatography on silica gel (hexanes:ethylacetate 5:1) afforded 42.14 g (198 mmol, 89%) 
product as a yellowish oil. 
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1H NMR (300 MHz, CDCl3): δ = 0.11 (s, 6H, SiMe2), 0.88 (s, 9H, SitBu), 2.25 (dd, J = 18.2, 
6.0 Hz, 1H, 5-H), 2.72 (dd, J = 2.3, 18.2 Hz, 1H, 5-H), 4.9 (m, 1H, 4-H), 6.20 (d, J = 5.7 Hz, 
1H, 3-H), 7.48 (dd, J = 5.7, 2.4 Hz, 1H, 2-H). 
 
 
(±)-cis-4-(tert-butyldimethylsilyloxy)cyclopent-2-enol ((±)-139) 
 
Under a nitrogen atmosphere LiAlH4 (1.97 g, 51.9 mmol, 0.7 eq.) and LiI (4.97 g, 37.1 mmol, 
0.5 eq.) were dissolved in abs. toluene (150 ml) and cooled to -30 °C. (±)-4-(tert-butyl-
dimethylsilyloxy)cyclopent-2-enone (±)-138 (15.76 g, 74.2 mmol, 1.0 eq.) dissolved in abs. 
TBME (80 ml) was added slowly over 30 min. After complete conversion of the starting 
material (TLC) sat. NH4Cl (100 ml) was added slowly. The mixture was warmed to rt and 
filtered. The layers were separated and the aqueous layer was extracted with toluene (5x50 
ml). The combined org. layers were dried (Na2SO4), filtered and concentrated in vacuo. 
Chromatography on silica gel (hexanes:ethylacetate 5:1) afforded 13.48 g (62.9 mmol, 85%, 
dr = 92:8) product as a yellowish oil. 
 
1H NMR (300 MHz, CDCl3): δ = 0.09 (s, 6H, SiMe2), 0.90 (s, 9H, SitBu), 1.52 (dt, J = 13.8, 
4.7 Hz, 1H, 5-H), 2.69 (dt, J = 13.8, 7.1 Hz, 1H, 5-H), 2.8 (bs, 1H, OH), 4.50 (m, 1H, 1-H), 
4.6 (m, 1H, 4-H), 5.84 (dt, J = 5.5, 1.6 Hz, 1H, 3-H), 5.93 (dt, J = 5.5, 1.7 Hz, 1H, 2-H). 
 
 
Representative procedure for enzymatic resolution: 
 
Racemic (±)-cis-4-(tert-butyldimethylsilyloxy)cyclopent-2-enol ((±)-139) (17.9 g, 83 mmol, 
1.0 eq.) was dissolved in TBME (220 ml). NEt3 (5.7 g, 7.97 ml, 57 mmol, 0.68 eq.), PPLE[251]  
(9.96 g, 120 mg/mmol) and vinylacetate (32 g, 35 ml, 4.50 eq.) were added and the mixture 
was stirred at rt for 48 h. The progress was monitored by chiral GC.[252] The reaction mixture 
was filtered over celite and concentrated in vacuo. The resulting yellow oil was purified by 
chromatography on silica gel (hexanes:ethylacetate 9:1-3:1) affording (+)-140 (8.56 g, 
33.4 mmol, 80%, >99%ee) and (-)-139 (8.47 g, 39.5 mmol, 95%, 92%ee) as slightly 
yellowish oils. 
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Upper spot: 
 
OAc
OTBDMS  
(+)-(1S,4R)-4-(tert-butyldimethylsilyloxy)cyclopent-2-enyl acetate ((+)-140) 
 
1H NMR (300 MHz, CDCl3): δ = 0.09 (s, 6H, SiMe2), 0.91 (s, 9H, SitBu), 1.6 (m, 1H, 5-H), 
2.05 (s, 3H, OAc), 2.80 (m, 1H, 5-H), 4.70 (m, 1H, 4-H), 5.50 (m, 1H, 1-H), 5.90 (m, 1H, 3-
H), 6.00 (m, 1H, 2-H). 
 
Lower spot: 
OH
OTBDMS  
(-)-(1R,4S)-4-(tert-butyldimethylsilyloxy)cyclopent-2-enol ((-)-139) 
 
1H NMR of (-)-139: identical to (±)-139. 
 
 
 
(+)-(1S,4R)-4-(tert-butyldimethylsilyloxy)cyclopent-2-enol ((+)-139) 
 
(+)-140 (3.75 g, 14.64 mmol, 1.0 eq.) was dissolved in THF/MeOH/H2O (3:1:1, 25 ml) and 
LiOH (0.42 g, 17.56 mmol, 1.20 eq.) was added in portions at rt. After stirring for 2 h the 
reaction mixture was diluted with Et2O (40 ml) and H2O (20 ml) and the layers were 
separated. The aqueous layer was extracted with Et2O (20 ml) and the combined org. layers 
were washed with 5% NaHCO3 (10 ml) and brine (10 ml). After drying (Na2SO4), the 
solution was filtered and concentrated to afford 3.00 g (13.99 mmol, 96%) crude product as a 
colorless oil which was used without further purification. 
 
1H NMR of (+)-139: identical to (±)-139 and (-)-139. 
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OTBDMS
OPMB
 
(+)-((1R,4S)-4-(p-methoxybenzyloxy)cyclopent-2-enyloxy)(tert-butyl)dimethylsilane 
((+)-141) 
 
Under an N2-atmosphere NaH (60% in paraffin oil, 1.02 g, 25.5 mmol, 1.25 eq.) was 
dissolved in abs. THF (75 ml) and cooled to 0 °C. Alcohol (+)-139 (4.372 mg, 20.39 mmol, 
1.00 eq.) dissolved in abs. THF (25 ml) was added over 30 min and the solution was stirred 
for further 30 min and allowed to warm to rt. NaI (3.06 g, 20.39 mmol, 1.0 eq.) and 
p-methoxybenzylbromid (6.66 g, 4.78 ml, 26.5 mmol, 1.30 eq.) was added and the reaction 
mixture was stirred for 5 h at rt. H2O (50 ml) and CH2Cl2 (100 ml) were added and the layers 
were separated. The aqueous layer was extracted with CH2Cl2 (3x100 ml). The combined org. 
layers were washed with brine (20 ml) and H2O (20 ml), dried over Na2SO4, filtered and 
concentrated at rt in vacuo. Chromatography on silica gel (hexanes:ethylacetate 9:1) afforded 
5.89 g (17.59 mmol, 86%) product as a colorless oil. 
 
Rf (hexanes:ethylacetate 9:1) = 0.46.- [ ]20Dα = +2.1 (c = 0.45, CHCl3).- 1H NMR (300 MHz, 
CDCl3): δ = 0.04 (s, 6H, SiMe2), 0.85 (s, 9H, tBu), 1.62 (dt, J = 13.2, 5.6 Hz, 1H, 5-H), 2.65 
(dt, J = 13.2, 7.1 Hz, 1H, 5-H), 3.76 (s, 3H, OMe), 4.32-4.41 (m, 1H, 4H), 4.41-4.48 (m, 2H, 
PMB), 5.58-5.66 (m, 1H, 1-H), 5.80-5.93 (m, 2H, CH=CH), 6.81-6.86 (m, 2H, PMB), 7.19-
7.27 (m, 2H, PMB).- 13C NMR (75 MHz, CDCl3): δ = -4.55 (+, SiMe), -4.61 (+, SiMe), 18.18 
(Cq, SiC), 25.91 (+, SiCMe3), 41.53 (-, 5-C), 55.33 (+, OMe), 70.03 (-, PMB), 74.90 (+, 1-C), 
81.10 (+, 4-C), 113.77 (+, 2xPMB), 129.35 (+, 2x PMB), 130.79 (Cq, PMB), 132.94 (+, 2-C), 
137.38 (+, 3-C), 159.1 (Cq, PMB).- IR (neat): ~ν = 2954, 2930, 2884, 2856, 2361, 2341, 1612, 
1512, 1462, 1367, 1300, 1249, 1172, 1078, 1038, 906, 836, 776, 669 cm-1.- MS (CI, NH3): 
m/z (%) = 335.2 (0.63) [M+H+], 352.2 (45.3) [M+NH4+].- HRMS (PI-LSIMS): 335.2044 
(C19H31O3Si: calc. 335.2042 [M+H+]). 
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OAc
OTBDMS  
(-)-(1R,4S)-4-(tert-butyldimethylsilyloxy)cyclopent-2-enyl acetate ((-)-140) 
 
(-)-(1R,4S)-4-(tert-butyldimethylsilyloxy)cyclopent-2-enol (-)-139 (4.07 g, 19.0 mmol, 1.0 
eq.) was dissolved in dry pyridine (40 ml). Acetic anhydride (8.73 g, 8.07 ml, 86 mmol, 4.5 
eq.) was added at rt. After stirring for 6 h the reaction mixture was diluted with Et2O (100 ml) 
and extracted with 1N HCl (2x100 ml). The organic layer was washed with sat. NaHCO3 (50 
ml), brine (50 ml), dried (Na2SO4) and concentrated in vacuo to yield 4.70 g (18.4 mmol, 
97%) product as a colorless oil. 
 
1H NMR of (-)-140: identical to (+)-140. 
 
 
(1R,4S)-4-hydroxycyclopent-2-enyl acetate ((+)-143) 
 
(-)-140 (3.67 g, 14.29 mmol, 1.0 eq.) and NEt3 (0.15 g, 0.2 ml, 1.43 mmol, 0.10 eq.) were 
dissolved in THF (55 ml). TBAF (4.60 g, 14.58 mmol, 1.02 eq.) was added in portions at rt 
and the reaction mixture was stirred for 2 h. After complete conversion of the starting material 
(TLC) H2O (2 ml) was added and stirring was continued for 20 min. After removal of the 
solvent, chromatography on silica gel (hexanes:ethylacetate 1:1) afforded 1.94 g (13.7 mmol, 
95%) product, which solidified with time to a colorless solid and was recrystallized from 
diethylether. 
 
1H NMR (300 MHz, CDCl3): δ = 1.6 (dt, J = 14.5, 3.8 Hz, 1H, 5-H), 2.08 (s, 3H, OAc), 2.22 
(d, J = 7.8 Hz, 1H, OH), 2.83 (dt, J = 14.5, 7.3 Hz, 1H, 5-H), 4.8 (m, 1H, 4-H), 5.5 (m, 1H, 1-
H), 6.0 (m, 1H, 2-H) 6.1 (m, 1H, 3-H). 
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OAc
OPMB  
(+)-(1R,4S)-4-(p-methoxybenzyloxy)cyclopent-2-enyl acetate ((+)-144) 
 
Under a N2-atmosphere p-methoxybenzyl-2,2,2-trichloroacetimidate (8.323 g, 29.46 mmol, 
1.67 eq.) was dissolved in abs. CH2Cl2 (40 ml). (1R,4S)-4-hydroxycyclopent-2-enyl acetate 
(+)-143 (3.100 g, 14.46 mmol, 1.0 eq.) and Cu(OTf)2 (262 mg, 0.723 mmol, 5 mol%) was 
added at 0 °C. The solution was stirred for 24 h at rt. The solvent was removed in vacuo and 
the crude mixture was purified by column chromatography on silica gel (hexanes:ethylacetate 
9:1) affording 4.000 g (11.96 mmol, 83%) product as a colorless oil. 
 
Rf (hexanes:ethylacetate 5:1) = 0.36.- [ ]20Dα = +0.8 (c = 1.05 CHCl3).- 1H NMR (300 MHz, 
CDCl3): δ = 1.74 (ddd, J = 14.3, 4.4, 4.4 Hz, 1H, 5-H), 1.05 (s, 3H, OAc), 2.76 (ddd, J = 
14.3, 7.1, 7.3 Hz, 1H, 5-H), 3.80 (s, 3H, OMe), 4.47-4.51 (m, 3H, OCH2, 4-H), 5.46- 5.54 (m, 
1H, 1-H), 5.95-6.02 (m, 1H, 2-H), 6.08-6.14 (m, 1H, 3-H), 6.82-6.94 (m, 2H, PMB), 7.21-
7.32 (m, 2H, PMB).- 13C NMR (75 MHz, CDCl3): δ = 21.21 (+, Ac), 37.59 (-, 5-C), 55.31 (+, 
OMe), 70.74 (-, PMB), 76.87 (+, 1-C), 80.90 (+, 4-C), 113.84 (+, 2xPMB), 129.43 (+, 
2xPMB), 130.39 (Cq, PMB), 132.75 (+, 2-C), 136.30 (+, 3-C), 159.26 (Cq, PMB), 170.93 
(Cq, C=O).- IR (neat): ~ν = 3065, 2999, 2938, 2909, 2860, 2837, 1732, 1613, 1586, 1514, 
1464, 1440, 1365, 1302, 1247, 1175, 1094, 1072, 1033, 954, 908, 821, 769, 680 cm-1.- MS 
(CI, NH3): m/z (%) = 121.0 (100) [CH2C6H4OMe+], 263.0 (1.82) [M+H+], 280.1 (24.31) 
[M+NH4+].- HRMS (EI, 70eV): 262.1201 (C15H18O4): calc. 262.1205 [M+]). 
 
 
(-)-(1R,4S)-4-(p-methoxybenzyloxy)cyclopent-2-enol ((-)-142) 
 
Starting from TBDMS-protected precursor (+)-141: 
TBDMS-protected (+)-141 (8.60 g, 25.7 mmol, 1.00 eq.) was dissolved in THF (100 ml) at rt 
and NEt3 (260 mg, 361 µl, 0.10 eq.) and TBAF (8.13 g, 25.8 mmol, 1.01 eq.) was added in 
small portions. The mixture was stirred at rt for 24 h and then the solvent was removed in 
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vacuo. Chromatography on silica gel (hexanes:ethylacetate 1:1) afforded 4.83 g (21.93 mmol, 
85%) product as a colorless oil. 
 
Starting from Ac-protected precursor (+)-144: 
Ac-protected (+)-144 (1.178 g, 4.491 mmol, 1.0 eq.) was dissolved in THF/MeOH/H2O (10 
ml, 3:1:1). LiOH (0.129 g, 5.39 mmol, 1.2 eq.) was added at rt and the reaction mixture was 
stirred for 2 h. H2O (20 ml) was added and the mixture was extracted with Et2O (3x 20 ml). 
The combined org. layers were washed with 5% NaHCO3 (10 ml) and brine (10 ml). The 
organic layer was dried (Na2SO4), filtered and concentrated, affording 0.911 g product 
(4.146 mmol, 92%) as a colorless oil. 
 
Rf (hexanes:ethylacetate 5:1) = 0.15.- [ ]20Dα = -21.5 (c = 1.01, CHCl3).- 1H NMR (300 MHz, 
CDCl3): δ = 1.59-1.69 (m, 1H, 5-H), 1.75 (bs, 1H, OH), 2.66 (m, 1H, 5-H), 3.79 (s, 3H, 
OMe), 4.37-4.45 (m, 1H, 1-H), 4.45-4.51 (m, 2H, 2-H, 3H), 4.56-4.68 (m, 1H, 4-H), 5.98-
6.05 (s, 2H, PMB), 6.83-6.90 (m, 2H, PMB), 7.22-7.29 (m, 2H, PMB).- 13C NMR (75 MHz, 
CDCl3): δ = 41.1 (-, 5-C), 55.3 (+, OCH3), 70.8 (-, OCH2), 75.1 (+, 1-C), 81.2 (+, 4-C), 113.9 
(+, 2xPMB), 129.4 (+, 2xPMB), 130.4 (Cq, PMB), 134.3 (+, 2-C), 137.1 (+, 3-C), 159.3 (Cq, 
PMB).- IR (neat): ~ν = 3394, 3059, 2998, 2935, 2905, 2860, 2837, 1612, 1585, 1513, 1462, 
1441, 1392, 1359, 1319, 1302, 1248, 1174, 1072, 1033, 821, 766, 598, 520 cm-1.- MS (EI, 
70eV): m/z (%) = 121.1 (100) [CH2C6H4OCH3+], 220.0 (19.89) [M+].- HRMS (EI, 70eV): 
220.1097 (C13H16O3: calc. 220.1099 [M+]). 
 
  
(-)-(S)-4-(p-methoxybenzyloxy)cyclopent-2-enone ((-)-145)) 
 
Under a N2-atmosphere alcohol (-)-142 (4.00 g, 18.16 mmol, 1.0 eq.) was dissolved in abs. 
CH2Cl2 (100 ml) and crushed molecular sieve (1.50 g, 4 Å) was added. PCC (4.70 g, 21.79 
mmol, 1.2 eq.) was added over a period of 30 min at rt. The reaction mixture was stirred for 
24 h, filtered over celite and the solvent removed in vacuo. Chromatography on silica gel 
(hexanes: ethylacetate 2:1) afforded 3.40 g product (15.59 mmol, 86%) as a yellowish oil. 
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Rf (hexanes:ethylacetate 2:1) = 0.49.- [ ]20Dα = -36.0 (c = 0.98, CHCl3).- 1H NMR (300 MHz, 
CDCl3): δ = 2.38 (dd, J = 18.3, 2.3 Hz, 1H, 5-H), 2.71 (dd, J = 18.1, 5.8 Hz, 1H, 5-H), 3.81 
(s, 3H, OMe), 4.49-4.62 (m, 2H, OCH2), 4.71-4.77 (m, 1H, 4-H), 6.22-6.27 (m, 1H, 2-H), 
6.86-6.93 (m, 2H, PMB), 7.24-7.32 (m, 2H, PMB), 7.56-7.61 (m, 1H, 3-H).- 13C NMR (75 
MHz, CDCl3): δ = 41.84 (-, 5-C), 55.33 (+, OCH3), 71.67 (-, OCH2), 76.54 (+, 4-C), 114.02 
(+, 2xPMB), 129.51 (Cq, PMB), 129.61 (+, 2xPMB), 135.66 (+, 2-C), 159.55 (Cq, PMB), 
161.34 (+, 3-C), 206.05 (Cq, C=O).- IR (neat): ~ν = 3066, 3001, 2954, 2935, 2908, 2863, 
2837, 1717, 1612, 1585, 1514, 1463, 1402, 1350, 1322, 1302, 1248, 1177, 1107, 1070, 1033, 
822, 793, 765, 589 cm-1.- MS (CI, NH3): m/z (%) = 121.0 (84.46) [CH2C6H4OMe+], 219.2 
(1.6) [M+H+], 236.1 (100) [M+NH4+].- HRMS (EI, 70eV): 218.0946 (C13H14O3: calc. 
218.0943, [M+]). 
 
 
(+)-((3S,4S)-3-((dimethyl(phenyl)silyl)methyl)-4-(p-methoxybenzyloxy)cyclopent-1-
enyloxy)trimethylsilane (150) 
 
Formation of Grignard: 
Under a N2-atmosphere chloromethyl-(dimethylphenylsilane) (924 mg, 5.00 mmol, 1.0 eq.) 
was dissolved in abs. THF (5 ml). At rt 2 ml of this solution was added at once to Mg curls 
(365 mg, 15 mmol, 3.0 eq.). After initiation the rest of the solution was added dropwise. After 
complete addition the Grignard-reagent was stirred for 2 h at rt. 
(Titration:[253] c(PhMe2SiCH2MgCl) = 1.09 mmol/ml) 
 
Formation of silylenolether: 
Under a N2-atmosphere LiCl (47 mg, 1.10 mmol, 0.3 eq.) and CuI (105 mg, 0.55 mmol, 
0.15 eq.) were dissolved in abs. THF (14 ml) and stirred for 30 min until a clear solution was 
obtained. Cyclopentenon (-)-145 (800 mg, 3.67 mmol, 1.0 eq.) dissolved in abs. THF (4 ml) 
was added and the mixture stirred for further 30 min. and then cooled to -78 °C before TMSCl 
(1.593 g, 1.874 ml, 14.66 mmol, 4.0 eq.) was added dropwise. The prepared Grignard solution 
(4.20 ml, 1.09 mmol/ml, 4.58 mmol, 1.25 eq.) was added slowly and the resulting mixture 
was stirred for 3 h at -78 °C until no more starting material was detected by TLC. The mixture 
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was quenched by adding NEt3 (6.18 ml, 44.0 mmol, 12 eq.) and allowed to come to 0 °C 
before being poured into n-pentane (100 ml). After stirring for 5 min. at rt the liquid was 
filtered over celite and the residue was washed with n-pentane (2x20 ml). The combined 
layers were extracted with NaHCO3 (4x10 ml) until a clear solution was obtained. The 
organic layer was dried (Na2SO4), filtered and concentrated in vacuo at rt. The resulting crude 
enolether (1.59 mg, 3.61 mmol, 99%, dr >99:1) was obtained as a colorless liquid and used 
without further purification. 
 
[ ]20Dα = + 62.2 (c = 0.675, CHCl3).- 1H NMR (300 MHz): δ = 0.19 (s, 9H, SiMe3), 0.35 (s, 3H, 
SiMe), 0.37 (s, 3H, SiMe), 0.86 (dd, J = 14.6, 9.9 Hz, 1H, SiCH2), 1.14 (dd, J = 14.6, 5.2 Hz, 
1H, SiCH2), 2.35 (dd, J = 16.0, 4.8 Hz, 1H, 5-H), 2.58 (dd, J = 16.0, 7.1 Hz, 1H, 5-H), 2.77-
2.88 (m, 1H, 3-H), 3.70-3.77 (m, 1H, 4-H), 2.85 (s, 3H, OMe), 4.32-4.49 (m, 2H, PMB), 4.44 
(m, 1H, 2-H), 6.89-6.96 (m, 2H, PMB), 7.27-7.32 (m, 2H, PMB), 7.37-7.43 (m, 3H, Ph), 
7.54-7.61 (m, 2H, Ph).- 13C NMR (75 MHz): δ = -2.0 (+, SiMe), -1.9 (+, SiMe), 0.28 (+, 
SiMe3), 22.9 (-, SiCH2), 39.9 (-, 5-C), 45.2 (+, 3-C), 55.6 (+, OMe), 71.1 (-, PMB), 86.0 (+, 4-
C), 106.6 (+, 2-C), 114.0 (+, 2x PMB), 128.1 (+, Ph), 129.1 (+, Ph), 129.6 (+, 2x PMB), 131.1 
(Cq, PMB), 133.9 (+, SiPh), 139.9 (Cq, Ph), 150.9 (Cq, 1-C), 159.4 (Cq, PMB).- IR (neat): 
~ν = 3068, 3048, 2999, 2955, 2899, 2864, 1880, 1746, 1644, 1613, 1586, 1512, 1464, 1426, 
1348, 1300, 1249, 1212, 1172, 1112, 1087, 1037, 1011, 920, 843, 758, 727, 700 cm-1.- MS 
(CI, NH3): m/z (%) = 121.1 (100), 231.2 (44.9), 248.2 (87.6), 441.2 (83.6) [M+H+]. 
 
 
(+)-iso-propoxy(((1S,5S)-5-(p-methoxybenzyloxy)-3-(trimethylsilyloxy)cyclopent-2-enyl) 
methyl)dimethylsilane (151) 
 
Formation of Grignard: 
Under a N2-atmosphere chloromethyldimethylisopropoxysilane (834 mg, 5.00 mmol, 1.0 eq.) 
was dissolved in abs. THF (5 ml). At rt 2 ml of this solution was added at once to Mg curls 
(365 mg, 15 mmol, 3.0 eq.). After initiation the rest of the solution was added dropwise. After 
complete addition the Grignard-reagent was stirred for 2 h at rt. 
(Titration:[253] c(Me2iPrOSiCH2MgCl) = 0.97 mmol/ml) 
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Formation of silylenolether: 
Under a N2-atmosphere LiCl (23 mg, 0.550 mmol, 0.3 eq.) and CuI (52 mg, 0.28 mmol, 
0.15 eq.) were dissolved in abs. THF (7 ml) and stirred for 30 min until a clear solution was 
obtained. Cyclopentenon (-)-145 (400 mg, 1.83 mmol, 1.0 eq.) dissolved in abs. THF (2 ml) 
was added and the mixture stirred for further 30 min. and then cooled to -78 °C before TMSCl 
(796 mg, 0.937 ml, 7.33 mmol, 4.0 eq.) was added dropwise. The prepared Grignard solution 
(4.68 ml, 0.97 mmol/ml, 4.58 mmol, 1.15 eq.) was added slowly and the resulting mixture 
was stirred for 3 h at -78 °C until no more starting material was detected by TLC. The mixture 
was quenched by adding NEt3 (3.09 ml, 21.99 mmol, 12 eq.) and was allowed to come to 0 °C 
before being poured into n-pentane (50 ml). After stirring for 5 min. at rt the liquid was 
filtered over celite and the residue was washed with n-pentane (2x10 ml). The combined 
layers were extracted with NaHCO3 (4x 10 ml) until a clear solution was obtained. The 
organic layer was dried (Na2SO4), filtered and concentrated in vacuo at rt. The resulting crude 
enolether (699 mg, 1.65 mmol, 90%, dr >99:1) was obtained as a colorless liquid and used 
without further purification. 
 
[ ]20Dα = +50.3 (c = 0.465, CHCl3).- 1H NMR (300 MHz): δ = 0.09 (s, 6H, SiMe2), 0.18 (s, 9H, 
SiMe3), 0.59 (dd, J = 14.4, 10.0 Hz, 1H, SiCH2), 0.87 (dd, J = 14.4, 5.2 Hz, 1H, SiCH2), 1.12 
(d, J = 6.0 Hz, 6H, iPr), 2.29 (dd, J = 15.9, 4.7 Hz, 1H, 4-H), 2.54 (dd, 15.9, 7.3 Hz, 1H, 4-
H), 2.69-2.80 (m, 1H, 1-H), 3.65-3.73 (m, 1H, 5-H), 2.77 (s, 3H, OMe), 3.96 (sept, J = 6.0 
Hz, 1H, iPr), 4.34-4.48 (m, 2H, PMB), 4.59 (d, J = 1.9 Hz, 1H, 2-H), 6.81-6.88 (m, 2H, 
PMB), 7.20-7.28 (m, 2H, PMB).- 13C NMR (75 MHz): δ = -0.3 (+, SiMe), -0.27 (+, SiMe), 
0.4 (+, SiMe3), 23.8 (-, SiCH2), 26.2 (+, 2xMe), 39.9 (-, 4-C), 44.6 (+, 1-C), 55.6 (+, OMe), 
65.1 (+, iPr), 71.1 (-, PMB), 86.0 (+, 5-C), 106.9 (+, 2-C), 114.1 (+, 2x PMB), 129.6 (+, 2x 
PMB), 131.2 (Cq, PMB), 150.9 (Cq, 3-C), 159.4 (Cq, PMB).- IR (neat): ~ν = 3066, 2959, 
2901, 2870, 2636, 1747, 1725, 1645, 1612, 1586, 1513, 1464, 1402, 1380, 1349, 1330, 1251, 
1212, 1172, 1123, 1086, 1025, 920, 863, 842, 756 cm-1.- MS (CI, NH3): m/z (%) = 230.1 
(100), 285.1 (66), 423.1 (30) [M+H+]. 
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(+)-1-((((1S,5S)-5-(p-methoxybenzyloxy)-3-((trimethylsilyl)methyl)cyclopent-2-
enyl)methyl) dimethylsilyl)benzene (152) 
 
Formation of the Grignard reagent: 
Mg curls (524 mg, 21.56 mmol) were stirred in abs. Et2O (10 ml) under a nitrogen 
atmosphere. At rt chloromethyltrimethylsilane (1.587 g, 1.797 ml, 12.93 mmol) was added 
slowly via a syringe to form the Grignard reagent. 
(Titration: [253] c(TMSCH2MgCl) = 1.0 mmol/ml) 
 
Ni(acac)2 - coupling: 
Silylenolether 150 (1.900 g, 4.31 mmol, 1.0 eq.) was dissolved in abs. Et2O (10 ml) under a 
nitrogen atmosphere and cooled to 0 °C. Ni(acac)2 (431 mg, 0.431 mmol, 0.1 eq.) was added 
and after stirring for 10 min the fresh prepared Grignard solution (8.62 ml, 1.0 mmol/ml, 
8.62 mmol, 2.0 eq.) was added slowly. The resulting black mixture was stirred for 5 days at rt. 
After cooling to 0 °C the reaction was quenched with sat. NaHCO3 (5 ml) and the mixture 
was extracted with Et2O (4x50 ml). The combined org. layers were washed with brine (20 ml) 
and water (20 ml), dried (Na2SO4), filtered and concentrated in vacuo. Chromatography on 
silica gel (hexanes:ethylacetate 98:2) afforded 750 mg (1.71 mmol, 40%) product as a 
yellowish oil. 
 
Rf (hexanes:ethylacetate 98:2, Vanilline) = 0.61.- [ ]20Dα = + 68.2 (c = 0.55, CHCl3).- 1H NMR 
(300 MHz): δ = 0.00 (s, 9H, SiMe3), 0.31 (s, 3H, SiMe), 0.32 (s, 3H, SiMe), 0.81 (dd, J = 
14.6, 9.3 Hz, 1H, CH2SiMe2Ph), 1.02 (dd, J = 14.6, 5.8 Hz, 1H, CH2SiMe2Ph), 1.41-1.55 (m, 
2H, CH2SiMe3), 2.21 (dd, J = 16.3, 3.99 Hz, 1H, 4-H), 2.49 (dd, J = 15.8, 6.5 Hz, 1H, 4-H), 
2.47-2.87 (m, 1H, 1-H), 3.68-3.76 (m, 1H, 5-H), 3.81 (s, 3H, OMe), 4.27-4.44 (m, 2H, PMB), 
4.97-5.03 (m, 1H, 2-H), 6.84-6.91 (m, 2H, PMB), 7.20-7.26 (m, 2H, PMB), 7.33-7.38 (m, 3H, 
SiPh), 7.50-7.56 (m, 2H, SiPh).- 13C NMR (75 MHz): δ = -1.04 (+, SiMe), -0.74 (+, SiMe), 
0.00 (SiMe3), 22.92 (-, CH2SiMe3), 22.98 (-,CH2SiMe2Ph), 44.04 (-, 4-C), 49.05 (+, 1-C), 
56.55 (+, OMe), 71.90 (-, PMB), 89.55 (+, 5-C), 114.95 (+, 2xPMB), 127.31 (+, 2-C), 128.99 
(+, SiPh), 130.04 (+, SiPh), 130.47 (+, 2xPMB), 132.27 (Cq), 134.87 (+, SiPh), 139.06 (Cq), 
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141.07 (Cq), 160.27 (Cq).- IR (neat): ~ν = 3068, 3046, 2999, 2953, 2898, 2866, 1725, 1639, 
1613, 1585, 1513, 1464, 1425, 1402, 1348, 1300, 1248, 1172, 1112, 1085, 1038, 838, 789, 
727 cm-1.- MS (CI, NH3): m/z = 439.0 (48.3) [M+H+], 456.1 (58.2) [M+NH4+].- HRMS (EI, 
70eV): 438.2402 (C26H38O2Si2: calc. 438.2410 [M+]). 
 
O
OPMB
SiMe2Ph  
(+)-(3S,4S)-4-(p-methoxybenzyloxy)-3-((dimethyl(phenyl)silyl)methyl)cyclopentenone 
(154) 
 
Rf (hexanes:ethylacetate 3:1) = 0.43.- [ ]20Dα = +42.4 (c = 0.50, CHCl3).- 1H NMR (300 MHz): 
δ = 0.30 (s, 3H, SiMe), 0.31 (s, 3H, SiMe), 0.68 (dd, J = 14.7, 10.0 Hz, 1H, CH2Si), 1.21 (dd, 
J = 14.7, 4.3 Hz, 1H, CH2Si), 1.74 (dd, J = 17.4, 6.4 Hz, 1H, 2-H), 2.17 (dd, J = 18.7, 5.5 Hz, 
1H, 2-H), 2.30-2.56 (m, 3H, 3-H, 5-H), 3.71 (m, 1H, 4-H), 3.81 (s, 3H, OMe), 4.33-4.46 (m, 
2H, PMB), 6.84-6.91 (m, 2H, PMB), 7.17-7.24 (m, 2H, PMB), 7.32-7.40 (m, 3H, Si-Ph), 
7.45-7.52 (m, 2H, SiPh).- 13C NMR (75.4 MHz): δ = -2.3 (+, SiMe), -2.2 (+, SiMe,), 20.5 (-, 
SiCH2), 38.5 (+, 3-C), 43.7 (-, 2-C), 45.4 (-, 5-C), 55.5 (+, OMe), 71.4 (-, PMB), 83.3 (+, 4-
C), 114.1 (+, 2xPMB), 128.2 (+, 2xSiPh), 129.4 (+, SiPh), 129.5 (+, 2xPMB), 130.3 (Cq), 
133.7 (+, 2xSiPh), 138.8 (Cq), 159.5 (Cq), 216.3 (Cq, 1-C).- IR (neat): ~ν = 3068, 3046, 3000, 
2954, 2901, 2836, 1744, 1712, 1612, 1586, 1512, 1464, 1425, 1402, 1349, 1302, 1248, 1173, 
1153, 1112, 1033, 832, 732, 702 cm-1.- MS (EI, 70 eV): m/z (%) = 121.1 (100), 368.2 (1) 
[M+].- HRMS (EI, 70 eV): 368.1802 (C22H28O3Si: calc. 368.1808 [M+]). 
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OPMB
SiMe2OiPr
TMS
 
(+)-(((3S,4S)-3-((dimethyl(iso-propoxy)silyl)methyl)-4-(p-methoxybenzyloxy)cyclopent-1-
enyl)methyl)trimethylsilane (153) 
 
Formation of the Grignard reagent: 
Mg curls (524 mg, 21.56 mmol) were stirred in abs. Et2O (10 ml) under a nitrogen 
atmosphere. At rt chloromethyltrimethylsilane (1.587 g, 1.797 ml, 12.93 mmol) was added 
slowly via a syringe to form the Grignard reagent. 
(Titration:[253] c(TMSCH2MgCl) = 0.77 mmol/ml) 
 
Ni(acac)2 - coupling: 
Silylenolether 151 (354 mg, 0.837 mmol, 1.0 eq.) was dissolved in abs. Et2O (7 ml) under a 
nitrogen atmosphere and cooled to 0 °C. Ni(acac)2 (215 mg, 0.837 mmol, 1.0 eq.) was added 
and after stirring for 10 min the fresh prepared Grignard solution (1.63 ml, 0.77 mmol/ml, 
1.256 mmol, 1.5 eq.) was added slowly. The resulting black mixture was stirred for 5 d at rt. 
After cooling to 0 °C the reaction was diluted with Et2O (30 ml) and quenched with sat. 
NaHCO3 (10 ml) and the mixture was extracted with Et2O (3x30 ml). The combined org. 
layers were dried (Na2SO4), filtered and concentrated in vacuo. Chromatography on silica gel 
(hexanes:ethylacetate 95:5) afforded 120 mg (0.285 mmol, 34%) product as a yellowish oil. 
 
Rf (hexanes:ethylacetate 95:5, Vanillin) = 0.61.- [ ]20Dα = + 61.4 (c = 0.560, CHCl3).- 1H NMR 
(300 MHz): δ = 0.00 (s, 9H, SiMe3), 0.17 (s, 6H, SiMe2), 0.57 (dd, J = 14.5, 9.6 Hz, 1H, 5-
H), 0.83 (dd, J = 14.5, 5.9 Hz, 1H, 5-H), 1.13 (d, J = 6.0 Hz, 6H, CH(CH3)2), 1.47-1.52 (m, 
2H, CH2SiMe3), 2.21 (dd, J = 16.2, 4.1 Hz, 1H, CH2SiOiPr), 2.49 (dd, J = 16.3, 6.7 Hz, 1H, 
CH2SiOiPr), 2.71-2.84 (m, 1H, 3-H), 3.69-3.77 (m, 1H, 4-H), 3.78 (s, 3H, OMe), 3.97 (sept, J 
= 6.0 Hz, 1H, CH(CH3)2), 4.35-4.50 (m, 2H, PMB), 5.07-5.14 (m, 1H, 2-H), 6.81-6.89 (m, 
2H, PMB), 7.21-7.30 (m, 2H, PMB).- 13C NMR (75 MHz): δ = -1.01 (+, SiMe3), -0.29 (+, 
SiMe), -0.30 (+, SiMe), 21.94 (-, CH2SiMe3), 22.84 (-, CH2SiMe2OiPr), 26.08 (+, 2xMe), 
42.99 (-, 5-C), 47.40 (+, 3-C), 55.52 (+, OMe), 65.01 (+, iPr), 70.97 (-, PMB), 88.57 (+, 4-C), 
113.93 (+, 2x PMB), 126.30 (+, 2-C), 129.45 (+, 2x PMB), 131.28 (Cq, PMB), 137.95 (Cq, 1-
C), 159.24 (Cq, PMB).- IR (neat): ~ν = 3035, 2955, 2898, 2870, 1729, 1641, 1612, 1586, 
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1512, 1464, 1402, 1380, 1365, 1348, 1300, 1248, 1172, 1124, 1086, 1027, 841, 758, 694 
cm-1.- MS (LSIMS, MeOH/Glycerin): m/z = 421.5 (35) [MH+].- HRMS (LSIMS, 
MeOH/Glycerin): 421.2585 (C23H41O3Si2: calc. 421.2594 [MH+]).  
 
O
OPMB
SiMe2OiPr  
(3S,4S)-3-((dimethyl(iso-propoxy)silyl)methyl)-4-(p-methoxybenzyloxy)cyclopentenone 
(155) 
 
Rf (hexanes:ethylacetate 3:1) = 0.43.- 1H NMR (300 MHz): δ = 0.1 (s, 6H, SiMe2), 0.54 (dd, J 
= 14.7, 10.0 Hz, 1H, CH2Si), 0.96 (dd, J = 14.8, 4.4 Hz, 1H, CH2Si), 1.11 (d, J = 6.0 Hz, 6H, 
iPr), 1.91 (dd, J = 18.4, 7.1 Hz, 1H, 2-H), 2.20 (dd, J = 18.4, 5.5 Hz, 1H, 2-H), 2.35-2.46 (m, 
1H, 3-H), 2.46-2.65 (m, 2H, 5-H), 3.79 (s, 3H, OMe), 3.74-3.82 (m, 1H, 4-H), 3.95 (sept, J = 
6.0 Hz, 1H, CH(CH3)2), 4.38-4.52 (m, 2H, PMB), 6.83-6.92 (m, 2H, PMB), 7.19-7.28 (m, 2H, 
PMB).- 13C NMR (75 MHz): δ = -0.7 (+, SiMe), -0.6 (+, SiMe), 21.4 (-, CH2Si), 25.9 (+, iPr), 
37.8 (+, 3-C), 43.6 (-, 2-C), 45.2 (-, 5-C), 55.4 (+, OMe), 65.1 (+, iPr), 71.4 (-, PMB), 83.3 (+, 
4-C), 124.0 (+, 2xPMB), 129.4 (+, 2xPMB), 130.3 (Cq, PMB), 159.4 (Cq, PMB), 216.6 (Cq, 
1-C). 
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11.4 Synthesis of the cyclopropylcarbaldehyde 
 
Representative procedure for the synthesis of bis(4-iso-propyloxazoline) (159)[181]  
 
 
(-)-(S,S)-N,N'-Bis(1-hydroxymethyl-2-methylpropyl)-2,2-dimethyl-malonamide (165)[181] 
 
An oven dried 250 ml, 3-necked round-bottom flask equipped with a stirring bar and two 
50 ml pressure-equalizing addition funnels connected to a mineral oil bubbler is purged with 
nitrogen and charged with (L)-valinol (5.13 g, 0.050 mol, 2.0 eq.). The flask is immersed in 
an ice bath at 0 °C and NEt3 (17.4 ml, 0.124 mol) is added dropwise via the first addition 
funnel. 2,2-Dimethylpropanedioyl dichloride (3.3 ml, 0.25 mol, 1.0 eq.) in dry CH2Cl2 
(25 ml) is then added dropwise over 25 min. via the second addition funnel. The internal 
temperature increases from 0 °C to 10 °C during the addition. Subsequently, the ice bath is 
removed and the reaction mixture is allowed to warm to rt. Stirring is continued for 45 min, 
resulting in a colorless precipitate that is dissolved by addition of dry CH2Cl2 (120 ml). After 
addition of aqueous HCl (1N, 30 ml), the aqueous layer is separated and extracted with 
CH2Cl2 (3x15 ml). The combined organic layers are washed with sat. NaHCO3 (30 ml) and 
brine (30 ml), dried over MgSO4, filtered and concentrated in vacuo to afford crude product as 
a pale yellow solid. Recrystallization of the crude product from ethyl acetate (40 ml) yields 
165 (4.30 g, 14.2 mmol, 57%) as white crystals. The mother liquor is concentrated and the 
residue recrystallized from ethyl acetate (10 ml) to yield a second crop of 165 (1.60 g, 5.27 
mmol, 21%); the process is repeated to yield a third crop of 165 (0.440 g, 1.45 mmol, 6%, 
total yield: 6.40 g, 21.1 mmol, 84%). 
 
Rf (ethylacetate:methanol 95:5) = 0.25.- [ ]20Dα = -6.0 (c = 0.50, CH2Cl2).- mp 98-99 °C; 1H 
NMR (300 MHz, CDCl3): δ = 0.92 (d, J = 6.8 Hz, 6 H), 0.96 (d, J = 6.8 Hz, 6 H), 1.50 (s, 6 
H), 1.82 (oct, J = 6.8 Hz, 2 H), 2.66 (bs, 2 H), 3.52 (m, 2 H), 3.69–3.86 (m, 4 H), 6.41 (d, J = 
8.6 Hz, 2 H).- 13C NMR (75 MHz, CDCl3): δ = 18.8, 19.6, 23.7, 29.1, 50.2, 57.1, 63.5, 174.5. 
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(-)-(S,S)-bis(4-iso-propyloxazoline) ((-)-159)[181] 
 
An oven dried 500 ml, 2-necked round-bottom flask equipped with a stirring bar and a 50 ml, 
pressure-equalizing addition funnel connected to a mineral oil bubbler is purged with nitrogen 
and charged with (-)-(S,S)-N,N'-bis-(1-hydroxymethyl-2-methylpropyl)-2,2-dimethylmalon-
amide (165) (5.5 g, 18.4 mmol), DMAP (0.204 g, 1.67 mmol) and dry CH2Cl2 (130 ml). The 
flask is immersed in a water bath at rt and NEt3 (10.25 ml, 73.4 mmol) is added slowly via 
syringe. Subsequently, tosyl-chloride (7.10 g, 37 mmol, 2.0 eq.), dissolved in dry CH2Cl2 
(15 ml), is added dropwise over 30 min. After completion of the addition the funnel is rinsed 
with dry CH2Cl2 (2.5 ml) and the reaction mixture is stirred for an additional 27 h at rt. The 
reaction mixture is treated with sat. NH4Cl (70 ml) followed by water (40 ml). The aqueous 
layer is separated and extracted with CH2Cl2 (3x55 ml), and the combined organic layers are 
dried over MgSO4. The organic solution is filtered and concentrated under vacuum. The oily 
residue is treated with hot pentane (40 ml), stirred for 5 min and the supernatant liquid is 
decanted. This procedure is repeated three times and the collected pentane layers are 
combined and concentrated under vacuum to yield (-)-159 (4.05 g, 15.2 mmol, 83%) as a 
colorless oil, which rendered solid while stored at -35 °C under a N2-atmosphere. 
An analytically pure sample for characterization purposes was obtained by Kugelrohr-
distillation (95-100 °C, 0.5 mm Hg) of the crude material.  
 
Rf (dichloromethane/methanol 9:1) = 0.25.- [ ]20Dα = -107.5 (c = 1.0, CH2Cl2).- 1H NMR (300 
MHz, CDCl3) δ = 0.85 (d, J = 6.8 Hz, 6 H), 0.91 (d, J = 6.8 Hz, 6 H), 1.51 (s, 6 H), 1.88-1.73 
(m, 2 H), 4.06-3.93 (m, 4 H), 4.26-4.15 (m, 2 H).- 13C NMR (75 MHz, CDCl3) δ = 17.3, 18.5, 
24.4, 32.2, 38.5, 69.9, 71.5, 168.7. 
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Representative procedure for the cyclopropanation of methyl-2-furoate (131): 
 
O CO2Me
H
H
EtO2C
 
(1S,2S,3S)-(-)-Oxalic acid 2-ethoxycarbonyl-3-formylcyclopropylester methyl ((-)-160) 
 
A 500 ml flask equipped with a stirring bar and a 500 ml, pressure-equalizing, addition funnel 
with incorporated Mariotte tube connected to a mineral oil bubbler, was purged with nitrogen 
and cooled to 0 °C. It was charged with Cu(OTf)2 (0.227 g, 0.628 mmol, 0.66%mol), (S,S)-
iso-propyl-bis(oxazoline) (-)-159 (0.211 g, 0.799 mmol, 0.84 mol%) and dry CH2Cl2 (10 ml) 
resulting in a deep blue solution. After stirring for 10 min furan-2-carboxylic acid methyl 
ester 131 (12 g, 95 mmol, 1.0 eq.) was poured in and phenyl hydrazine (3 drops) was added 
via a syringe leading to a color change to red-brown which indicates the reduction of 
copper(II) to copper(I). This solution was stirred for 30 min and subsequently ethyl 
diazoacetate (215 ml solution of 10.14%mass, 0.25 mol, 2.67 eq.) in CH2Cl2 was added via 
the addition funnel during 5 days. On completion of addition the solution was stirred for 1 h 
until no gas evolution was observed any longer. The reaction mixture was passed through a 
pad of basic alumina (10x5.5 cm), followed by CH2Cl2 (500 ml). The organic layers were 
combined and concentrated under reduced pressure to afford a yellow-brown oil. The residue 
was purified by fractioned distillation under reduced pressure (p = 3x10-2 mbar, b.p. = 38-
44 °C) and starting material (4.78 g, 37.9 mmol, 40%) was recovered. The brown residue was 
purified by column chromatography (silica, 4x36 cm, hexanes:ethylacetate 9:1) to yield the 
desired product (-)-160 (10.8 g, 50.90 mol, 85% ee, 54% yield, 89% yield based on recovered 
starting material) as a yellowish oil. To obtain enantiomeric pure product the oil was treated 
with n-pentane (200 ml) followed by CH2Cl2 (8 ml) with stirring until the solution changed 
from cloudy to clear. The solution was kept for 16 h at -27 °C and a small enantiomerical pure 
crystal was added which gave rise to colorless crystals after 6 d. The supernatant liquid was 
removed by filtration and the remaining crystals were dried in vacuo to afford (-)-160 (6.90 g, 
33.0 mmol, 34%, >99% ee) as colorless crystals. After concentration of the mother liquor in 
vacuo the residue was again treated with n-pentane (120 ml) and CH2Cl2 (2 ml) and set for 
crystallization at -27 °C for 5 d. Removal of the supernatant liquid and drying in vacuo 
afforded (-)-160 (0.609 g, 2.87 mmol, 3%, >99% ee, total yield: 7.51 g, 35.39 mol, 37% yield, 
62% yield based on recovered starting material) as colorless crystals. 
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R
f 
(hexanes:ethyl acetate 5:1) = 0.29.- m.p. = 42 °C.- [ ]20Dα = -272 (c = 1.0, CH2Cl2); 1H NMR 
(300 MHz, CDCl3): δ = 1.17 (dd, J = 2.6, 1.1 Hz, 1 H), 1.27 (t, J = 7.1 Hz, 3 H), 2.87 (ddd, J 
= 5.3, 2.9, 2.7 Hz, 1 H), 3.81 (s, 3 H), 4.16 (q, J = 7.1 Hz, 2 H), 4.98 (dd, J = 5.2, 1.1 Hz, 1 
H), 6.40 (d, J = 3.0 Hz, 1 H,).- 13C NMR (100.6 MHz, CDCl3): δ = 14.20, 21.43, 31.97, 
52.26, 61.08, 67.54, 116.19, 149.15, 159.54, 171.78. 
 
 
(1S,2S,3S)-(-)-oxalic acid 2-ethoxycarbonyl-3-formyl-cyclopropyl ester methyl ester 
((-)-130) 
 
A 100 ml flask was charged with a solution of (-)-160 (3.022 g, 14.24 mmol, 1.0 eq.) in dry 
CH2Cl2 (50 ml). The flask was equipped with a gas passing tube connected with one side to 
an ozone generator and with the other side to a drying tube containing KOH coated clay 
ending up in the hood. The solution was cooled to -78 °C and a constant stream of oxygen 
containing ozone (O2 = 150 l/h, O3 = 7 g/h) was immersed into the solution until a deep blue 
color appeared (approx. 15 min). Excess of ozone was expelled by passing a constant flow of 
oxygen for another 10 min into the solution. The gas inlet tube was replaced by a drying tube. 
DMS (2.28 ml, 57 mol, 4.0 eq.) was added at -78 °C, and the reaction mixture was allowed to 
warm up slowly to rt and stirred for 22 h. The solution was washed with sat. NaHCO3 (10 ml) 
and the aqueous layer was extracted with CH2Cl2 (10 ml). The combined organic layers were 
washed with H2O (5 ml) and the aqueous layer was extracted again with CH2Cl2 (5 ml). The 
combined organic layers were dried (Na2SO4) and concentrated under reduced pressure to 
yield the aldehyde (3.199 g, 13.10 mmol, 92%) as a pale yellow oil which can be used 
without any further purification. To obtain a colorless microcrystalline solid the crude product 
was crystallized from Et2O (3 ml) and stored at -35 °C for 2 weeks. The solvent was removed 
by a pipette and the solid was dried in vacuo to give (-)-130 (3.124 g, 12.78 mmol) in 90% 
yield. 
 
m.p. = 52 °C.- [ ]20Dα  = -37.6 (c = 1.0, CH2Cl2); 1H NMR (300 MHz, CDCl3): δ = 1.30 (t, J = 
7.2 Hz, 3 H), 2.81 (ddd, J = 7.2, 6.0, 4.0 Hz, 1 H), 2.93 (dd, J = 6.0, 3.6 Hz, 1 H), 3.92 (s, 3 
H), 4.20 (q, J = 7.2 Hz, 1 H), 4.21 (q, J = 7.1 Hz, 1 H), 4.83 (dd, J = 7.2, 3.6 Hz, 1 H), 9.47 
(d, J = 4.0 Hz, 1 H).- 13C NMR (100.6 MHz, CDCl3): δ = 14.10, 26.36, 34.86, 54.00, 58.87, 
62.03, 156.59, 156.86, 168.13, 192.13. 
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11.5 Formation of the anti-substituted lactone aldehyde 
 
CO2Et
O
OH
OPMB
SiMe2Ph
HMeO
O
O
 
(1R,2S,3R)-2-((R)-((1´S,2´S,3´S)-2-((dimethyl(phenyl)silyl)methyl)-3-(p-methoxy-
benzyloxy)-5´-methylenecyclopentyl)(hydroxy)methyl)-3-(ethoxycarbonyl)cyclopropyl 
methyl oxalate (171) 
 
Under a nitrogen atmosphere cyclopropylcarbaldehyde (+)-130 (370 mg, 1.516 mmol, 0.95 
eq.) was dissolved in abs. CH2Cl2 (10 ml) and cooled to -78 °C. BF3⋅OEt2 (249 mg, 216 µl, 
1.10 eq.) was added via a syringe and after stirring for 30 min. Allylsilane 152 (700 mg, 
1.595 mmol, 1.0 eq.) dissolved in abs. CH2Cl2 (5 ml) was added slowly resulting in a color 
change to red brown. After stirring for 16 h at -78 °C, sat. NaHCO3 (2 ml) was added and the 
mixture was allowed to warm to rt. The layers were separated and the aqueous layer was 
again extacted with CH2Cl2 (2x2 ml). The combined org. layers were washed with brine 
(2 ml), H2O (2 ml), dried (Na2SO4) and concentrated in vacuo to yield 928 mg (1.519 mmol, 
95%) product as a yellowish oil containing only a single stereoisomer which was used without 
further purification. 
 
[ ]20Dα = + 14.9 (c = 1.06, CHCl3).- 1H NMR (600 MHz): δ = 0.30 (s, 3H, SiCH3), 0.32 (s, 3H, 
SiCH3), 0.85 (d, J = 7.4 Hz, 2H, CH2Si), 1.29 (t, J = 7.1 Hz, 3H, CH2CH3), 1.75-1.86 (m, 1H, 
2-H), 2.16 (dd, J = 5.9, 2.6 Hz, 1H, 3-H), 2.39-2.44 (m, 1H, 1´-H), 2.49-2.59 (m, 3H, 2´-H, 
4´-H), 3.55-3.59 (m, 1H, 3´-H), 3.69 (dd, J = 8.8, 3.3 Hz, 1H, CHOH), 3.81 (s, 3H, PMB), 
3.89 (s, 3H, CO2Me), 4.09- 4.19 (q, J = 7.1 Hz, 2H, CH2CH3), 4.22-4.35 (m, 2H, PMB), 4.58 
(dd, J = 7.3, 2.6 Hz, 1H, 1-H), 5.00-5.12 (m, 2H, C=CH2), 6.83-6.91 (m, 2H, PMB), 7.13-
7.19 (m, 2H, PMB), 7.33-7.39 (m, 3H, Ph), 7.46-7.52 (m, 2H, Ph).- 13C NMR (150 MHz) δ = 
-2.4 (+, SiCH3), -2.3 (+, SiCH3), 14.1 (+, CH2CH3), 22. 5 (-, SiCH2), 28.1 (+, 3-C), 31.1 (+, 2-
C), 37.4 (-, 4´-C), 41.1 (+, 2´-C), 53.6 (+, PMB), 55.3 (+, OMe), 58.4 (+, 1-C), 58.9 (+, 1´-C), 
61.12 (-, CH2CH3), 69.8 (-, PMB), 71.3 (+, C-OH), 84.5 (+, 3´-C), 109.1 (-, C=CH2), 113.9 
(+, 2xPMB), 127.9 (+, 2x Ph), 129.1 (+, Ph), 129.4 (Cq, PMB), 129.4 (+, 2xPMB), 133.5 (+, 
2x Ph), 138.8 (Cq, SiPh), 150.1 (Cq, C=CH2), 157.0 (Cq, CO), 157.3 (Cq, CO), 159.3 (Cq, 
PMB), 170.7 (Cq, CO2Et).- IR (neat): ~ν = 3392, 3069, 2978, 2955, 2905, 1779, 1753, 1728, 
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1612, 1586, 1514, 1443, 1427, 1370, 1305, 1249, 1199, 1159, 1112, 1035, 835, 734, 702 cm-
1.- MS (FAB): m/z = 611.2 [M+H+], 703.3 8 [MH++Glyc].- HRMS (FAB): 611.2662 
(C33H43O9Si: calc. 611.2676 [MH+]). 
 
 
(2R,3S)-2-((1´S,2´S,3´S)-3´-(p-methoxybenzyloxy)-2´-((dimethyl(phenyl)silyl)methyl)-5´-
methylenecyclopentyl)-tetrahydro-5-oxofuran-3-carbaldehyde (175) 
 
The crude cyclopropylalcohol 171 (503 mg, 0.824 mmol, 1.0 eq.) was dissolved in MeOH 
(20 ml) and cooled to 0 °C. Ba(OH)2⋅8H2O (143 mg, 0.453 mmol, 0.55 eq.) was added over a 
period of 1 h and the mixture was stirred for additional 1 h. CH2Cl2 (20 ml) and H2O (20 ml) 
were added and the layers separated. The aqueous layer was again extracted with CH2Cl2 
(4x20 ml). The combined org. layers were washed with brine (10 ml), dried (Na2SO4) and 
concentrated in vacuo. Chromatography on flash silica gel (hexanes:ethylacetate 2:1) afforded 
283 mg product (0.591 mmol, 72%) as a single diastereomer as a colorless oil. 
 
Rf (hexanes:ethylacetate 2:1, Mostain) = 0.26.- [ ]20Dα = - 1.9 (c = 0.54, CHCl3).- 1H NMR (400 
MHz): δ = 0.31 (s, 3H, SiMe), 0.35 (s, 3H, SiMe), 0.74-0.78 (m, 2H, CH2Si), 2.25-2.30 (m, 
1H, 1´-H), 2.34-2.41 (m, 1H, 4´-H), 2.49 (dd, J = 18, 10 Hz, 1H, 4-H), 2.45-2.50 (m, 1H, 2´-
H), 2.67-2.75 (m, 1H, 4´-H), 2.81 (dd, J = 18, 7 Hz, 1H, 4-H), 3.15-3.22 (m, 1H, 3-H), 3.58- 
3.63 (m, 1H, 3´-H), 3.80 (s, 3H, OMe), 4.27 (dd, J = 24, 11 Hz, 2 H, PMB), 4.86 (dd, J = 8, 6 
Hz, 1H, 2-H), 4.92 (m, 1H, C=CH2), 5.50 (m, 1H, C=CH2), 6.83-6.88 (m, 2H, PMB), 7.13-
7.18 (m, 2H, PMB), 7.34-7.38 (m, 3H, Ph), 7.47-7.53 (m, 2H, Ph), 9.42 (d, J = 1 Hz, 1H, 
CHO).- 13C NMR (75.5 MHz): δ = -2.8 (+, SiMe), -2.2 (+, SiMe), 20.9 (-, CH2Si), 28.8 (-, 4-
C), 38.5 (-, 4´-C) , 42.4 (+, 2´-C), 49.9 (+, 3-C), 55.3 (+, OMe), 56.5 (+, 1´-C), 70.4 (-, PMB), 
80.3 (+, 2-C), 86.4 (+, 3´-C) , 112.7 (-, C=CH2), 113.8 (+, 2xPMB), 127.9 (+, 2xPh), 129.1 (+, 
Ph), 129.3 (+, 2xPMB), 130.2 (Cq, PMB), 133.7 (+, 2xPh), 139.1 (Cq, Ph), 147.8 (Cq, PMB), 
159.2 (Cq, 5´-C), 174.3 (Cq, 5-C), 197.8 (+, CHO).- IR (neat): ~ν = 2953, 2901, 1779, 1729, 
1653, 1613, 1514, 1462, 1421, 1353, 1302, 1249, 1174, 1109, 1067, 1034, 906, 831, 731 
cm-1.- MS (EI, 70 eV): m/z (%) = 135.0 (43.36) [SiMe2Ph+], 343.1 (1.12) [M-SiMe2Ph], 478.1 
(0.58) [M+].- HRMS (EI): 478.2163 (C28H34O5Si: calc. 478.2176 [M+]). 
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11.6 Radical cyclization 
OO
H
H
H
OPMB
SiMe2Ph
CO2Et
Br
 
(Z)-ethyl 2-bromo-3-((2´S,3´R)-2´-((1´´S,2´´S,3´´S)-2´´-((dimethyl(phenyl)silyl)methyl)-
3´´-(p-methoxybenzyloxy)-5´´-methylenecyclopentyl)-5´-oxo-tetrahydrofuran-3´-yl) 
acrylate (183) 
 
Under a nitrogen atmosphere NaH (60% suspension, 18 mg, 0.439 mmol, 1.05 eq.) was 
dissolved in dry THF (2 ml) and cooled to 0 °C. Triethylposphonoacetate (98 mg, 88 µl, 
0.439 mmol, 1.05 eq.) was added dropwise and the clear solution was stirred for 20 min at 
0 °C. Bromine (74 mg, 24 µl, 0.466 mmol, 1.11 eq.) was added dropwise and the reaction 
mixture was stirred for 1 h at 0 °C. NaH (60% suspension, 18 mg, 0.439 mmol, 1.05 eq.) was 
added slowly to the reaction mixture and stirring was continued for 20 min. Aldehyde 175 
(200 mg, 0.418 mmol, 1.00 eq.) was dissolved in dry THF (2 ml) and added slowly to the 
bromophosphonate. The mixture was allowed to warm to rt and stirred for further 60 min and 
the reaction was quenched with H2O (3 mL). The mixture was extracted with CH2Cl2 
(3x10 ml), the combined organic layers were washed with water (2 ml), dried over Na2SO4, 
filtered and concentrated. Chromatography on silica gel (hexanes:ethylacetate 3:1) afforded 
190 mg (0.303 mg, 72%, E/Z = 17:83) product as a colorless oil. 
 
Rf (hexanes:ethylacetate 2:1) = 0.44.- 1H NMR (600 MHz): δ = 0.31 (s, 3H, SiMe), 0.35 (s, 
3H, SiMe), 0.74-0.75 (m, 2H, SiCH2), 1.34 (t, J = 7.1 Hz, 3H, CH2CH3), 2.26 (dd, J = 17.8, 
7.7 Hz, 1H, 4´-H), 2.20-2.26 (m, 1H, 1´´-H), 2.34-2.41 (m, 1H, 4´´-H), 2.49-2.55 (m, 1H, 2´´-
H), 2.65-2.69 (m, 1H, 4´´-H),2.72 (dd, J = 17.8, 9.2 Hz, 1H, 4´-H), 3.33-3.39 (m, 1H, 3´-H), 
3.56-3.61 (m, 1H, 3´´-H), 3.81 (s, 3H, OMe), 4.23-4.33 (m, 4H, CH2CH3, PMB), 4.60 (dd, J 
= 8.7, 6.3 Hz, 1H, 2´-H), 4.91-4.95 (m, 1H, C=CH2), 5.00-5.04 (m, 1H, C=CH2), 6.84-6.89 
(m, 2H, PMB), 7.15 (d, J = 8.9 Hz, 1H, 3-H), 7.17-7.20 (m, 2H, PMB), 7.35-7.40 (m, 3H, 
Ph), 7.49-7.53 (m, 2H, Ph); E-isomer: 1.33 (t, J = 6.9 Hz, 3H, CH2CH3), 2.28 (dd, J = 17.5, 
8.3 Hz, 1H, 4´-H), 2.75 (dd, J = 17.9, 9.2 Hz, 1H, 4´-H), 3.82 (s, 3H, OMe), 4.47 (dd, J = 8.6, 
6.6 Hz, 1H, 2´-H), 6.44 (d, J = 9.7 Hz, 1H, 3-H).- 13C NMR (150 MHz): δ = -2.76 (+, SiMe), 
-2.24 (+, SiMe), 14.12 (+, CH2CH3), 20.57 (-, SiCH2), 33.65 (-, 4´-C), 38.46 (-, 4´´-C), 42.02 
(+, 2´´-C), 42.06 (+, 3´-C), 55.27 (+, OMe), 56.16 (+, 1´´-H), 62.81 (-, CH2CH3), 70.39 (-, 
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PMB), 84.71 (+, 2´-C), 86.25 (+, 3´´-C), 112.80 (-, C=CH2), 113.77 (+, 2xPMB), 117.78 (Cq, 
5´´-C), 127.88 (+, 2x Ph), 129.03 (+, Ph), 129.23 (+, 2x PMB), 130.44 (Cq, CO2Et), 133.64 
(+, 2x Ph), 139.33 (Cq, SiC), 143.40 (+, 3-C), 146.68 (Cq, 2-C), 159.12 (Cq, PMB), 161.75 
(Cq, PMB), 174.44 (Cq, CO); E-isomer: 34.66, 40.99, 42.14, 56.27, 62.51, 85.23, 112.67.- 
IR (neat): ~ν = 3069, 2982, 2954, 2904, 2872, 1783, 1729, 1652, 1612, 1586, 1514, 1464, 
1425, 1369, 1300, 1250, 1198, 1172, 1112, 1038, 997, 898, 833, 728, 702 cm-1.- MS (LSI): 
m/z = 627 [M+H+], 629 [M+H+], 719 [MH++Glyc.], 721 [MH++Glyc.].- HRMS (FAB): 
627.17487 (C32H40BrO6Si: calc. 627.1749 [M+H+]). 
 
 
(3aR, 6aR,8S,9S,9aR,9bS,E)-ethyl 9-((dimethyl(phenyl)silyl)methyl)-8-(p-methoxybenzyl-
oxy)-2-oxo-2,3,3a,6,6a,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-5-carboxylate (184) 
 
Under a nitrogen atmosphere bromocompound 183 (158 mg, 0.252 mmol, 1.0 eq.) and AIBN 
(4 mg, 0.025 mmol, 0.1 eq.) were dissolved in abs. benzene (5 ml) and heated to reflux. Via a 
syringe pump Bu3SnH (110 mg, 101 µl, 0.378 mmol, 1.5 eq.) and AIBN (4 mg, 0.025 mmol, 
0.1 eq.) in abs. benzene (4 ml) were added slowly over a period of 1 h. After refluxing the 
reaction mixture for 1 h the reaction mixture was allowed to cool to rt and the solvent was 
removed in vacuo. Chromatography on silica gel (hexanes:ethylacetate 3:1) afforded 123 mg 
(0.224 mmol, 89%) product as a colorless oil (dr = 87:13). 
 
Rf (hexanes:ethylacetate 2:1) = 0.46.- 1H NMR (400 MHz): δ = 0.33 (s, 3H, SiMe), 0.34 (s, 
3H, SiMe), 0.85 (dd, J = 14.6, 8.6 Hz, 1H, CH2Si), 1.06 (dd, J = 14.9, 6.3 Hz, 1H, CH2Si), 
1.28 (t, J = 7.1 Hz, 3H, CH2CH3), 1.46-1.55 (m, 1H, 7-H), 1.83-1.91 (m, 1H, 9a-H), 2.01-2.10 
(m, 1H, 7-H), 2.33-2.39 (m, 1H, 9-H), 2.41-2.47 (m, 1H, 6a-H), 2.48 (dd, J = 16.9, 12.8 Hz, 
1H, 3-H), 2.49-2.57 (m, 1H, 6-H), 2.76 (dd, J = 16.9, 8.1 Hz, 3-H), 2.78-2.88 (m, 1H, 6-H), 
3.01-3.13 (m, 1H, 3a-H), 3.52-3.59 (m, 1H, 8-H), 3.80 (s, 3H, OMe), 4.03-4.22 (m, 4H, 
CH2CH3, PMB), 4.22-4.29 (m, 1H, 9b-H), 6.81-6.90 (m, 3H, PMB, 4-H), 7.12-7.19 (m, 1H, 
PMB), 7.29-7.37 (m, 3H, Ph), 7.49-7.59 (m, 2H, Ph).- 13C NMR (100 MHz): δ = -2.59 (+, 
SiMe), -2.28 (+, SiMe), 14.23 (+, CH2CH3), 21.74 (-, CH2Si), 29.39 (-, 6-C), 35.43 (-, 3-C), 
36.36 (-, 7-C), 37.41 (+, 6a-C), 41.48 (+, 3a-C), 46.08 (+, 9-C), 55.29 (+, OMe), 56.03 (+, 9a-
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C), 61.05 (-, CH2CH3), 70.57 (-, PMB), 83.73 (+, 9b-C), 87.90 (+, 8-C), 113.73 (+, 2xPMB), 
127.74 (+, 2xPh), 128.86 (+, 1xPh), 129.16 (+, 2xPMB), 130.66 (Cq, CO2Et), 133.77 (+, 
2xPh), 135.28 (Cq, PMB), 138.04 (+, 4-C), 139.51 (Cq, SiC), 159.06 (Cq, PMB), 166.94 (Cq, 
5-C), 174.98 (Cq, 2-C).- IR (neat): ~ν = 3066, 3045, 2953, 2906, 1784, 1708, 1644, 1612, 
1586, 1513, 1443, 1425, 1392, 1361, 1353, 1300, 1248, 1205, 1173, 1113, 1034, 993, 925, 
897, 829, 790, 730, 701 cm-1.- MS (EI, 70eV): m/z = 533.2 (1.35) [M-CH3+], 547.2 (0.94) [M-
H+], 548.2 [M+].- HRMS (PI-LSIMS, MeOH/Glycerin): 549.26710 (C32H41O6Si: calc. 
549.2672 [M+H+]). 
 
OO
H
H
H
OH
SiMe2Ph
CO2Et
H
 
(3aR,6aR,8S,9S,9aR,9bS,E)-ethyl-9-((dimethyl(phenyl)silyl)methyl)-8-hydroxy-2-oxo-
2,3,3a, 6,6a,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-5-carboxylate (185) 
 
Compound 184 (104 mg, 0.19 mmol, 1.0 eq.) was dissolved in CH2Cl2 (8 ml) and pH 7 
phosphate buffer (3 ml). At rt DDQ (56 mg, 0.25 mmol, 1.3 eq.) was added in small portions 
and the solution was stirred for 4 h. H2O (5 ml) and CH2Cl2 (10 ml) was added and the layers 
were separated. The aqueous layer was extracted with CH2Cl2 (2x 10 ml), dried (Na2SO4) and 
concentrated in vacuo. Chromatography on silica gel (hexanes:ethylacetate 3:1) afforded 72 
mg (0.17 mmol, 89%) product as a colorless oil (dr = 87:13). 
 
Rf (hexanes:ethylacetate 3:1) = 0.13.- 1H NMR (600 MHz): δ = 0.35 (s, 3H, SiMe), 0.39 (s, 
3H, SiMe), 0.86 (dd, J = 15.1, 10.0 Hz, 1H, CH2Si), 1.21 (dd, J = 14.9, 4.4 Hz, 1H, CH2Si), 
1.29 (t, J = 7.2 Hz, 3H, CH2CH3), 1.32-1.37 (m, 1H, 7-H), 1.87-1.94 (m, 1H, 9a-H), 2.02-2.09 
(m, 1H, 9-H), 2.15-2.23 (m, 1H, 7-H), 2.38-2.44 (m, 1H, 6a-H), 2.48 (dd, J = 17.0, 13.1 Hz, 
1H, 3-H), 2.55-2.62 (m, 1H, 6-H), 2.67-2.75 (m, 1H, 6-H), 2.79 (dd, J = 16.9, 8.3 Hz, 1H, 3-
H), 3.10-3.18 (m, 1H, 3a-H), 3.68-3.74 (m, 1H, 8-H), 4.19 (q, J = 7.1 Hz, CH2CH3), 4.28-
4.33 (m, 1H, 9a-H), 6.84-6.87 (m, 1H, 4-H), 7.36-7.40 (m, 3H, Ph), 7.57-7.61 (m, 2H, Ph).- 
13C NMR (150 MHz): δ =-2.88 (+, SiCH3), -1.91 (+, SiCH3), 14.22 (+, CH2CH3), 20.55 (-, 
CH2Si), 30.65 (-, 6-C), 35.18 (-, 3-C), 37.29 (+, 6a-C), 40.16 (-, 7-C), 41.39 (+, 3a-C), 49.17 
(+, 9-C), 55.91 (+, 9a-C), 61.09 (-, CH2CH3), 80.35 (+, 8-C), 84.71 (+, 9b-C), 128.04 (+, 
2xPh), 129.20 (+, Ph), 133.68 (+, 2x Ph), 135.11 (Cq, CO2Et), 137.39 (+, 4-C), 139.31 (Cq, 
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Si-C), 166.96 (Cq, 5-C), 174.96 (Cq, 2-C).- IR (neat): ~ν = 3519, 3068, 3048, 2979, 2953, 
2907, 2361, 2252, 1789, 1760, 1713, 1644, 1444, 1426, 1366, 1253, 1208, 1112, 1053, 1014, 
911, 837, 729, 701 cm-1.- MS (FAB): m/z = 429.2 [MH+], 521.2 [MH++Glyc], 857.3 
[2M+H+].- HRMS (FAB): 429.20869 (C24H33O5Si: calc. 429.2097 [MH+]). 
11.7 Precursors for ring closing metathesis 
 
OO
H
H
H
OPMB
HO
SiMe2Ph  
(4R,5R)-5-((1´S,2´S,3´S)-2´-((dimethyl(phenyl)silyl)methyl)-3´-(p-methoxybenzyloxy)-5´-
methylenecyclopentyl)-4-(1´´R/S-hydroxybut-3´´-enyl)dihydrofuran-2(3H)-one (195) 
 
Aldehyde 175 (200 mg, 0.418 mmol, 1.0 eq.) was dissolved in abs. CH2Cl2 (5 ml) under a N2-
atmosphere and cooled to -78 °C. Allyltrimethylsilane (80 µl, 62 mg, 1.3 eq.) was added and 
the mixture stirred for 30 min. BF3⋅Et2O (60 µl, 68 mg, 1.15 eq.) was added and the mixture 
was stirred at -78 °C for 24 h. The reaction was quenched by adding NaHCO3 (1 ml), the 
mixture was diluted with CH2Cl2 (10 ml) and allowed to warm to rt. The layers were 
separated and the aqueous layer was again extracted with CH2Cl2 (2x6 ml). The combined 
organic layers were dried (Na2SO4), filtered and concentrated in vacuo. Chromatography on 
silica gel (hexanes:ethylacetate 2:1) afforded 159 mg (0.305 mmol, 73%) product as a 
colorless oil (dr = 50:50). 
 
Rf (hexanes:ethylacetate 2:1, Mostain) = 0.32.- 1H NMR (300 MHz): δ = 0.29 (s, 3H, SiMe, 
diast: 0.31), 0.34 (s, 3H, SiMe, diast: 0.35), 0.71-0.85 (m, 2H, SiCH2), 1.70-2.60 (m, 8H, 3-H, 
4-H, 1´-H, 2´-H, 4´-H, 2´´-H), 2.71 (dd, J = 17.3, 6.3 Hz, 1H, 3-H), 3.37-3.48 (m, 1H, 1´´-H), 
3.53-3.63 (m, 1H, 3´-H), 3.79 (s, 3H, OMe), 4.21-4.38 (m, 2H, PMB), 4.71 (dd, J = 7.8, 2.3 
Hz, 1H, 5-H, diast: 4.59, dd, J = 8.2, 3.6 Hz), 4.82-4.89 (m, 1H, =CH2), 4.99-5.04 (m, 1H, 
=CH2), 5.04-5.16 (m, 2H, =CH2), 5.55-5.75 (m, 1H, 3´´-H), 6.81-6.88 (m, 2H, PMB), 7.15-
7.23 (m, 2H, PMB), 7.30-7.39 (m, 3H, Ph), 7.45-7.55 (m, 2H, Ph).- 13C NMR (75.5 MHz): δ 
= -2.8 (+, SiMe, diast: -2.6), -2.2 (+, SiMe, diast: -2.1), 20.7 (-, CH2Si, diast: 21.1), 28.7 (-, 
4´-C, diast: 31.5), 38.8 (-, 3-C), 38.9 (-, 2´´-C, diast: 39.7), 41.7 (+, 4-C, diast: 41.4), 42.1 (+, 
2´-C, diast: 41.9), 55.2 (+, OMe), 56.1 (+, 1´-C, diast: 56.0), 70.2 (+, 1´´-C, diast: 72.0), 70.4 
Experimental Part 
 
125
(-, PMB, diast: 70.3), 83.3 (+, 5-C, diast: 82.9), 86.5 (+, 3´-C, diast: 86.4), 112.0 (-, =CH2, 
diast: 111.8), 113.7 (+, 2xPMB), 119.0 (-, =CH2, diast: 118.9), 127.8 (+, 2xPh), 128.8 (+, Ph, 
diast: 128.9), 129.4 (+, 2xPMB, diast: 129.3), 130.4 (Cq, PMB, diast: 130.2), 133.6 (+, 2xPh, 
diast: 133.5), 133.8 (+, 3´´-C, diast: 133.7), 139.4 (Cq, Ph, diast: 139.3), 148.5 (Cq, PMB, 
diast: 147.8), 159.0 (Cq, 5´-C), 176.8 (Cq, 2-C, diast: 176.7).- IR (neat): ~ν = 3460, 3009, 
2954, 2903, 1770, 1642, 1612, 1512, 1423, 1353, 1300, 1249, 1179, 917, 831, 755, 702 cm-1.- 
MS (CI, NH3): m/z (%) = 137.1 (22.8), 154.1 (82.3), 538.2 (100) [M+NH4+].- HRMS (EI, 70 
eV): 520.2635 (C31H40O5Si: calc. 520.2645 [M +]). 
 
 
(4R,5R)-5-((1´S,2´S,3´S)-3´-(p-methoxybenzyloxy)-2´-((dimethyl(phenyl)silyl)methyl)-5´-
methylenecyclopentyl)-dihydro-4-(1´´R/S-hydroxy-3´´-methylbut-3´´-enyl)furan-2(3H)-
one (196) 
 
Aldehyde 175 (395 mg, 0.825 mmol, 1.0 eq.) was dissolved in abs. CH2Cl2 (8 ml) under a N2-
atmosphere and cooled to -78 °C. Trimethyl(2-methylallyl)silane (300 µl, 220 mg, 2.0 eq.) 
was added and the mixture stirred for 30 min. BF3⋅Et2O (133 µl, 150 mg, 1.06 eq.) was added 
and the mixture was stirred at -78 °C for 24 h. The reaction was quenched by adding NaHCO3 
(1 ml), the layers were separated and the organic layer was dried over Na2SO4, filtered and 
concentrated in vacuo. Chromatography on silica gel (hexanes:ethylacetate 3:1) afforded 
316 mg (591 mmol, 72%) product as an inseparable 80:20 mixture of both diastereomers as a 
colorless oil. 
 
Rf (hexanes:ethylacetate 3:1, Mostain) = 0.14.- 1H NMR (400 MHz): δ = 0.31 (s, 3H, SiMe, 
diast: 0.29), 0.34 (s, 3H, SiMe, diast: 0.35), 0.72-0.84 (m, 2H, SiCH2), 1.63 (s, 3H, CH3, diast: 
1.66), 1.69-1.79 (bs, 1H, OH), 1.89-2.02 (m, 2H, 2´´-H), 2.17-2.23 (m, 1H, 1´-H), 2.26-2.42 
(m, 3H, 3-H, 4´-H, 4-H), 2.47-2.54 (m, 1H, 2´-H), 2.54-2.63 (m, 1H, 4´-H), 2.71 (dd, J = 
17.0, 6.3 Hz, 1H, 3-H), 3.51-3.63 (m, 2H, 1´´-H, 3´-H), 3.79 (s, 3H, OMe, diast: 3.80), 4.21-
4.38 (m, 2H, PMB), 4.63 (dd, J = 8.4, 3.7 Hz, 1H, 5-H), 4.70-4.75 (m, 1H, =CH2), 4.84-4.89 
(m, 2H, =CH2), 5.00-5.05 (m, 1H, =CH2), 6.81-6.88 (m, 2H, PMB), 7.15-7.20 (m, 2H, PMB), 
7.33-7.38 (m, 3H, Ph), 7.48-7.53 (m, 2H, Ph).- 13C NMR (75.5 MHz): δ = -2.5 (+, SiMe), -2.0 
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(+, SiMe), 20.9 (-, CH2Si), 22.3 (+, CH3), 28.9 (-, 4´-C), 39.1 (-, 3-C), 41.9 (+, 4-C), 42.5 (+, 
2´-C), 43.9 (-, 2´´-C), 55.4 (+, OMe), 56.4 (+, 1´-C), 68.4 (+, 1´´-C), 70.5 (-, PMB), 83.4 (+, 
5-C), 86.6 (+, 3´-C), 112.1 (-, =CH2), 113.9 (+, 2xPMB), 114.4 (-, =CH2), 128.0 (+, 2xPh), 
129.1 (+, Ph), 129.4 (+, 2xPMB), 130.6 (Cq, PMB), 133.8 (+, 2xPh), 139.5 (Cq, Ph), 141.7 
(Cq, 3´´-C), 148.1 (Cq, PMB), 159.2 (Cq, 5´-C), 177.0 (Cq, 2-C).- IR (neat): ~ν = 3468, 3070, 
2951, 2903, 1774, 1648, 1613, 1586, 1514, 1462, 1425, 1373, 1354, 1302, 1248, 1192, 1174, 
1112, 1090, 1069, 1036, 894, 833, 727, 702 cm-1.- MS (CI, NH3): m/z (%) = 121.1 (13.3), 
137.2 (17.6), 154.1 (64.9), 552.3 (100) [M+NH4+].- HRMS (EI, 70 eV): 534.2786 
(C32H42O5Si: calc. 534.2802 [M+]). 
 
OO
H
H
H
OPMB
HO
Br
SiMe2Ph  
(4R,5R)-4-(3´-bromo-1´-hydroxybut-3-enyl)-5-((1´´S,2´´S,3´´S)-2´´-((dimethyl(phenyl) 
silyl)methyl)-3´´-(p-methoxybenzyloxy)-5´´-methylenecyclopentyl)-dihydrofuran-2(3H)-
one (197) 
 
Under an Ar-atmosphere aldehyde 175 (294 mg, 0.614 mmol, 1.0 eq.) was dissolved in abs. 
CH2Cl2 (2 ml) and cooled to -78 °C. 2-Bromo-trimethylallylsilane[254] (158 mg, 141 µl, 
0.737 mmol, 1.2 eq.) was added and the mixture was stirred for 15 min. BF3⋅OEt2 (100 mg, 
87 µl, 0.706 mmol, 1.15 eq.) was added dropwise and the mixture was stirred for 10 h at -78 
°C. The reaction mixture was quenched with sat. NaHCO3 (0.5 ml) and allowed to warm to rt. 
CH2Cl2 (10 ml) was added and the layers were separated. The aqueous layer was again 
extracted with CH2Cl2 (3 ml) and the combined organic layers were washed with brine (3 ml), 
dried (Na2SO4) and concentrated in vacuo. Chromatography on silica gel 
(hexanes:ethylacetate 2:1) afforded 130 mg (0.217 mmol, 35%, dr = 78:22) product as a 
colorless oil, along with 120 mg (0.250 mmol, 41%) recovered starting material 175. 
 
Rf (hexanes:ethylacetate 2:1, Mostain) = 0.34.- 1H NMR (500 MHz): δ = 0.31 (s, 3H, SiMe, 
diast: 0.29), 0.34 (s, 3H, SiMe, diast: 0.35), 0.74-0.79 (m, 2H, SiCH2), 2.19-2.25 (m, 1H, 1´´-
H), 2.30-2.36 (m, 4H, 4-H, 2´-H, 4´´-H), 2.36-2.39 (m, 1H, 3-H), 2.47-2.53 (m, 1H, 2´´-H), 
2.55-2.60 (m, 1H, 4´´-H), 2.71 (dd, J = 17.3, 6.3 Hz, 1H, 3-H), 3.57-3.62 (m, 1H, 3´´-H), 3.79 
(s, 3H, OMe), 3.77-3.82 (m, 1H, 1´-H),4.21-4.37 (m, 2H, PMB), 4.60 (dd, J = 8.4, 4.3 Hz, 
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1H, 5-H diast: 4.73), 4.87-4.91 (m, 1H, C=CH2), 5.02-5.06 (m, 1H, C=CH2), 5.45-5.64 (m, 
2H, CBr=CH2), 6.82-6.87 (m, 2H, PMB), 7.16-7.21 (m, 2H, PMB), 7.33-7.38 (m, 3H, Ph), 
7.48-7.53 (m, 2H, Ph).- 13C NMR (125.8 MHz): δ= -2.41 (+, SiMe), -1.98 (+, SiMe), 20.93 (-, 
SiCH2), 28.85 (-, 4´´-C), 39.01 (-, 3-C), 42.23 (+, 4-C, 2´´-C), 47.38 (-, 2´-C), 55.49 (+, 
OMe), 56.54 (+, 1´´-C), 68.85 (+, 1´-C), 70.60 (-, PMB), 83.34 (+, 5-C), 86.73 (+, 3´´-C), 
112.52 (-, C=CH2), 113.99 (+, 2x PMB), 120.53 (-, CBr=CH2), 128.12 (+, 2x Ph), 129.24 (+, 
Ph), 129.57 (+, 2xPMB), 129.69 (+, Ph), 130.55 (Cq, Ph), 133.92 (+, 2xPh), 133.85 (Cq, 3´-
C), 139.54 (Cq, PMB), 147.96 (Cq, 5´´-C), 159.33 (Cq, PMB), 176.70 (Cq, 2-C).- IR (neat): 
~ν = 3458, 3068, 2999, 2952, 2902, 2871, 2837, 2358, 1770, 1731, 1629, 1612, 1514, 1463, 
1427, 1415, 1396, 1353, 1301, 1247, 1193, 1174, 1112, 1089, 1066, 1035, 987, 896, 833, 730, 
702 cm-1.- MS (ES+): m/z = 599.2 (M+H+), 616.2 (M+NH4+), 617.2 (M+NH4+), 618.2 
(M+NH4+).- HRMS (EI): 616.2099 (C31H43O5SiBrN: calc. 616.2094 [M+NH4+]). 
 
OO
H
H
H
OPMB
Et3SiO
SiMe2Ph  
(4S,5R)-5-((1´S,2´S,3´S)-3´-(p-methoxybenzyloxy)-2´-((dimethyl(phenyl)silyl)methyl)-5´-
methylenecyclopentyl)-dihydro-4-(1´´R/S-triethylsilanyloxy-3´´-methylbut-3´´-enyl) 
furan-2(3H)-one (198a) 
 
Under a N2-atmosphere alcohol 196 (353 mg, 0.66 mmol, 1.0 eq.) was dissolved in abs. 
CH2Cl2 (3 ml) and abs. NEt3 (134 mg, 183 µl, 1.32 mmol, 2.0 eq.) was added. Via a syringe 
TESCl (149 mg, 0.99 mmol, 1.5 eq.) was added dropwise and the solution was stirred for 48 h 
at rt. The solution was diluted with 50 ml CH2Cl2 and the reaction mixture was extracted with 
sat. NaHCO3 (8 ml). The organic layer was dried (Na2SO4) and concentrated in vacuo. 
Chromatography on silica gel (hexanes:ethylacetate 9:1) afforded 293 mg (0.452 mmol, 68%) 
product as a colorless oil in an inseparable mixture of 80:20. 
 
Rf (hexanes:ethylacetate 6:1, Mostain) = 0.47.- 1H NMR (300 MHz): δ = 0.28 (s, 3H, SiMe, 
diast: 0.27), 0.31 (s, 3H, SiMe, diast: 0.34), 0.52 (q, J = 8.1 Hz, 6H, 3x SiCH2CH3, diast: 
0.54),0.68-0.79 (m, 2H, CH2SiMe2Ph), 0.87 (t, J = 7.8 Hz, 9H, SiCH2CH3, diast: 0.89), 1.63 
(s, 3H, CH3, diast: 1.58), 1.94-2.41 (m, 6H, 2x 2´´-H, 1´-H, 4´-H, 3´-H, 3-H), 2.45-2.76 (m, 
2H, 2´-H, 4´-H), 2.62 (dd, J = 16.7, 4.1 Hz, 1H, 3-H), 3.50-3.58 (m, 1H, 4-H, diast: 3.58-
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3.63), 3.81-3.87 (m, 1H, 1´´-H, diast: 3.68-3.76), 3.79 (s, 3H, OMe, diast: 3.79),4.23-4.28 (m, 
2H, PMB), 4.51 (dd, J = 8.8, 4.1 Hz, 1H, 5-H), 4.62-4.66 (m, 1H, =CH2, diast: 4.95-4.61), 
4.74-4.77 (m, 1H, C=CH2, diast: 4.71-4.73), 4.77-4.81 (m, 1H, =CH2), 4.95-5.00 (m, 1H, 
=CH2), 6.79-6.88 (m, 2H, PMB), 7.13-7.21 (m, 2H, PMB), 7.29-7.37 (m, 3H, Ph), 7.43-7.51 
(m, 2H, Ph).- 13C NMR (75 MHz): δ = -2.4 (+, SiMe), -2.2 (+, SiMe), 5.2 (-, SiCH2CH3), 6.9 
(+, SiCH2CH3), 21.0 (-, CH2Si, diast: 20.7), 22.8 (+, CH3, diast: 23.1), 27.6 (-, 4´-C, diast: 
31.2), 39.1 (-, 3-C), 41.4 (+ , 4-C, diast: 41.2), 41.8 (+, 2´-C), 44.9 (-, 2´´-C), 55.2 (+, OMe), 
57.3 (+, 1´-C), 70.3 (-, PMB), 71.1 (+, 1´´-C), 83.8 (+, 5-C), 86.6 (+, 3´-C), 111.7 (-, =CH2), 
113.6 (+, 2xPMB), 113.7 (-,=CH2), 127.8 (+, 2x Ph), 128.8 (+, Ph), 129.2 (+, 2x PMB), 130.7 
(Cq, PMB), 133.6 (+, 2x Ph), 139.6 (Cq, Ph), 141. 5 (Cq, 3´´-C), 148.0 (Cq, PMB), (158.9 
(Cq, 5´-C), 177.2 (Cq, 2-C).- IR (neat): ~ν = 3070, 2998, 2954, 2910, 2876, 1776, 1648, 1613, 
1587, 1514, 1458, 1423, 1414, 1375, 1352, 1302, 1248, 1186, 1173, 1110, 1066, 1036, 1008, 
962, 893, 833, 746, 728, 701 cm-1.- MS (ES-MS): m/z (%)= 666.6 (100) [M+NH4+], 707.7 
(10) [M+NH4++CH3CN].- HRMS (EI, 70 eV): 648.3667 (C38H56O5Si2: calc. 648.3666 [M+]). 
 
OO
H
H
H
OPMB
AcO
SiMe2Ph  
1-((2R,3R)-2-((1S,2S,3S)-2-((dimethyl(phenyl)silyl)methyl)-3-(p-methoxybenzyloxy)-5-
methylenecyclopentyl)-5-oxotetrahydrofuran-3-yl)but-3-enyl acetate (198b) 
 
Alcohol 195 (154 mg, 0.296 mmol, 1.0 eq.) was dissolved in abs. CH2Cl2 (5 ml). NEt3 (62 µl, 
0.444 mmol, 1.5 eq.), DMAP (4 mg, 0.1 eq.) and Ac2O (42 µl, 0.444 mmol, 1.5 eq.) was 
added and the reaction mixture was stirred at rt for 24 h under an N2-atmosphere. 
Subsequently the solvent was removed and chromatography on silica gel 
(hexanes:ethylacetate 3:1) afforded 133 mg (0.236 mmol, 80%) product as a colorless oil (dr 
= 50:50). 
 
Rf (hexanes:ethylacetate 2:1) = 0.31.- 1H NMR (300 MHz): δ = 0.28 (s, 3H, SiMe, diast: 
0.29), 0.34 (s, 3H, SiMe, diast: 0.36), 0.63-0.81 (m, 2H, SiCH2), 1.86 (s, 3H, OAc, diast: 
1.96), 2.00-2.80 (m, 9H, 3-H, 4-H, 1´-H, 2´-H, 4´-H, 2´´-H), 3.50-3.61 (m, 1H, 3´-H, diast: 
3.61-3.67), 3.79 (s, 3H, OMe), 4.18-4.44 (m, 2H, PMB), 4.75 (dd, J = 9.6, 1.7 Hz, 1H, 5-H, 
diast: 4.51, dd, J = 9.2, 4.3 Hz), 4.80-5.08 (m, 5H, 2x =CH2, 1´´-H), 5.55-5.67 (m, 1H, 3´´-H), 
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6.81-6.88 (m, 2H, PMB), 7.15-7.23 (m, 2H, PMB), 7.30-7.39 (m, 3H, Ph), 7.45-7.55 (m, 2H, 
Ph).- 13C NMR (75.5 MHz): δ = -3.2 (+, SiMe, diast: -2.9), -2.2 (+, SiMe, diast: -2.0), 20.5 (-, 
CH2Si, diast: 20.6), 20.7 (+, OAc, diast: 20.8), 28.9 (-, 4´-C, diast: 31.0), 35.9 (-, 3-C, diast. 
36.6), 38.2 (-, 2´´-C, diast: 38.4), 39.3 (+, 4-C, diast: 40.3), 41.0 (+, 2´-C, diast: 42.4), 55.2 (+, 
OMe), 56.2 (+, 1´-C, diast: 57.2), 70.2 (-, PMB), 72.6 (+, 1´´-C, diast: 74.2), 81.6 (+, 5-C, 
diast: 82.7), 86.5 (+, 3´-C, diast: 86.8), 112.1(-, =CH2, diast: 112.6), 113.7 (+, 2xPMB), 118.4 
(-, =CH2), 127.8 (+, 2xPh), 128.9 +, Ph, diast: 128.9), 129.1 (+, 2xPMB, diast: 129.2), 130.4 
(Cq, PMB, diast: 130.5), 132.6 (+, 2xPh), 133.6 (+, 3´´-C), 139.3 (Cq, Ph), 147.9 (Cq, PMB, 
diast: 148.1), 158.9 (Cq, 5´-C, diast: 159.0), 170.2 (Cq, OAc, diast: 170.5), 175.9 (Cq, 2-C, 
diast: 176.2).- IR (neat): ~ν = 3070, 2953, 2905, 1778, 1738, 1644, 1612, 1512, 1425, 1371, 
1300, 1244, 1178, 1109, 1035, 920, 833, 726, 702 cm-1.- MS (LSIMS, MeOH, CH2Cl2, 
Glycerin): m/z (%) = 425.4 (30), 485.4 (25), 545.4 (20), 563.4 (35) [MH+], 655.0 (24) 
[MH++Gly.].- HRMS (LSIMS): 563.2819 (C33H43O6Si: calc. 563.2829). 
 
OO
H
H
H
OPMB
AcO
SiMe2Ph  
1-((2´R,3´R)-2´-((1´´S,2´´S,3´´S)-2´´-((dimethyl(phenyl)silyl)methyl)-3´´-(p-methoxy-
benzyloxy)-5´´-methylenecyclopentyl)-5´-oxo-tetrahydrofuran-3´-yl)-3-methylbut-3-enyl 
acetate (198c) 
 
Alcohol 196 (300 mg, 0.561 mol, 1.0 eq.) was dissolved in abs. CH2Cl2 (12 ml). NEt3 (118 µl, 
0.842 mol, 1.5 eq.), DMAP (7 mg, 0.1 eq.) and Ac2O (79 µl, 0.842 mol, 1.5 eq.) was added 
and the reaction mixture was stirred at rt for 24 h under an argon atmosphere. Subsequently 
the solvent was removed and chromatography on silica gel (hexanes:ethylacetate 3:1) 
afforded 323 mg (0.560 mmol, 99%) product as a colorless oil (dr = 80:20). 
 
Rf (hexanes:ethylacetate 2:1) = 0.47.- 1H NMR (500 MHz): δ = 0.29 (s, 3H, SiMe, diast: 
0.28), 0.34 (s, 3H, SiMe, diast: 0.36), 0.64-0.78 (m, 2H, CH2Si), 1.66 (s, 3H, CH3, diast: 
1.64), 1.85 (s, 3H, OAc, diast: 1.94), 1.99 (dd, J = 13.4, 6.2 Hz, 1H, 4´´-H), 2.05-2.11 (m, 1H, 
1´´-H), 2.20 (dd, J = 8.0, 13.4 Hz, 1H, 4´-H), 2.33-2.51 (m, 4H, 2-H, 3´-H, 4´´-H), 2.52-2.59 
(m, 1H, 2´´-H), 2.64-2.74 (m, 1H, 4´´-H), 3.56-3.60 (m, 1H, 3´´-H, diast: 3.62-3.65), 3.79 (s, 
3H, OMe), 4.18-4.30 (m, 2H, PMB), 4.53 (dd, J = 9.4, 4.1 Hz, 1H, 2´-H), 4.64-4.67 (m, 1H, 
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=CH2, diast: 4.56-4.58), 4.75-4.79 (m, 1H, =CH2, diast: 4.70-4.72), 4.81-4.85 (m, 1H, =CH2), 
5.00-5.03 (m, 1H, =CH2), 5.03-5.09 (m, 1H, 1-H), 6.81-6.88 (m, 2H, PMB), 7.14-7.22 (m, 
2H, PMB), 7.31-7.38 (m, 3H, Ph), 7.45-7.53 (m, 2H, Ph).- 13C NMR ( MHz): δ = -3.79 (+, 
SiMe, diast: -4.10), -3.19 (+, SiMe, diast: -2.99), 19.60 (-, SiCH2, diast: 21.73), 19.73 (+, 
OAc, diast: 19.79), 21.16 (+, CH3, diast: 21.29), 27.95 (-, 2-C, diast: 28.06), 37.22 (-, 4´´-C, 
diast: 37.43), 39.49 (+, 3´-C, diast: 38.93), 39.70 (-, 4´-C, diast: 39.11), 41.03 (+, 2´´-C, diast: 
40.11), 54.30 (+, OMe), 56.34 (+, 1´´-C, diast: 55.43), 69.21 (-, PMB), 70.39 (+, 1-C, diast: 
71.63), 80.76 (+, 2´-C, diast: 81.77), 85.51 (+, 3´´-C, diast: 85.83), 111.07 (-, =CH2, diast: 
111.74), 112.68 (+, 2x PMB), 113.08 (-, =CH2, diast: 112.92), 126.88 (+, 2x Ph, diast: 
126.94), 127.99 (+, 1x Ph, diast: 128.04), 128.13 (+, 2x PMB, diast: 128.23), 129.58 (Cq, Ph), 
132.66 (+, 2x Ph), 138.42 (Cq, PMB), 139.64 (Cq, C=CH2, diast: 139.55), 147.19 (Cq, 
C=CH2, diast: 146.95), 158.02 (Cq, PMB), 169.19 (Cq, Ac, diast: 169.53), 175.12 (Cq, 5´-C, 
diast: 175.29).- IR (neat): ~ν = 3070, 3047, 2997, 2952, 2906, 2869, 2837, 2358, 2341, 1778, 
1739, 1652, 1612, 1514, 1456, 1442, 1427, 1373, 1355, 1301, 1245, 1174, 1112, 1083, 1068, 
1033, 989, 896, 835, 732, 702 cm-1.- MS (EI): m/z = 594 (M+NH4+), 600 [M+Na+].- HRMS 
(EI): 594.3239 (C34H48O6Si: calc. 594.3251 [M+NH4+]). 
 
OO
H
H
H
OPMB
AcO
SiMe2Ph
Br
 
3-bromo-1-((2´R,3´R)-2´-((1´´S,2´´S,3´´S)-2´´-((dimethyl(phenyl)silyl)methyl)-3´´-(p-
methoxybenzyloxy)-5´´-methylenecyclopentyl)-5´-oxo-tetrahydrofuran-3´-yl)but-3-enyl 
acetate (198d) 
 
Alcohol 197 (130 mg, 0.217 mmol, 1.0 eq.) was dissolved in abs. CH2Cl2 (2 ml). NEt3 (44 
mg, 61 µl, 0.434 mmol, 2.0 eq.), DMAP (3 mg, 0.022 mmol, 0.1 eq.) and Ac2O (44 mg, 41 µl, 
0.434 mmol, 2.0 eq.) was added, and the mixture was stirred for 16 h at rt. Subsequently the 
solvent was removed in vacuo and chromatography on silica gel (hexanes:ethylacetate 3:1) 
afforded 120 mg product (0.187 mmol, 86%) as a colorless oil (dr = 75:25). 
 
Rf (hexanes:ethylacetate 2:1, Mostain) = 0.47.- 1H NMR (500 MHz): δ = 0.28 (s, 3H, SiMe, 
diast: 0.27), 0.34 (s, 3H, SiMe, diast: 0.36), 0.65-0.78 (m, 2H, SiCH2), 1.87 (s, 3H, OAc), 
2.09-2.14 (m, 1H, 1´´-H), 2.30-2.50 (m, 4H, 2-H, 4´´-H, 4´-H), 2.52-2.59 (m, 2H, 3´-H, 2´´-
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H), 2.65 (dd, J = 14.5, 7.9 Hz, 1H, 4´-H), 2.68-2.76 (m, 1H, 4´´-H), 3.56-3.61 (m, 1H, 3´´-H, 
diast: 3.63-3.68), 3.79 (s, 3H, OMe), 4.19-4.31 (m, 2H, PMB), 4.55 (dd, J = 9.4, 4.1 Hz, 1H, 
2´-H), 4.84-4.87 (m, 1H, C=CH2, diast: 4.81-4.84), 5.02-5.05 (m, 1H, C=CH2, diast: 5.05-
5.07), 5.16-5.22 (m, 1H, 1-H), 5.44-5.47 (m, 1H, CBr=CH2, diast: 5.36-5.39), 5.55-5.57 (m, 
1H, CBr=CH2, diast: 5.41-5.43), 6.81-6.88 (m, 2H, PMB), 7.17-7.25 (m, 2H, PMB), 7.31-
7.38 (m, 3H, Ph), 7.46-4.53 (m, 2H, Ph).- 13C NMR (75 MHz): δ = -2.9 (+, SiMe, diast: -3.3), 
-2.2 (+, SiMe, diast: -2.0), 20.5 (-, CH2Si, diast: 20.4), 20.5 (+, OAc, diast: 20.6), 28.9 (-, 4´´-
C, diast: 30.9), 38.1 (-, 4´-C, diast: 38.2), 40.1 (+, 2´´-C, diast: 39.4), 41.9 (+, 3´-C, diast: 
41.0), 43.6 (-, 2-C, diast: 43.5), 55.3 (+, 1´´-C, diast: 56.3), 57.0 (+, OMe), 70.2 (-, PMB), 
71.2 (+, 1-C, diast: 72.2), 82.5 (+, 2´-C, diast: 81.5), 86.5 (+, 3´´-C, diast: 86.9), 112.4 (-, 
C=CH2, diast: 113.0), 113.7 (+, 2x PMB), 120.2 (-, CBr=CH2, diast: 120.1), 127.8 (Cq, 3-C, 
diast: 127.9), 127.8 (+, 2xPh), 129.1 (+, 2xPMB), 129.2 (+, Ph), 130.5 (Cq, Ph, diast: 130.4), 
133.6 (+, 2xPh), 139.4 (Cq, PMB, diast: 139.3), 147.7 (Cq, 5´´-C, diast: 147.9), 158.9 (Cq, 
PMB, diast: 159.0), 169.8 (Cq, OAc, diast: 170.2), 175.7 (Cq, 5´-C, diast: 175.9).- IR (neat): 
~ν = 3068, 2999, 2952, 2916, 2871, 2837, 1778, 1745, 1612, 1514, 1427, 1373, 1355, 1301, 
1247, 1228, 1174, 1112, 1106, 1033, 989, 896, 835, 756, 727, 702 cm-1.- MS (EI): m/z = 371, 
658 [M+NH4+], 663 [M+Na+], 665 [M+Na+], 666 [M+Na+].- HRMS (EI): 658.2185 
(C33H45O6SiBrN: calc. 658.2199 [M+NH4+]). 
 
11.8 Ring closing metathesis 
 
OO
H
H
H
OPMB
SiMe2Ph
AcO
 
(3aR,8S,9S,9aS,9bR)-9-((dimethyl(phenyl)silyl)methyl)-8-(p-methoxybenzyloxy)-2-oxo-
2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl acetate (199a) 
 
Ac-protected diene 198b (127 mg, 0.226 mmol, 1.0 eq, dr = 50:50) was dissolved in abs. 
toluene (5 ml). A gentle stream of N2 was introduced into the solution throughout the reaction 
and the reaction setup was put down into a preheated 90 °C hot oil bath. Grubbs 2nd catalyst 
(9 mg, 11.3 µmol 5 mol%) dissolved in abs. toluene (1 ml) was added followed by two 
additional 5 mol% batches every 2 h (total catalyst loading 15 mol%). After cooling to rt the 
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solvent was removed and chromatography on silica gel (hexanes:ethylacetate 3:1) afforded 45 
mg (0.084 mmol, 75%) pure 4S-diastereomer and 54 mg (0.101 mmol, 90%) pure 4R-
diastereomer. 
 
OO
H
H
H
OPMB
SiMe2Ph
AcO
 
(3aR,4S,8S,9S,9aS,9bR)-9-((dimethyl(phenyl)silyl)methyl)-8-(p-methoxybenzyloxy)-2-
oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl acetate (4S-199a) 
 
Rf (hexanes:ethylacetate 3:1, Mostain) = 0.27.- [ ]20Dα = -32.7 (c = 1.00, CHCl3).- 1H NMR 
(300 MHz): δ = 0.33 (s, 3H, SiMe), 0.39 (s, 3H, SiMe), 0.71-0.78 (m, 2H, CH2Si), 2.02 (s, 
3H, OAc), 1.90-2.09 (m, 2H, 5-H, 3a-H), 2.20-2.29 (m, 1H, 9a-H), 2.30-2.40 (m, 2H, 5-H, 7-
H), 2.33 (dd, J = 16.6, 12.8 Hz, 1H, 3-H), 2.53 (dd, J = 16.6, 7.0 Hz, 1H, 3-H), 2.57-2.69 (m, 
1H, 7-H), 2.70-2.80 (m, 1H, 9-H), 3.45 (m, 1H, 8-H), 3.79 (s, 3H, OMe), 3.92 (dd, J = 10.3, 
10.3 Hz, 1H, 9b-H), 4.21-4.36 (m, 2H, PMB), 4.61 (dt, J = 10.7, 3.0 Hz, 1H, 4-H), 5.52-5.67 
(m, 1H, 6-H), 6.77-6.89 (m, 2H, PMB), 7.09-7.22 (m, 2H, PMB), 7.29-7.41 (m, 3H, Ph), 
7.46-7.59 (m, 2H, Ph).- 13C NMR (75.5 MHz): δ = -2.9 (+, SiMe), -2.4 (+, SiMe), 20.9 (+, 
OAc), 21.6 (-, CH2Si), 33.6 (-, 5-C), 35.2 (-, 3-C), 39.1 (-, 7-C), 42.1 (+, 9-C), 52.9 (+, 3a-C), 
53.4 (+, 9a-C), 55.2 (+, OMe), 69.5 (-, PMB), 71.5 (+, 4-C), 82.8 (+, 9b-C), 85.3 (+, 8-C), 
113.7 (+, 2xPMB), 117.6 (+, 6-C), 127.7 (+, 2xPh), 128.9 (+, Ph), 129.2 (+, 2xPMB), 130.4 
(Cq, PMB), 133.8 (+, 2xPh), 139.2 (Cq, 6a-C), 146.1 (Cq, Ph), 159.0 (Cq, PMB), 169.9 (Cq, 
OAc), 174.3 (Cq, 2-C).- IR (neat): ~ν = 3068, 3044, 2998, 2952, 2900, 1781, 1738, 1732, 
1613, 1586, 1513, 1443, 1426, 1371, 1301, 1244, 1181, 1112, 1062, 1029, 959, 905, 881, 821, 
727, 701 cm-1.- MS (LSIMS, MeOH, CH2Cl2,Glycerin): m/z = 399.3 (10), 415 (15), 457.3 
(20), 507.3 (15), 535.3 (40) [MH+], 627.3 (50) [MH++Glyc.], 719.3 (10) [MH++2Glyc.].- 
HRMS (LSIMS): 535.2527 (C31H39O6Si: calc.535.216 [MH+]). 
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OO
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H
H
OPMB
SiMe2Ph
AcO
 
(3aR,4R,8S,9S,9aS,9bR)-9-((dimethyl(phenyl)silyl)methyl)-8-(p-methoxybenzyloxy)-2-
oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl acetate (4R-199a) 
 
Rf (hexanes:ethylacetate 3:1, Mostain) = 0.14.- [ ]20Dα = -87.8 (c = 1.00, CHCl3).- 1H NMR 
(300 MHz): δ = 0.32 (s, 3H, SiMe), 0.39 (s, 3H, SiMe), 0.72-0.89 (m, 2H, CH2Si), 1.87-2.10 
(m, 2H, 5-H, 3a-H), 2.01 (s, 3H, OAc), 2.21-2.30 (m, 1H, 9a-H), 2.31-2.44 (m, 3H, 3-H, 5-H, 
7-H), 2.54 (dd, J = 8.9, 5.3 Hz, 1H, 3H), , 2.60-2.70 (m, 1H, 7-H), 2.70-2.79 (m, 1H, 9-H), 
3.48-3.56 (m, 1H, 8-H), 3.79 (s, 3H, OMe), 4.22 (dd, J = 10.4, 10.4 Hz, 1H, 9b-H), 4.26-4.39 
(m, 2H, PMB), 4.90-5.05 (m, 1H, 4-H), 5.40-5.50 (m, 1H, 6-H), 6.80-6.87 (m, 2H, PMB), 
7.14-7.19 (m, 2H, PMB), 7.30-7.38 (m, 3H, Ph), 7.49-7.57 (m, 2H, Ph).- 13C NMR (75.5 
MHz): δ = -2.9 (+, SiMe), -2.2 (+, SiMe), 20.9 (+, OAc), 21.6 (-, CH2Si), 31.1 (-, 5-C), 33.4 (-
, 3-C), 39.0 (-, 7-C), 42.6 (+, 9-C), 50.7 (+, 9a-C), 54.3 (+, 3a-C), 55.4 (+, OMe), 68.1 (+, 4-
C), 69.4 (-, PMB), 80.1 (+, 9b-C), 85.6 (+, 8-C), 113.6 (+, 2xPMB), 117.9 (+, 6-C), 127.6 (+, 
2xPh), 128.8 (+, Ph), 128.9 (+, 2xPMB), 130.7 (Cq, PMB), 133.9 (+, 2xPh), 139.4 (Cq, 6a-C), 
144.9 (Cq, Ph), 158.9 (Cq, PMB), 170.5 (Cq, OAc), 174.4 (Cq, 2-C).- IR (neat): ~ν = 2951, 
2899, 1783, 1739, 1612, 1512, 1426, 1369, 1300, 1246, 1112, 1076, 999, 910, 833, 731, 644 
cm-1.- MS (LSIMS, MeOH, CH2Cl2, Glycerin): m/z = 415.3 [M-PMB], 535.4 [M+H+], 627.4 
[MH++Gly].- HRMS (LSIMS): 535.2520 (C31H39O6Si: calc.535.2516 [M+H+]). 
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(3aR,8S,9S,9aS,9bR,Z)-9-((dimethyl(phenyl)silyl)methyl)-8-(p-methoxybenzyloxy)-6-
methyl-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl acetate (199b) 
 
Ac-protected diene 198c (100 mg, 0.173 mmol, 1.0 eq, dr = 80:20) was dissolved in abs. 
toluene (5 ml). A gentle stream of argon was introduced into the solution throughout the 
reaction and the reaction setup was put down into a preheated 90 °C hot oil bath. Grubbs 2nd 
catalyst (7 mg, 7.7 µmol 5 mol%) dissolved in abs. toluene (1 ml) was added followed by two 
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additional 5 mol% batches every 2 h (total catalyst loading 15 mol%). After cooling to rt the 
solvent was removed and chromatography on silica gel (hexanes:ethylacetate 2:1) afforded 70 
mg (0.128 mmol, 93%) pure 4S-Diastereomer) and 19 mg mixture of both diastereomers. 
 
Major isomer: 
OO
H
H
OPMB
SiMe2Ph
AcO
H
 
(3aR,4S,8S,9S,9aS,9bR,Z)-9-((dimethyl(phenyl)silyl)methyl)-8-(p-methoxybenzyloxy)-6-
methyl-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl acetate (4S-199b) 
 
Rf (hexanes:ethylacetate 2:1, Mostain) = 0.39.- [ ]20Dα = -32.5 (c = 0.65, CHCl3).- 1H NMR (600 
MHz): δ = 0.32 (s, 3H, SiMe), 0.38 (s, 3H, SiMe), 0.57-0.73 (m, 2H, CH2Si), 1.71 (s, 3H, 
CH3), 1.87-1.98 (m, 1H, 9a-H), 2.02 (s, 3H, OAc), 2.04-2.12 (m, 1H, 5-H), 2.14-2.26 (m, 2H, 
5-H, 3a-H), 2.29 (dd, J = 16.6, 13.2 Hz, 1H, 3-H), 2.35-2.57 (m, 1H, 7-H), 2.49 (dd, J = 16.6, 
6.6 Hz, 1H, 3-H), 2.45-2.55 (m, 1H, 7-H), 2.75-2.85 (m, 1H, 9-H), 3.52-3.58 (m, 1H, 8-H), 
3.79 (s, 3H, OMe), 3.87-3.94 (m, 1H, 9b-H), 4.32 (dd, J = 68.2, 10.8 Hz, 2H, PMB), 4.56 (dt, 
J = 10.7, 2.2 Hz, 1 H, 4-H), 6.77-6.89 (m, 2H, PMB), 7.09-7.19 (m, 2H, PMB), 7.30-7.40 (m, 
3H, Ph), 7.46-7.57 (m, 2H, Ph).- 13C NMR (125.8 MHz): δ = -2.7 (+, SiMe), -2.2 (+, SiMe), 
21.2 (-, CH2Si), 21.3 (+, OAc), 23.6 (+, CH3), 35.6 (-, 3-C), 36.8 (-, 7-C), 40.7 (+, 9-C), 41.4 
(-, 5-C), 53.8 (+, 3a-C), 53.8 (+, 9a-C), 55.5 (+, OMe), 69.8 (-, PMB), 71.04 (+, 4-C), 82.95 
(+, 9b-C), 86.05 (+, 8-C), 113.96 (+, 2xPMB), 126.44 (Cq, Ph), 127.96 (+, 2xPh), 129.18 (+, 
Ph), 129.55 (+, 2xPMB), 130.65 (Cq, PMB), 134.07 (+, 2xPh), 138.13 (Cq, 6-C), 139.39 (Cq, 
6a-C), 159.27 (Cq, PMB), 170.14 (Cq, OAc), 174.76 (Cq, 2-C).- IR (neat): ~ν = 3068, 3045, 
2997, 2950, 2904, 2858, 2837, 1784, 1737, 1612, 1514, 1463, 1427, 1371, 1301, 1245, 1172, 
1112, 1081, 1064, 1031, 997, 958, 835, 729, 702, 605 cm-1.- MS (EI): m/z = 121.1, 351.2, 
383.2, 549.3 [M+H+], 566.3 [M+NH4+].- HRMS (EI): 549.2676 (C32H41O6Si: calc. 
549.2673 [M+H+]). 
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Minor isomer: 
OO
H
H
OPMB
SiMe2Ph
AcO
H
 
(3aR,4R,8S,9S,9aS,9bR,Z)-9-((dimethyl(phenyl)silyl)methyl)-8-(p-methoxybenzyloxy)-6-
methyl-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl acetate (4R-199b) 
 
Rf (hexanes:ethylacetate 2:1, Mostain) = 0.30.- [ ]20Dα = -79.3 (c = 0.67, CHCl3).- 1H NMR (500 
MHz): δ = 0.34 (s, 3H, SiMe), 0.41 (s, 3H, SiMe), 0.71-0.79 (m, 2H, SiCH2), 1.64 (s, 3H, 
CH3), 1.77-1.86 (m, 1H, 9a-H), 2.05 (s, 3H, OAc), 2.13-2.19 (m, 1H, 5-H), 2.23-2.29 (m, 1H, 
5-H), 2.31-2.38 (m, 2H, 3-H, 7-H), 2.41-2.50 (m, 2H, 3-H), 2.54-2.63 (m, 1H, 7-H), 2.78-2.87 
(m, 1H, 9-H), 3.57-3.65 (m, 1H, 8-H), 3.83 (s, 3H, OMe), 4.10-4.19 (m, 1H, 9b-H), 4.27-4.15 
(m, 2H, PMB), 4.96-5.07 (m, 1H, 4-H), 6.84-6.93 (m, 2H, PMB), 7.17-7.25 (m, 2H, PMB), 
7.34-7.42 (m, 3H, Ph), 7.52-7.61 (m, 2H, Ph).- 13C NMR (125.8 MHz): δ =-2.01 (+, SiMe), -
1.93 (+, SiMe), 21.15 (-, CH2Si), 21.24 (+, OAc), 24.63 (+, CH3), 33.59 (-, 3-C), 36.62 (-, 7-
C), 37.99 (+, 9-C), 41.00 (-, 5-C), 51.79 (+, 3a-C), 54.56 (+, 9a-C), 55.48 (+, OMe), 68.39 (-, 
PMB), 69.87 (+, 4-C), 80.43 (+, 9b-C), 86.35 (+, 8-C), 113.92 (+, 2xPMB), 126.49 (Cq, Ph), 
127.93 (+, 2xPh), 129.12 (+, Ph), 129.44 (+, 2xPMB), 130.89 (Cq, PMB), 134.19 (+, 2xPh), 
137.18 (Cq, 6-C), 139.68 (Cq, 6a-C), 159.22 (Cq, PMB), 170.81 (Cq, OAc), 174.85 (Cq, 2-
C).- IR (neat): ~ν = 3068, 3045, 2950, 2902, 2858, 2837, 2358, 2331, 1784, 1731, 1612, 1585, 
1514, 1463, 1440, 1427, 1373, 1301, 1247, 1201, 1182, 1112, 1062, 1035, 989, 948, 925, 835, 
756, 730, 702 cm-1.- MS (EI+): m/z = 371.16, 387.16, 529.26, 566.29 [M+NH4+], 571.2 
[M+Na+].- HRMS (EI): 549.2688 (C32H41O6Si: calc. 549.2673 [M+H+]). 
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(3aR, 4R/S, 8S,9S,9aS,9bR,Z)-9-((dimethyl(phenyl)silyl)methyl)-4-hydroxy-8-(p-methoxy 
benzyloxy)-6-methyl-3,3a,4,5,7,8,9,9a-octahydroazuleno[4,5-b]furan-2(9bH)-one (199c) 
 
In a 50-ml Schlenk flask equipped with a condenser, TES-protected diene 198a (100 mg, 
154 mmol, 1.0 eq, dr = 80:20) was dissolved in abs. toluene (5 ml). A gentle stream of argon 
was introduced into the solution throughout the reaction and the reaction setup was put down 
into a preheated 90 °C hot oil bath. Grubbs 2nd catalyst (7 mg, 7.7 µmol 5 mol%) dissolved in 
1 ml abs. toluene was added followed by two additional 5 mol% batches every 2 h (total 
catalyst loading 15 mol%). After cooling to rt TBAF (385 µl, 385 mmol, 2.5 eq, 1N in THF) 
was added and the mixture was allowed to stir over night. The solvent was removed and 
chromatography on silica gel (hexanes:ethylacetate 1:1) afforded 60 mg (118 mmol, 77%) 
product as a inseparable mixture of diastereomers (dr = 80:20). 
 
Rf (hexanes:ethylacetate 1:1, Mostain) = 0.37.- H NMR (600 MHz): δ = 0.32 (s, 3H, SiMe), 
0.38 (s, 3H, SiMe), 0.65-0.72 (m, 2H, CH2Si), 1.68 (s, 3H, CH3), 1.72-1.84 (m, 1H, 9a-H), 
2.01-2.08 (m, H, 5-H), 2.19-2.26 (m, 2H, 3a-H, 7-H), 2.36 (dd, J = 16.7, 13.1 Hz, 3-H), 2.28-
2.41 (m, 1H, 7-H), 2.48-2.58 (m, 1H, 7-H), 2.67 (dd, J = 16.7, 6.6 Hz, 1H, 3-H), 2.78-2.86 
(m, 1H, 9-H), 3.33-3.53 (m, 1H, 4-H), 3.53-3.62 (m, 1H, 8-H), 3.79 (s, 3H, PMB), 3.81-3.88 
(m, 1H, 9b-H), 4.31 (dd, J = 97.4, 11.4 Hz, 2H, PMB), 5.77-6.88 (m, 2H, PMB), 7.12-7.21 
(m, 2H, PMB), 7.31-7.50 (m, 3H, Ph), 7.49-7.58 (m, 2H, Ph).- 13C NMR (75.5 MHz): δ =-
2.65 (+, SiMe), -2.13 (+, SiMe), 21.26 (-, CH2Si), 23.86 (+, CH3), 35.91 (-, 3-C), 36.90 (-, 7-
C), 40.54 (+, 9-C), 45.46 (-, 5-C), 53.76 (+, 3a-C), 55.47 (+, 9b-C), 56.47 (+, 9a-C), 69.81 (-, 
PMB), 69.85 (+, 4-C), 83.07 (+, OMe), 86.16 (+, 8-C), 113.97 (+, 2x PMB) , 126.62 (Cq, 6-
C) , 127.97 (+, 2xPh), 129.20 (+, 2xPh), 129.66 (+, 2xPMB), 130.68 (Cq, PMB), 134.08 (+, 
Ph), 137.71 (Cq, Ph), 139.42 (Cq, 6a-C), 159.28 (Cq, PMB), 175.58 (Cq, 2-C).- IR (neat): ~ν = 
3434, 2950, 2933, 2358, 2329, 1749, 1733, 1614, 1515, 1301, 1247, 1217, 1172, 1112, 1091, 
1064, 1039, 962, 838, 729, 702 cm-1.- MS (EI): m/z = 507 [M+H+], 524 [M+NH4+].- HRMS 
(EI): 507.2570 (C30H39O5Si: calc. 507.2567 [M+H+]). 
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11.9 Synthesis of a 3x3 scaffold library 
11.9.1 Preparation of lactone aldehydes 
 
General procedure for preparation of lactone aldehydes 210: 
Under a N2-atmosphere cyclopropylcarbaldehyde (-)-130 (1.00 eq.) was dissolved in abs. 
CH2Cl2 (5 ml/mmol) and cooled to -78 °C. BF3⋅OEt2 (1.10 eq.) was added and the mixture 
stirred for 30 min. Allylsilane (1.10 eq.) was added via a syringe and the reaction mixture was 
stirred for 18 h at -78 °C. The reaction was quenched with NaHCO3 sat. (0.2 ml/mmol 
BF3⋅OEt2) and allowed to warm to rt. The layers were separated and the organic layer was 
dried (Na2SO4) and concentrated in vacuo. 
The crude alcohol (1.0 eq.) was dissolved in MeOH (10 ml/mmol) and cooled to 0 °C. 
Ba(OH)2⋅8H2O (0.55 eq.) was added in small portions over 4 h. After 5 h stirring at 0 °C 
CH2Cl2 (10 ml/mmol) and H2O (10 ml/mmol) were added and the layers were separated. The 
aqueous layer was again extracted with CH2Cl2 (3x10 ml/mmol). The combined organic 
layers were dried (Na2SO4), filtered and concentrated in vacuo. Chromatography on silica gel 
(hexanes:ethylacetate 1:1) afforded the corresponding lactone aldehyde as a colorless oil. 
 
OO
CHO
H
H
 
(2S,3R)-2-allyl-5-oxo-tetrahydrofuran-3-carbaldehyde (210a) 
 
Yield: 51%, dr = 95:5.- Rf (hexanes:ethylacetate 1:1, Mostain) = 0.20.- 1H NMR (300 MHz, 
CDCl3): δ = 2.67-2.44 (m, 2H, 1´-H), 2.75 (dd, J = 17.9, 10.1 Hz, 1H, 4-H), 2.93 (dd, J = 
17.9, 7.5 Hz, 1H, 4-H), 3.26-3.16 (m, 1H, 3-H), 4.77 (dd, J = 12.1, 6.1 Hz, 1H, 2-H), 5.30-
5.17 (m, 2H, 3´-H), 5.87-5.70 (m, 1H, 2´-H), 9.73 (d, J = 1.6 Hz, 1H, CHO); diast: δ = 3.00 
(dd, J = 17.7, 5.8 Hz, 1H, 4-H), 9.86 (d, J = 1.6 Hz, 1H, CHO).- 13C NMR (75 MHz, CDCl3): 
δ = 28.9 (-, 4-C, diast: 30.2), 39.2 (-,1´-C, diast: 39.4), 51.3 (+, 3-C, diast: 49.6), 78.0 (+, 2-C, 
diast: 79.6), 120.5 (-, 3´-C, diast: 120.0), 130.9 (+, 2´-C, diast: 131.3), 174.0 (Cq, CO), 197.3 
(+, CHO, diast: 198.0).- IR (neat): ~ν = 3080, 2980, 2939, 2841, 1774, 1727, 1642, 1419, 
1359, 1193, 1111, 1000, 924 cm-1.- MS (EI, 70 eV): m/z (%) = 154.2 (5) [M+], 113.1 (100) 
[M-C3H5], 85.1 (95), 57.1 (95).- CH: C8H10O3 calc. C 62.33, H 6.54; found: C 62.36, H 6.83. 
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(2S,3R)-2-(2-methylallyl)-5-oxo-tetrahydrofuran-3-carbaldehyde (210b) 
 
Yield: 50%, dr = 96:4.- Rf (hexanes:ethylacetate 1:1, Mostain) = 0.21. - 1H NMR (300 MHz, 
CDCl3): δ = 1.79 (s, 3H, CH3), 2.39 (dd, J = 14.1, 8.1 Hz, 1H, 1´-H), 2.60 (dd, J = 14.1, 6.5 
Hz, 1H, 1´-H), 2.76 (dd, J = 17.8, 9.9 Hz, 1H, 4-H), 2.96 (dd, J = 17.9, 7.6 Hz, 1H, 4-H), 
3.15-3.25 (m, 1H, 3-H), 4.79-4.88 (m, 2H, 3´-H), 4.92-4.97 (m, 1H, 2-H), 9.72 (d, J = 1.4 Hz, 
1H, CHO, diast: d, 9.83, J = 1.9 Hz).- 13C NMR (75 MHz, CDCl3): δ = 22.7 (+, CH3), 28.9 (-, 
4-C), 43.3 (-, 1´-C), 51.9 (+, 2-C), 77.5 (+, 3-C), 115.2 (-, 3´-C), 139.6 (Cq, 2´-C), 173.8 (Cq, 
CO), 197.2 (+, CHO).- IR (neat): ~ν = 3078, 2934, 2854, 2735, 1778, 1726, 1651, 1420, 1360, 
1193, 1018, 986, 898, 827 cm-1.- MS (CI, NH3): m/z (%) = 169.1 (100) [M+H+]. 
 
 
(2S,3R)-2-((R)-2-methylenecyclopentyl)-5-oxo-tetrahydrofuran-3-carbaldehyde (210c) 
 
Yield: 45%, dr = 95:5:0:0.- Rf (hexanes:ethylacetate 1:1, Mostain) = 0.36. - 1H NMR (600 
MHz, CDCl3): δ = 1.57-1.69 (m, 2 H, CH2), 1.73-1.84 (m, 1 H, CH2), 1.86-1.96 (m, 1 H, 
CH2), 2.25-2.40 (m, 2 H, CH2), 2.73 (dd, J = 18.1, 10.2 Hz, 1 H, 4-H), 2.75-2.80 (m, 1 H, 1'-
H), 2.88 (dd, J = 18.1, 7.5 Hz, 1 H, 4-H), 3.29 (dddd, J = 10.2, 7.4, 6.5, 1.1 Hz, 1 H, 3-H), 
4.72 (t, J = 6.2 Hz, 1 H, 2-H), 4.97 (d, J = 2.0 Hz, 1 H, =CH2), 5.06 (d, J = 2.0 Hz, 1 H, 
=CH2), 9.71 (d, J = 1.3 Hz, 1 H, CHO, diast.: 9.67).- 13C NMR (150.9 MHz, CDCl3): δ = 
23.94 (-, CH2), 27.88 (-, CH2), 29.34 (-, 4-C), 33.61 (-, CH2), 47.74 (+, 1'-C), 50.08 (+, 3-C), 
80.48 (+,2-C), 108.91 (-, =CH2), 150.83 (Cq, 2'-C), 174.13 (Cq, 5-C), 197.61 (+, CHO).- IR 
(neat): ~ν = 3426, 2955, 2873, 1771, 1653, 1435, 1198, 882 cm-1.- MS (CI, NH3): m/z (%) = 
212.2 (100) [M+NH4+].- HRMS (EI, 70 eV): 194.0943 (C11H14O3: calc. 194.0943 [M+]). 
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11.9.2 Hosomi-Sakurai allylation and acetyl-protection 
 
General procedure for Hosomi-Sakurai allylation and acetyl-protection: 
Aldehyde 210 (1.00 eq.) was dissolved in abs. CH2Cl2 (4 ml/mmol) under a N2-atmosphere 
and cooled to -78 °C. Allylsilane 211 (1.50 eq.) was added via a syringe and the solution was 
stirred for 15 min. BF3⋅OEt2 (1.15 eq.) was added dropwise via a syringe and the reaction 
mixture was stirred for 18 h at -78 °C. NaHCO3 sat. (1 ml/mmol BF3⋅OEt2) was added and the 
solution was warmed to rt. The layers were separated and the aqueous layer was again 
extracted with CH2Cl2 (1x4 ml/mmol). The combined organic layers were dried (Na2SO4) and 
concentrated in vacuo. 
The crude alcohol (1.00 eq.) was dissolved in abs. CH2Cl2 (1x5 ml/mmol), DMAP (0.10 eq.), 
abs. NEt3 (1.75 eq.) and Ac2O (1.50 eq.) were added and the reaction mixture was stirred for 
18 h at rt. The solvent was removed in vacuo and chromatography on silica gel 
(hexanes:ethylacetate 3:1) afforded the product as a slightly yellowish oil. 
 
 
(R/S)-1-((2´S,3´S)-2´-allyl-5´-oxo-tetrahydrofuran-3´-yl)but-3-enyl acetate (213a) 
 
Yield: 67%, dr = 73:27.- Rf (hexanes:ethylacetate 3:1, Mostain) = 0.30.- 1H NMR (300 MHz, 
CDCl3): δ = 2.05 (s, 3H, Ac, diast: 2.04), 2.15-2.72 (m, 7H, 2-H, 3´-H, 4´-H, 1´´-H), 4.23-
4.31 (m, 1H, 1-H, diast: 4.44-4.51), 4.95-5.17 (m, 4H, 4-H, 3´´-H), 5.17-5.20 (m, 1H, 2´-H), 
5.58-5.86 (m, 2 H, 3-H, 2´´-H).- 13C NMR (75 MHz, CDCl3): δ = 20.9 (+, CH3), 29.1 (-, 4´-C, 
diast: 31.8), 37.3 (-, 1´´-C, diast: 36.8), 38.6 (-, 2-C, diast: 39.55), 42.4 (+, 3´-C, diast: 41.5), 
71.2 (+, 1-C, diast: 73.9), 80.9 (+, 2´-C), 118.9 (+, =CH2), 119.5 (-, =CH2), 131.7 (+, CH=C, 
diast: 131.9), 132.3 (+,CH=C diast: 132.2), 170.4 (Cq, OAc, diast: 170.3), 175.5 (Cq, 5´-C, 
diast: 175.2).- IR (neat): ~ν = 3628, 3535, 3079, 2939, 1779, 1738, 1644, 1422, 1371, 1234, 
1180, 1030, 997, 921, 833 cm-1.- MS (EI, 70 eV): m/z (%) = 43.1 (100.00) [H3C-C=O+], 239.0 
(0.90) [MH+].- HRMS (EI, 70 eV): 238.1201 (C13H18O4: calc. 238.1205 [M+]). 
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(R/S)-1-((2´S,3´R)-2´-allyl-5´-oxo-tetrahydrofuran-3´-yl)-3-methylbut-3-enyl-acetate 
(213b) 
 
Yield: 49%, dr = 67:33.- Rf (hexanes:ethylacetate 3:1, Mostain) = 0.35. - 1H NMR (300 MHz, 
CDCl3): δ = 1.74 (s, 3H, CH3, diast: 1.75), 2.05 (s, 3H, Ac, diast: 2.04), 2.06-2.56 (m, 6H, 2-
H, 3´-H, 4´-H, 1´´-H), 2.60 (dd, J = 8.5, 2.5 Hz, 1H, 4´-H, diast: 2.69 dd, J = 17.6, 9.61 Hz), 
4.29 (dd, J = 12.1, 6.0 Hz, 1H, 1-H, diast: 4.52, dd, J = 11.3, 4.9 Hz), 4.72-4.75 (m, 1H, 4-H), 
4.81-4.85 (m, 1H, 4-H), 5.07-5.23 (m, 3H, 3´´-H, 2´-H), 5.69-5.87 (m, 1H, 2´´-H).- 13C NMR 
(75 MHz, CDCl3): δ = 20.9 (+, CH3), 22.1 (+, OAc, diast: 22.3), 28.9 (-, 4´-C, diast: 31.9), 
38.65 (-, 1´´-C, diast: 39.65), 41.3 (-, 2-C, diast: 41.0), 42.5 (+, 3´-C, diast: 41.8), 69.9 (+, 
1-C, diast: 72.65), 80.9 (+, 2´-C, diast: 80.7), 114.4 (-, =CH2, diast: 114.5), 119.5 (-, =CH2), 
131.75 (+, 2´´-C, diast: 131.85), 140.4 (Cq, 3-C, diast: 140.3), 170.4 (Cq, Ac), 175.5 (Cq, 
5´-C, diast: 175.4).- IR (neat): ~ν = 3078, 2939, 1780, 1738, 1645, 1429, 1374, 1236, 1186, 
1032, 985, 911 cm-1.- MS (EI, 70 eV): m/z (%) = 43.0 (100.00) [H3C-C=O+], 252.8 (3) 
[MH+].- HRMS (EI, 70 eV): 252.1361 (C14H20O4: calc. 252.1362 [M+]). 
 
OO H
H
AcO H
 
(R/S)-((2´S,3´R)-2´-allyl-5´-oxo-tetrahydrofuran-3´-yl)((S)-2-methylenecyclopentyl) 
methyl acetate (213c) 
 
Yield: 53%, dr = 82:18:0:0.- Rf (hexanes:ethylacetate 3:1, Mostain) = 0.43.- 1H NMR 
(300 MHz, CDCl3): δ = 1.57-1.67 (m, 2H, CH2), 1.71-1.88 (m, 2H, CH2), 2.09 (s, 3H, OAc, 
diast: 2.08), 2.19-2.77 (m, 8H, CH2, 2-H, 3´-H, 4´-H, 1´´-H), 4.26 (dd, J = 11.7, 5.9 Hz, 1H, 
1-H), 4.85-4.89 (m, 1H, =CH2), 4.98-5.04 (m, 1H, =CH2), 5.10-5.25 (m, 3H, 3´´-H, 2´-H), 
5.71-5.89 (m, 1H, 2´´-H).- 13C NMR (75.5 MHz, CDCl3): δ = 20.8 (+, OAc), 23.8 (-, CH2), 
28.5 (-, 4-C), 29.6 (-, CH2), 32.8 (-, CH2), 38.5 (-, 1´´-C), 42.2 (+, 3´-C), 47.3 (+, 2-C), 72.1 
(+, 1-C), 81.4 (+, 2´-C), 108.4 (-, =CH2), 119.4 (-, =CH2), 131.9 (+, 2´´-C), 151.45 (Cq, C=), 
170.8 (Cq, OAc), 175.7 (Cq, 5´-C).- IR (neat): ~ν = 3076, 2954, 2873, 1779, 1738, 1644, 1431, 
1371, 1234, 1177, 1116, 1028, 986, 947, 914, 892, 857 cm-1.- MS (EI, 70 eV): m/z (%) = 43.0 
Experimental Part 
 
141
(100.00) [H3C-CO+], 278.9 (0.80) [M+H+].- HRMS (EI, 70 eV): 278.1512 (C16H22O4: calc. 
278.1518 [M+]). 
 
 
(R/S) – 1 - ((2´S,3´S) -2´- (2´´- methylallyl)-5´-oxo-tetrahydrofuran-3´-yl) but-3-enyl 
acetate (213d) 
 
Yield: 73%, dr = 77:23.- Rf (hexanes:ethylacetate 3:1, Mostain) = 0.23.- 1H NMR (300 MHz, 
CDCl3): δ = 1.75 (s, 3H, CH3, diast: 1.77), 2.05 (s, 3H, OAc, diast: 2.04), 2.14-2.73 (m, 7H, 
2-H, 3´-H, 4´-H, 1´´-H), 4.31-4.39 (m, 1H, 1-H, diast: 4.50-4.58), 4.76-4.82 (m, 1H, 3´´-H), 
4.84-4.89 (m, 1H, 3´´-H), 4.56-5.09 (m, 2H, 4-H), 5.10-5.15 (m, 1H, 2´-H), 5.58-5.76 (m, 1H, 
3-H).- 13C NMR (75.5 MHz, CDCl3): δ = 20.9 (+, CH3), 22.7 (+, OAc, diast: 22.8), 28.9 (-, 
4´-C, diast: 31.6), 37.3 (-, 1´´-C, diast: 36.8), 42.8 (+, 3´-C, diast: 42.2), 43.0 (-, 2-C, diast: 
43.8), 71.2 (+, 1-C, diast: 73.9), 80.4 (+, 2´-C, diast: 80.3), 114.4 (-, =CH2), 118.9 (-, =CH2), 
132.4 (+, 3-C, diast: 132.2), 140.3 (Cq, 2´´-C), 170.3 (Cq, OAc), 175.5 (Cq, 5´-C, diast: 
175.2).- IR (neat): ~ν = 3078, 2976, 2939, 1775, 1736, 1644, 1425, 1374, 1234, 1199, 1030, 
986, 947, 921, 830 cm-1.- MS (CI, NH3): m/z (%) = 253.2 (100.00) [M+H+].- HRMS 
(EI, 70 eV): 253.1438 (C14H21O4: calc. 253.1440 [M+H+]). 
 
 
(R/S)-3-methyl-1-((2´S,3´S)-2´-(2´´-methylallyl)-5´-oxo-tetrahydrofuran-3´-yl)but-3-enyl-
acetate (213e) 
 
Yield: 57%, dr = 70:30.- Rf (hexanes:ethylacetate 3:1, Mostain) = 0.25.- 1H NMR (300 MHz, 
CDCl3): δ = 1.74 (s, 3H, Me, diast: 1.75), 1.77 (s, 3H, Me, diast: 1.79), 2.05 (s, 3H, OAc, 
diast: 2.04), 2.08-2.77 (m, 7H, 2-H, 3´-H, 4´-H, 1´´-H), 4.33-4.42 (m, 1H, 1-H, diast: 4.54-
4.61), 4.07-4.75 (m, 1H, =CH2), 4.78-4.85 (m, 2H, =CH2), 4.87-4.92 (m, 1H, =CH2), 5.09-
5.23 (m, 1H, 2´-H). 13C NMR (75.5 MHz, CDCl3): δ = 20.9 (+, CH3), 22.1 (+, CH3, diast: 
22.4), 22.7 (+, OAc, diast: 22.8), 28.7 (-, 4´-C, diast: 31.8), 41.3 (-, 1´´-C, diast: 41.0), 42.9 
(+, 3´-C, diast: 42.7), 43.1 (-, 2-C, diast: 43.9), 69.9 (+, 1-C, diast: 72.7), 80.2 (+, 2´-C), 114.4 
Experimental Part 
 
142
(-, 2x =CH2), 140.3 (2x Cq, 3-C, 2´´-C), 170.4 (Cq, OAc), 175.6 (Cq, 5´-C, diast: 175.3).- 
IR (neat): ~ν = 3077, 2971, 2939, 1779, 1738, 1649, 1445, 1429, 1374, 1235, 1189, 1029, 985, 
937, 896, 830 cm-1.- MS (CI, NH3): m/z (%) = 267.2 (100.00) [M+H+].- HRMS (EI, 70 eV): 
267.1592 (C15H23O4: calc. 267.1596 [M+H+]). 
 
OO H
H
AcO H
 
(R/S)-((2´S,3´R)-2´-(2´´-methylallyl)-5´-oxo-tetrahydrofuran-3´-yl)(2-methylenecyclo-
pentyl) methyl acetate (213f) 
 
Yield = 59%, dr = 79:21:0:0.- Rf (hexanes:ethylacetate 3:1, Mostain) = 0.33.- 1H NMR (300 
MHz, CDCl3): δ = 1.53-1.67 (m, 2H, CH2), 1.71-1.91 (m, 2H, CH2), 1.79 (s, 3H, CH3), 2.09 
(s, 3H, OAc), 2.23-2.45 (m, 5H, CH2, 2-H, 4´-H), 2.55-2.77 (m, 3H, 3´-H, 1´´-H), 4.34 (dd, J 
= 12.6, 6.3 Hz, 1H, 1-H), 4.77-5.04 (m, 4H, 2x =CH2), 5.13 (dd, J = 7.6, 2.1 Hz, 1H, 2´-H).- 
13C NMR (75.5 MHz, CDCl3): δ = 20.8 (+, CH3), 22.7 (+, OAc), 23.7 (-, CH2), 28.5 (-, 4´-C), 
29.4 (-, CH2), 32.8 (-, CH2), 42.7 (-, 2´-C), 42.8 (+, 3´-C), 47.4 (+, 2-C), 72.0 (+, 1-C), 80.8 
(+, 2´-C), 108.8 (-, =CH2), 114.4 (-, =CH2), 140.5 (Cq, C=CH2), 151.5 (Cq, C=CH2), 170.8 
(Cq, OAc), 175.7 (Cq, 5´-C).- IR (neat): ~ν = 3075, 2952, 1780, 1738, 1652, 1431, 1373, 1233, 
1090, 1024, 986, 946, 893, 719 cm-1.-MS (CI, NH3): m/z (%) = 293.2 (100.00) [M+H+].- 
HRMS (EI, 70 eV): 293.1747 (C17H25O4: calc. 293.1753 [M+H+]). 
 
OO H
H
AcO
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(R/S)-1-((2´S,3´S)-2´-((R)-2´´-methylenecyclopentyl)-5´-oxo-tetrahydrofuran-3-yl)but-3-
enyl-acetate (213g) 
 
Yield = 57%, dr = 80:20.- Rf (hexanes:ethylacetate 3:1, Mostain) = 0.33.- 1H NMR (300 
MHz, CDCl3): δ = 1.51-1.67 (m, 2H, CH2), 1.68-1.89 (m, 2H, CH2), 2.05 (s, 3H, OAc, diast: 
2.03), 2.12-2.39 (m, 5H, CH2, 3´-H, 4´-H), 2.54-2.59 (m, 2H, CH2), 2.62-2.71 (m, 1H, 1´´-H), 
4.27-4.32 (m, 1H, 1-H, diast: 4.54-4.59), 4.87 (dd, J = 3.9, 2.0 Hz, 1H, 2´-H), 4.94-5.17 (m, 
4H, =CH2), 5.58-5.78 (m, 1H, 3-H).- 13C NMR (75.5 MHz, CDCl3): δ = 20.9 (+, OAc), 24.2 
(-, CH2, diast: 24.4), 27.3 (-, CH2, diast: 26.7), 29.3 (-, 4´-C), 33.7 (-, CH2, diast: 33.9), 37.2 (-
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, CH2, diast: 36.6), 41.2 (+, 3´-C, diast: 40.6), 47.1 (+, 1´´-C, diast: 47.6), 71.9 (+, 1-C, diast: 
74.2), 83.6 (+ 2´-C, diast: 83.3), 107.9 (-, =CH2, diast: 107.5), 118.9 (-, =CH2), 132.4 (+, 3-C), 
151.6 (Cq, 2´´-C, diast: 151.8), 170.4 (Cq, OAc), 175.8 (Cq, 5´-C, diast: 175.6).- IR (neat): 
~ν = 3077, 2955, 2872, 1774, 1742, 1644, 1431, 1373, 1235, 1199, 1176, 1030, 993, 967, 920, 
887 cm-1.- MS (CI, NH3): m/z (%) = 279.2 (100.00) [MH+].- HRMS (EI, 70 eV): 279.1599 
(C16H23O4: calc. 279.1596 [M+]). 
 
 
(R/S)-3-methyl-1-((2´S,3´S)-2´-((R)-2´´-methylenecyclopentyl)-5´-oxo-tetrahydrofuran-
3´-yl)but-3-enyl acetate (213h) 
 
Yield: 47%, dr = 70:30.- Rf (hexanes:ethylacetate 3:1, Mostain) = 0.28. - 1H NMR (300 MHz, 
CDCl3): δ = 1.52-1.69 (m, 2H, CH2), 1.74 (s, 3H, CH3), 1.77-1.90 (m, 2H, CH2), 2.05 (s, 3H, 
OAc, diast: 2.03), 2.06-2.40 (m, 5H, CH2, 3´-H, 4´-H), 2.55-2.70 (m, 3H, CH2, 1´´-H), 4.27-
4.34 (m, 1H, 1-H, diast: 4.55-4.61), 4.67-4.77 (m, 1H, =CH2), 4.79-4.85 (m, 1H, =CH2), 4.86-
4.90 (m, 1H, =CH2, diast: 4.90-4.94), 5.00-5.04 (m, 1H, =CH2, diast: 5.04-5.07), 5.16-5.24 
(m, 1H, 2´-H, diast: 5.10-5.16).- 13C NMR (MHz, CDCl3): δ = 20.9 (+, OAc, diast: 20.8), 22.2 
(+, CH3, diast: 22.4), 24.2 (-, CH2, diast: 24.4), 27.4 (-, CH2, diast: 26.7), 29.1 (-, CH2), 33.7 (-
, CH2), 41.2 (-,CH2, diast: 40.7), 41.3 (+, 3´-C, diast: 41.1), 47.2 (+, 1´´-C, diast: 47.7), 70.6 
(+, 1-C, diast: 72.8), 83.6 (+, 2´-C, diast: 83.1), 107.9 (-, =CH2, diast: 107.5), 114.3 (-, =CH2), 
140.4 (Cq, 4-C), 151.6 (Cq, 2´´-C, diast: 151.8), 170.4 (Cq, OAc), 175.5 (Cq, 5´-C, diast: 
175.7).- IR (neat): ~ν = 3075, 2955, 2873, 1774, 1742, 1651, 1431, 1373, 1235, 1190, 1134, 
1088, 1030, 967, 941, 893, 732 cm-1.- MS (CI, NH3): m/z (%) = 233.2 (38.58) [M-
CH3COOH], 293.3 (100.00) [MH+].- HRMS (EI, 70 eV): 292.16849 (C17H24O4 calc. 
292.1685 [M+]). 
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(R/S)-(2-methylenecyclopentyl)((2´S,3´S)-2´-((R)-2´´-methylenecyclopentyl)-5´-oxo-
tetrahydro-furan-3´-yl)methyl acetate (213i) 
 
Yield = 52%, dr = >99:1:0:0.- Rf (hexanes:ethylacetate 3:1, Mostain) = 0.46.- m.p. = 77 °C.- 
1H NMR (300 MHz, CDCl3): δ = 1.50-1.69 (m, 4H, 2x CH2), 1.72-1.91 (m, 4H, 2x CH2), 2.09 
(s, 3H, OAc), 2.27-2.40 (m, 4H, 2x CH2), 2.51-2.87 (m, 5H, 2-H, 3´-H, 4´-H, 1´´-H), 4.26-
4.32 (m, 1H, 1-H), 4.85-4.92 (m, 2H, =CH2), 5.03-3.07 (m, 2H, =CH2), 5.15 (dd, J = 7.7, 2.5 
Hz, 1H, 2´-H).- 13C NMR (MHz, CDCl3): δ = 20.8 (+, OAc), 23.7 (-, CH2), 24.3 (-, CH2), 
27.3 (-, CH2), 28.6 (-, CH2), 29.7 (-, CH2), 32.7 (-, CH2), 33.7 (-, CH2), 41.0 (+, 3´-C), 47.0 
(+, 1´´-C), 47.5 (+, 2-C), 72.6 (+, 1-C), 84.0 (+, 2´-C), 107.8 (-, =CH2), 108.4 (-, =CH2), 151.6 
(Cq, C=), 151.8 (Cq, C=), 170.8 (Cq, OAc), 176.0 (Cq, 5´-C).- IR (KBr): ~ν = 3077, 2948, 
2869, 1755, 1737, 1654, 1447, 1373, 1311, 1283, 1234, 1204, 1165, 1124, 1099, 1055, 1019, 
988, 963, 947, 908, 886, 738, 702, 648, 628, 592 cm-1.- MS (EI, 70 eV): m/z (%) = 318.3 (4) 
[M+].- HRMS (EI, 70 eV): 318.1835 (C19H26O4: calc. 318.1831 [M+]). 
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11.9.3 Ring Closing Metathesis 
General procedure for RCM: 
Diene 213 was dissolved in abs. toluene (10 ml/mmol dien) and a gentle stream of nitrogen 
was passed through the solution via a Teflon tube. The reaction vessel was heated to 95 °C in 
an oil bath and Grubbs 2nd gen (5 mol% in abs. toluene (1 ml)) was added every 2 h to a total 
of 15 mol%). The reaction mixture was cooled to rt and the solvent was evaporated in vacuo 
and flash chromatography (hexanes:ethylacetate 3:1) afforded the corresponding products. 
 
 
(3aR,4R/S,8aS,Z)-6-methyl-2-oxo-3,3a,4,5,8,8a-hexahydro-2H-cyclohepta[b]furan-4-yl 
acetate (209b) 
 
Yield: 96%, dr = 68:32.- Rf (hexanes:ethylacetate 3:1, Mostain) = 0.17.- 1H NMR (300 MHz, 
CDCl3): δ = 1.79 (s, 3H, Me, diast: 1.73), 2.06 (s, 3H, OAc, diast: 2.09), 2.23-2.82 (m, 7H, 3-
H, 3a-H, 5-H, 8-H), 3.94-4.06 (m, 1H, 4-H, diast: 4.29-4.41), 4.73-4.85 (m, 1H, 8a-H, diast: 
5.15-5.23), 5.51-5.66 (m, 1H 7-H).- 13C NMR (75 MHz, CDCl3): δ = 20.9 (+, OAc, diast: 
21.0), 27.6 (+, Me, diast: 28.2), 32.0 (-, CH2, diast: 32.7), 35.3 (-, 3-C, dist: 33.0), 39.4 (-, 
CH2, diast: 37.0), 52.3 (+, 3a-C, diast: 50.3), 71.3 (+, 4-C, diast: 67.5), 77.4 (+, 8a-C, diast: 
79.75), 119.9 (+, 7-C, diast: 120.7), 135.3 (Cq, 6-C, diast: 135.7) , 170.1 (Cq, OAc, diast: 
170.35), 174.5 (Cq, 2-C, diast: 174.7).- IR (neat): ~ν = 3630, 3548, 3032, 2935, 2855, 1938, 
1788, 1738, 1435, 1373, 1238, 1200, 1131, 1095, 1032, 1005, 964, 923, 904, 872, 817, 712 
cm-1.- MS (EI, 70V): m/z (%) = 43.1 (100) [CH3CO+], 164.0 (70) [M+-CH3COOH).- HRMS 
(EI, 70 eV): 225.1132 (C12H17O4: calc. 225.1127 [M+H+]).  
 
 
(3aR,4R/S,4aS,9aS,Z)-2-oxo-2,3,3a,4,4a,5,6,7,9,9a-decahydroazuleno[6,5-b]furan-4-yl-
acetate (209c) 
 
Yield: 76%, dr = 84:16.- Rf (hexanes:ethylacetate: 3:1, Mostain) = 0.25.- 1H NMR (300 MHz, 
CDCl3): δ = 1.30-1.53 (m, 2H, CH2), 1.59-1.77 (m, 2H, CH2), 1.89-2.01 (m, 1H, 4a-H), 2.07 
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(s, 3H, OAc), 2.19-2.75 (m, 7H, 3-H, 3a-H, 2xCH2), 3.92-4.06 (m, 1H, 4-H), 4.69-4.87 (m, 
1H, 9a-H), 5.56-5.75 (m, 1H, 8-H).- 13C NMR (75 MHz, CDCl3): δ = 20.8 (+, OAc), 24.4 (-, 
CH2), 31.95 (-, CH2), 32.2 (-, CH2), 34.9 (-, 3-C), 36.45 (-, CH2), 48.65 (+, 4a-C), 52.4 (+, 3a-
C), 74.7 (+, 4-C), 80.2 (+, 9a-C), 116.3 (+, 8-C), 145.8 (Cq, 7a-C) 170.4 (Cq, OAc), 174.4 
(Cq, 2-C).- IR (neat): ~ν = 2944, 2868, 1790, 1771, 1738, 1429, 1372, 1237, 1173, 1155, 1133, 
1078, 1025, 1006, 954, 915, 869, 849, 822, 611 cm-1.- MS (CI, NH3): m/z (%) = 191.1 (100) 
[M-CH3COO-], 251.1 (12) [M+H+], 267.1 (20) [M+NH4+]. 
 
 
(3aS,4R/S,8aS,Z)-7-methyl-2-oxo-3,3a,4,5,8,8a-hexahydro-2H-cyclohepta[b]furan-4-yl 
acetate (209d) 
 
Yield: 93%, dr = 80:20.- Rf (hexanes:ethylacetate 3:1, Mostain) = 0.19, diast: 0.16.- 1H NMR 
(300 MHz, CDCl3): δ = 1.79 (s, 3H, Me, diast: 1.66), 2.04 (s, 3H, OAc, diast: 2.08), 2.13-2.32 
(m, 1H, 3a-H), 2.35-2,73 (m, 6H, 3-H, 5-H, 8-H), 3.98-4.11 (m, 8a-H, 1H diast: 4.34-4.51), 
4.68-4.79 (m, 1H, 4-H, diast: 5.10-5.17), 5.42-5.52 (m, 1H, 6-H, diast: 5.29-5.39).- 13C NMR 
(75 MHz, CDCl3): δ = 21.1 (+, OAc), 26.9 (+, CH3), 33.4 (-, 5-C, diast: 31.2), 35.3 (-, 3-C, 
diast: 32.8), 37.8 (-, 8-C, diast: 39.0), 52.2 (+, 3a-C, diast: 49.4), 72.1 (+, 4-C, diast: 67.9), 
79.1, (+, 8a-C, diast: 76.7), 120.2 (+, 6-C), 136.1 (Cq, 7-C, diast: 135.4), 170.1 (Cq, OAc, 
diast: 170.4), 174.7 (Cq, 2-C, diast: 174.9).- IR (neat): ~ν = 2937, 2855, 1788, 1743, 1664, 
1445, 1373, 1242, 1203, 1149, 1133, 1069, 1030, 1001, 964, 908, 870, 831, 795, 699 cm-1.- 
MS (EI, 70 eV): m/z (%) = 43.1 (100) [CH3CO+], 164.1 (32) [M+-CH3CO2H), 225.2 (2) 
[MH+].- HRMS (EI, 70 eV): 225.1121 (C12H17O4: calc. 225.1127 [M+H+]). 
 
 
(3aS,4R/S,8aS,Z)-6,7-dimethyl-2-oxo-3,3a,4,5,8,8a-hexahydro-2H-cyclohepta[b]furan-4-
yl acetate (209e) 
 
Yield: 91%, dr = 75:25.- Rf (hexanes:ethylacetate 3:1, Mostain) = 0.26, diast: 0.20.- 1H NMR 
(300 MHz, CDCl3): δ = 1.76 (s, 6H, 2x Me, diast: 1.67, 1.77), 2.05 (s, 3H, OAc, diast: 2.08), 
2.22 (dd, J = 14.0, 2.2 Hz, 1H, 3-H), 2.37-2.65 (m, 6H, 3-H, 3a-H, 5-H, 8-H), 3.87-3.97 (m, 
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1H, 8a-H, diast: 4.19-4.31), 4.61-4.74 (m, 1H, 4-H, diast: 4.09-5.19).- 13C NMR (75 MHz, 
CDCl3): δ = 21.1 (+, OAc, diast: 20.9), 21.9 (+, CH3, diast: 22.0), 22.3 (+, CH3, diast: 23.2), 
35.4 (-, 3-C, diast: 32.7), 38.9 (-, CH2, diast: 38.0), 41.1 (-, CH2, diast: 39.9), 52.7 (+, 3a-C, 
diast: 50.2), 71.4 (+, 4-C, diast: 67.7), 79.5 (+, 8a-C, diast: 77.4), 127.0 (Cq, C=C, diast: 
126.7), 128.4 (Cq, C=C, diast: 127.7), 170.2 (Cq, OAc, diast: 170.4), 174.8 (Cq, 2-C, diast: 
174.9).- IR (neat): ~ν = 2994, 2920, 2861, 1788, 1730, 1445, 1372, 1242, 1203, 1177, 1137, 
1096, 1032, 984, 962, 912, 880, 857, 821, 701 cm-1.- MS (EI, 70 eV): m/z (%) = 43.1 (100) 
[CH3CO+], 178.1 (34) [M+-CH3CO2H), 238.2 (2) [MH+].- HRMS (EI, 70 eV): 238.1203 
(C13H18O4: calc. 238.1205 [M+H+]). 
 
 
(3aR,4R,4aS,9aS,Z)-8-methyl-2-oxo-2,3,3a,4,4a,5,6,7,9,9a-decahydroazuleno[6,5-b] 
furan-4-yl acetate (209f) 
 
Yield: 78%, dr >99:1.- [ ]20Dα = +83.8 (c = 0.525, CHCl3).- Rf (hexanes:ethylacetate 3:1, 
Mostain) = 0.33.- m.p. = 106 °C.- 1H NMR (300 MHz, CDCl3): δ = 1.29-1.48 (m, 2H, CH2), 
1.52-1.69 (m, 2H, CH2), 1.74 (s, 3H, CH3), 1.81-1.96 (m, 1H, 4a-H), 2.0 (s, 3H, OAc), 2.08-
2.29 (m, 2H, CH2), 2.34-2.52 (m, 4H, 3-H, CH2,), 2.53-2.68 (m, 1H, 3a-H), 3.93 (ddd, J = 
8.9, 8.8, 4.3 Hz, 1H, 9a-H), 4.64-4.76 (m, 1H, 4a-H).- 13C NMR (75 MHz, CDCl3): δ = 20.8 
(+, OAc), 23.7 (+, CH3), 24.3 (-, CH2), 31.8 (-, CH2), 33.6 (-, CH2), 35.2 (-, 3-C), 38.9 (-, 
CH2), 48.6 (+, 4a-C), 53.1 (+, 3a-C), 74.4 (+, 4-C), 79.7 (+, 9a-C), 124.8 (Cq, C=C), 138.1 
(Cq, C=C), 170.5 (Cq, OAc), 174.6 (Cq, 2-C).- IR (KBr): ~ν  = 2953, 2858, 1789, 1734, 1435, 
1374, 1240, 1198, 1123, 1080, 1026, 989, 960, 916, 856, 670, 601, 563 cm-1.- MS (CI, NH3): 
m/z (%) = 205.2 (18.7) [M+H+-CH3CO2H), 222.2 (1.9) [M+NH4+-CH3CO2H], 282.3 (100) 
[M+NH4+].- CH: C15H20O4 calc. C 68.16, H 7.63; found: C 68.01, H 7.85.  
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(3aS,4R/S,9aR,9bS,Z)-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl 
acetate (209g) 
 
Yield: 87%, dr = 79:21.- Rf (hexanes:ehtylacetate 3:1, Mostain) = 0.21, diast: 0.15.- 1H NMR 
(300 MHz, CDCl3): δ = 1.41-1.58 (m, 2H, CH2, diast: 1.18-1.28), 1.60-1.83 (m, 3H, 9a-H, 
CH2), 2.04 (s, 3H, OAc, diast: 2.08), 2.27-2.73 (m, 6H, 2xCH2, 3-H, 3a-H), 2.63 (dd, J = 
14.3, 5.21 Hz, 1H, 3-H), 3.74-3.83 (m, 1H, 9b-H), 4.72 (dt, J = 10.3, 3.3 Hz, 1H, 4-H, diast: 
5.15), 5.56-5.66 (m, 1H, 6-H).- 13C NMR (75 MHz, CDCl3): δ = 21.0 (+, OAc), 24.9 (-, 8-C, 
diast: 25.2), 32.1 (-, 9-C, diast: 32.2), 33.8 (-, 7-C), 35.0 (-, 5-C), 35.4 (-, 3-C), 46.9 (+, 9a-C), 
49.6 (+, 3a-C, diast: 51.8), 71.7 (+, 4-C), 83.8 (+, 9b-C, diast: 81.1), 115.8 (+, 6-C, diast: 
116.1), 146.9 (Cq, 6a-C), 170.1 (Cq, OAc), 174.7 (Cq, 2-C).- IR (neat): ~ν  = 2969, 2948, 2864, 
1769, 1734, 1433, 1376, 1239, 1190, 1159, 1121, 1084, 1028, 1002, 971, 953, 917, 895, 842, 
768, 706, 659, 524 cm-1.- MS (EI, 70V): m/z (%) = 43.1 (100) [CH3CO+], 190.1 (93) [M+-
CH3COOH).- HRMS (EI, 70 eV): 251.1282 (C14H19O4: calc. 251.1283 [M+H+]). 
 
 
(3aS,4R/S,9aR,9bS,Z)-6-methyl-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b] 
furan-4-yl acetate (209h) 
 
Yield: 96%, dr = 72:28.- Rf (hexanes:ehtylacetate 3:1, Mostain) = 0.24, diast: 0.15.- 1H NMR 
(300 MHz, CDCl3): δ = 1.39-1.56 (m, 2H, CH2, diast: 1.11-1.33), 1.60-1.83 (m, 2H, CH2), 
1.74 (s, 3H, Me, diast: 1.66), 2.04 (s, 3H, OAc, diast: 2.07), 2.08-2.17 (m, 1H, 9a-H), 2.21 
(dd, J = 14.1, 2.6 Hz, 1H, 3-H), 2.27-2.73 (m, 6H, 2xCH2, 3-H, 3a-H), 3.66-3.77 (m, 1H, 9b-
H), 4.70 (dt, J = 10.4, 2.3 Hz, 1H, 4-H, diast: 5.12).- 13C NMR (75 MHz, CDCl3): δ = 21.1 
(+, OAc, diast: 20.9), 23.9 (+, CH3, diast: 24.7), 24.8 (-, 8-C, diast: 25.1), 31.9 (-, 9-C, diast: 
32.0), 32.9 (-, 7-C, diast: 32.8), 35.2 (-, 3-C, diast: 33.3), 41.4 (-, 5-C, diast: 38.3), 46.8 (+, 9a-
C, diast: 47.9), 52.3 (+, 3a-C, diast: 50.2), 71.0 (+, 4-C, diast: 67.7), 84.2 (+, 9b-C, diast: 
81.7), 123.8 (Cq, C=C, diast: 123.9), 139.5 (Cq, C=C, diast: 138.6), 170.1 (Cq, OAc, diast: 
170.5), 174.8 (Cq, 2-C, diast: 174.9).- IR (neat): ~ν  = 2940, 2868, 1788, 1729, 1627, 1428, 
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1372, 1254, 1186, 1113, 1091, 1030, 992, 955, 920, 850, 705, 675 cm-1.- MS (EI, 70V): m/z 
(%) = 43.1 (100) [CH3CO+], 204.1 (71) [M+-CH3COOH).- HRMS (EI, 70 eV): 265.1442 
(C15H21O4: calc. 265.1440 [M+H+]). 
 
OO H
H
AcO
H
H
 
(3aS,4R,5S,9aR,9bS)-6,5-cyclopentanyl-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno 
[4,5-b]furan-4-yl acetate (209i) 
 
Yield: 48%, dr = >99:1.- [ ]20Dα = -34.2 (c = 0.500, CHCl3).- Rf (hexanes:ethylacetate 3:1, 
Mostain) = 0.23.- mp = 125 °C.- 1H NMR (400 MHz, CDCl3): δ = 1.34-1.64 (m, 4H, 2x CH2), 
1.69-1.85 (m, 2H, CH2), 1.91-2.01 (m, 1H, CH2), 2.07 (s, 3H, OAc), 2.11-2.25 (m, 3H, CH2), 
2.27-2.40 (m, 2H, CH2), 2.44-2.56 (m, 3H, 3a-H, CH2), 2.56-2.67 (m, 2H, 4a-H, 10a-H), 3.74-
3.86 (m, 1H, 10b-H), 4.74-4.87 (m, 1H, 4-H).- 13C NMR (100 MHz, CDCl3): δ = 20.8 (+, 
OAc), 24.3 (-, CH2), 24.8 (-, CH2), 32.5 (-, CH2), 32.8 (-, CH2), 34.01 (-, CH2), 34.6 (-, CH2), 
34.7 (-, CH2), 47.6 (+, 4a-C), 49.0 (+, 10a-C), 50.9 (+, 3a-C), 75.3 (+, 4-C), 84.7 (+, 10b-C), 
134.0 (Cq, 7a-C), 135.2 (Cq, 7b-C), 170.4 (Cq, OAc), 174.7 (Cq, 2-C).- IR (KBr): ~ν = 2962, 
2887, 1785, 1733, 1448, 1425, 1371, 1340, 1235, 1190, 1114, 1084, 1057, 1022, 998, 957, 
934, 916, 881, 667, 604, 588 cm-1.- MS (EI, 70V): m/z (%) = 43.1 (100) [CH3CO+], 230.1 
(85) [M+-CH3COOH).- HRMS (EI, 70 eV): 290.1525 (C17H22O4: calc. 290.1518 [M+]). 
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11.10 Towards Cynaropicrin and Ixerin Y 
OO
H
H
H
OPMB
SiMe2Ph
HO
 
(3aR,4R,8S,9S,9aS,9bR,Z)-9-((dimethyl(phenyl)silyl)methyl)-4-hydroxy-8-(p-methoxy-
benzyloxy)-6-methyl-3,3a,4,5,7,8,9,9a-octahydroazuleno[4,5-b]furan-2(9bH)-one 
(4R-216) 
 
Deprotection of 4R-199: 
Minor diastereomer 4R-199 (115 mg, 0.210 mmol, 1.0 eq.) was dissolved in MeOH (4 ml) 
and cooled to 0 °C. K2CO3 (16 mg, 0.115 mmol, 0.55 eq.) was added and the mixture was 
stirred for 1 h at 0 °C and over night at rt. Et2O (20 ml) was added and the mixture was 
extracted with H2O (5 ml) and brine (4 ml). The organic layer was dried (Na2SO4) and 
concentrated in vacuo. The residue was purified by flash chromatography on silica gel 
(hexanes:ethylacetate 3:1 to 1:1) to give 80 mg (0.158 mmol, 75%) product as a colorless oil. 
 
Reduction of ketone 217: 
Ketone 217 (29 mg, 0.058 mmol, 1.0 eq.) was dissolved in MeOH (2 ml) and CeCl3 (28 mg, 
0.075 mmol, 1.3 eq.) was added. The mixture was stirred until a clear solution was obtained 
and than cooled to -5 °C before NaBH4 (3 mg, 0.075 mmol, 1.3 eq.) was added. The reaction 
mixture was stirred for 30 min and than quenched by addition of H2O (1 ml). The reaction 
mixture was extracted with CH2Cl2 (5 ml). The aqueous layer was again extracted with 
CH2Cl2 (2x5 ml) and the combined org. layers were washed with brine (3 ml), dried 
(Na2SO4), filtered and concentrated to obtain 24 mg (0.048 mmol, 82%) pure product as a 
colorless oil.  
 
Rf (hexanes:ethylacetate 1:1, Mostain) = 0.37.- [ ]20Dα = -43.8 (c = 0.5, CHCl3).- 1H NMR 
(600 MHz): δ = 0.31 (s, 3H, SiMe), 0.38 (s, 3H, SiMe), 0.63-0.73 (m, 2H, CH2Si), 1.56-1.77 
(m, 1H, 3a-H), 1.69 (s, 3H, CH3), 2.13-2.24 (m, 2H, 5-H, 9a-H), 2.25-2.34 (m, 1H, 5-H), 2.30 
(dd, J = 16.5, 6.5 Hz, 1H, 3-H), 2.37-2.47 (m, 1H, 7-H), 2.50-2.59 (m, 1H, 7-H), 2.64 (dd, J = 
16.4, 13.6 Hz, 1H, 3-H), 2.78-2.88 (m, 1H, 9-H), 3.55 (m, 1H, 8-H), 3.79 (s, 3H, OMe), 3.81-
3.86 (m, 1H, 4-H), 4.04 (dd, J = 10.6, 10.6 Hz, 1H, 9b-H), 4.18-4.48 (m, 2H, PMB), 6.77-
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6.87 (m, 2H, PMB), 7.11-7.20 (m, 2H, PMB), 7.30-7.38 (m, 3H, Ph), 7.47-7.56 (m, 2H, Ph).- 
13C NMR (75.5 MHz): δ = -2.7 (+, SiMe), -2.0 (+, SiMe), 21.28 (-, CH2Si), 25.4 (+, CH3), 
33.8 (-, 3-C), 37.0 (-, 7-C), 40.5 (+, 9-C), 41.7 (-, 5-C), 53.9 (+, 3a-C), 54.9 (+, 9a-C), 55.5 (+, 
OMe), 66.3 (+, 4-C), 69.8 (-, PMB), 79.6 (+, 9b-C), 86.3 (+, 8-C), 113.9 (+, 2xPMB), 126.2 
(Cq, Ph), 127.9 (+, 2xPh), 129.1 (+, Ph), 129.7 (+, 2xPMB), 130.6 (Cq, PMB), 134.1 (+, 
2xPh), 138.7 (Cq, 6-C), 139.5 (Cq, 6a-C), 159.3 (Cq, PMB), 175.6 (Cq, 2-C).- IR (neat): ~ν = 
3442, 3068, 3045, 2950, 2916, 2900, 2398, 2341, 1772, 1743, 1716, 1612, 1514, 1425, 1247, 
1197, 1110, 1076, 1037 cm-1.- MS (ES): m/z (%) = 298 (72), 338 (73), 391 (59), 428 (40), 507 
(100) [M+H+], 524 (90) [M+NH4+], 529 (83) [M+Na+].- HRMS (ES): 524.2828 
(C30H42O5SiN: calc. 524.2832 [M+NH4+]). 
 
 
(3aS,8S,9S,9aS,9bR,Z)-9-((dimethyl(phenyl)silyl)methyl)-8-(p-methoxybenzyloxy)-6-
methyl-3,3a,7,8,9,9a-hexahydroazuleno[4,5-b]furan-2,4(5H,9bH)-dione (217) 
 
Alcohol 4R-216 (40 mg, 0.079 mmol, 1.0 eq.) was dissolved in abs. CH2Cl2 (5 ml) under a 
N2-atmosphere. Crushed activated molecular sieve (200 mg, 4 Å) was added and at rt PCC 
(25 mg, 0.116 mmol, 1.5 eq.) was added in portions over 5 min. The reaction mixture was 
stirred for 5 h. After filtration over celite, the solvent was removed under reduced pressure. 
Chromatography on silica gel (hexanes:ethylacetate 2:1) afforded the product (30 mg, 
0.059 mmol, 75%) as a colorless oil. 
 
Rf (hexanes:ethylacetate 2:1, Vanillin) = 0.39.- [ ]20Dα = 227.8 (c = 0.500, CHCl3).- 1H NMR 
(400 MHz): δ = 0.32 (s, 3H, SiMe), 0.43 (s, 3H, SiMe), 0.71 (d, J = 7.4 Hz, 2H, SiCH2), 1.73 
(s, 3H, Me), 2.37 (dd, J = 16.2, 5.5 Hz, 1H, 3-H), 2.40-2.60 (m, 3H, 7-H, 3a-H), 2.61-2.72 
(m, 2H, 9a-H, 5-H), 2.79 (dd, J = 16.2, 12.6 Hz, 1H, 3-H), 2.82-2.91 (m, 1H, 9-H), 3.10-3.20 
(m, 1H, 5-H), 3.57-3.63 (m, 1H, 8-H), 3.79 (s, 3H, OMe), 3.95 (dd, J = 10.4, 10.4 Hz, 1H, 9b-
H), 4.19-4.45 (m, 2H, PMB), 6.79-6.88 (m, 2H, PMB), 7.11-7.19 (m, 2H, PMB), 7.32-7.41 
(m, 3H, Ph), 7.52-760 (m, 2H, Ph).- 13C NMR (75.5 MHz): δ = -3.2 (+, SiMe), -2.1 (+, SiMe), 
21.0 (-, SiCH2), 23.6 (+, Me), 31.7 (-, 3-C), 37.7 (-, 7-C), 40.9 (+, 9-C), 50.1 (-, 5-C), 54.2 (+, 
9a-C), 55.4 (+, OMe), 60.4 (+, 3a-C), 69.9 (-, PMB), 83.9 (+, 9b-C), 86.0 (+, 8-C), 113.9 (+, 
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2x PMB), 123.6 (Cq, Ph), 127.9 (+, 2xPh), 129.3 (+, Ph), 129.5 (+, 2x PMB), 130.4 (Cq, 
PMB), 134.2 (+, 2xPh), 138.9 (Cq, 6a-C), 139.4 (Cq, 6-C), 159.3 (Cq, PMB), 174.3 (Cq, 2-
C), 198.9 (Cq, 4-C).- IR (neat): ~ν = 3014, 2953, 2904, 1784, 1715, 1610, 1512, 1426, 1300, 
1249, 1193, 1112, 1064, 1035, 959, 925, 876, 835, 754, 701 cm-1.- MS (EI, 70 eV): m/z (%) = 
44.0 (13.6), 121.0 (100), 135.0 (18.3), 305.1 (39.1), 398.1 (40.0), 426.1 (21.2), 489.2 (20.2) 
[M+-CH3], 504.4 (12.3) [M+], 505.6 (3.0) [M+H+].- HRMS (EI, 70eV): 504.2333 
(C30H40O5Si): calc. 504.2332 [M+]). 
 
OO
H
H
H
OH
SiMe2Ph
AcO
 
(3aR,4S,8S,9S,9aS,9bR,Z)-9-((dimethyl(phenyl)silyl)methyl)-8-hydroxy-6-methyl-2-oxo-
2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl acetate (218) 
 
PMB protected 4S-199 (85 mg, 155 mmol, 1.0 eq.) was dissolved in CH2Cl2 (4 ml) and water 
(0.2 ml). Subsequently DDQ (42 mg, 186 mmol, 1.2 eq.) was added at rt and the reaction 
mixture was stirred for 2 h. The mixture was diluted with CH2Cl2 (10 ml) and quenched with 
NaHCO3 (4 ml). The layers were separated and the aqueous layer was again extracted with 
CH2Cl2 (2x5 ml). The combined org. layers were washed with water (3 ml), dried (Na2SO4) 
and concentrated in vacuo. Purification on flash silica gel (hexanes:ethylacetate 3:1) afforded 
60 mg (140 mmol, 90%) product as a colorless oil. 
 
Rf (hexanes:ethylacetate 3:1, Mostain) = 0.17.- [ ]20Dα = -46.6 (c = 0.50, CHCl3).- 1H NMR (600 
MHz): δ = 0.33 (s, 3H, SiMe), 0.36 (s, 3H, SiMe), 0.72-0.78 (m, 2H, SiCH2), 1.72 (s, 3H, 
CH3), 1.87-1.99 (m, 1H, 9a-H), 2.02 (s, 3H, OAc), 2.07-2.12 (m, 1H, 5-H), 2.16-2.21 (m, 1H, 
5-H,), 2.21-2.25 (m, 1H, 3a-H), 2.31 (dd, J = 16.7, 13.3 Hz, 1H, 3-H), 2.26-2.34 (m, 1H, 7-
H), 2.39-2.45 (m, 1H, 9-H), 2.49 (dd, J = 16.6, 6.8 Hz, 1H, 3-H), 2.52-2.58 (m, 1H, 7-H), 
3.85-3.89 (m, 1H, 8-H), 3.93 (dd, J = 10.4, 10.4 Hz, 1H, 9b-H), 4.58 (dt, J = 10.6, 2.4 Hz, 
1H, 4-H), 7.34-7.37 (m, 3H, Ph), 7.51-7.55 (m, 2H, Ph).- 13C NMR (75.5 MHz): δ = -2.59 (+, 
SiMe), -2.23 (+, SiMe), 21.17 (-, CH2Si), 21.26 (+, OAc), 23.39 (+, CH3), 35.48 (-, 3-C), 
38.67 (-, 7-C), 41.38 (-, 5-C), 46.14 (+, 9-C), 53.40 (+, 3a-C), 53.67 (+, 9a-C), 71.07 (+, 4-C), 
79.76 (+, 8-C), 83.30 (+, 9b-C), 126.62 (Cq, Ph), 128.03 (+, 2xPh), 129.26 (+, Ph), 134.05 (+, 
2xPh), 137.62 (Cq, 6-C), 139.36 (Cq, 6a-C), 170.19 (Cq, OAc), 174.70 (Cq, 2-C).- IR (neat): 
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~ν = 3458, 3419, 3068, 3047, 2950, 2923, 2907, 2858, 2358, 2341, 1784, 1770, 1733, 1716, 
1427, 1373, 1236, 1112, 1027, 835, 700 cm-1.- MS (ES): m/z (%) = 220, 221, 295, 304, 429 
(M+H+), 446 (M+NH4+), 451 (M+Na+).- HRMS (ES): 446.2355 (C24H36O5SiN, calc. 
446.2363 [M+NH4+]). 
 
   
(3aR,4S,8S,9S,9aS,9bR,Z)-9-((dimethyl(phenyl)silyl)methyl)-8-hydroxy-6,6a-epoxy-6-
methyl-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl acetate (219) 
 
Alcohol 218 (60 mg, 0.14 mmol, 1.0 eq.) was dissolved in CH2Cl2 (2 ml) and cooled to 0 °C. 
mCPBA (59 mg, 0.24 mmol, 1.7 eq.) was added and the reaction was allowed to warm slowly 
to rt over night. CH2Cl2 (10 ml) was added and the reaction mixture was extracted with sat. 
NaHCO3 (2x5 ml) and washed with brine (5 ml). The organic layer was dried (Na2SO4) and 
concentrated in vacuo. Flash chromatography (hexanes:ethylacetate 3:1) afforded 60 mg 
(0.135 mmol, 96%) product as a colorless oil (α:β = 20:80). 
 
Rf (hexanes:ethylacetat 3:1, Mostain) = 0.10.- 1H NMR (500 MHz): δ = 0.34 (s, 3H, SiMe, 
diast: 0.37), 0.36 (s, 3H, SiMe, 0.38), 0.83-0.98 (m, 2H, CH2Si), 1.23-1.28 (m, 1H, 7-H), 1.37 
(s, 3H, CH3, diast: 1.31), 1.45-1.57, m, 1H, 5-H), 1.69-1.76 (m, 1H, 9a-H), 1.86-1.97 (m, 1H, 
3a-H), 2.05 (s, 3H, OAc), 2.23 (dd, J = 13.6, 1.9 Hz, 1H, 5-H), 2.34 (dd, J = 16.7, 12.9 Hz, 
1H, 3-H), 2.44-2.55 (m, 1H, 7-H), 2.55 (dd, J = 16.7, 6.9 Hz, 1H, 3-H), 4.05-4.09 (m, 1H, 8-
H, diast: 3.70-3.78), 4.27 (dd, J = 11.0, 11.0 Hz, 1H, 9b-H, diast: 4.12), 4.71-4.78 (m, 1H, 4-
H, diast: 4.84-4.90), 7.33-7.39 (m, 3H, Ph), 7.51-7.55 (m, 2H, Ph, diast: 7.55-7.59).- 13C 
NMR (75.5 MHz): δ = -2.7 (+, SiMe, diast: -2.6), -2.6 (+, SiMe, diast: -2.3), 19.9 (-, CH2Si, 
diast: 22.3), 20.9 (+, OAc, diast: 22.9), 21.4 (+, CH3), 35.2 (-, 3-C, diast: 34.5), 38.6 (-, 7-C, 
diast: 39.6), 44.6 (-, 5-C, diast: 39.9), 46.5 (+, 9-C, diast: 48.7), 52.2 (+, 3a-C, diast: 50.8), 
54.9 (+, 9a-C), 57.3 (Cq, 6-C, diast: 61.5), 72.4 (+, 4-C, diast: 72.1), 73.7 (Cq, 6a-C), 81.2 (+, 
8-C, diast: 80.3), 83.1 (+, 9b-C, diast: 84.2), 130.2 (+, 2xPh, diast:130.27), 131.50 (+, Ph), 
136.18 (+, 2xPh, diast: 136.12), 141.04 (Cq, Ph), 172.27 (Cq, OAc), 176.43 (Cq, 2-C).- IR 
(neat): ~ν = 3465, 3068, 3047, 2999, 2954, 2935, 1784, 1737, 1456, 1427, 1373, 1236, 1180, 
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1168, 1112, 1089, 1029, 999, 966, 891, 837, 792, 754, 734, 702, 667 cm-1.- MS (ES): m/z (%) 
= 197 (50), 343 (22), 371 (30), 399 (25), 445 (10) [M+H+], 462 (100) [M+NH4+], 468 (30) 
[M+Na+].- HRMS (ES): 445.2030 (C24H33O6Si: calc. 445.2046 [M+H+]). 
 
OO
H
H
H
OPMB
OH
AcO
O
 
(3aR,4S,6S,6aS,8S,9R,9aS,9bR)-9-(hydroxymethyl)-8-(p-methoxybenzyloxy)-6-methyl-
6,6a-epoxy-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl acetate (225) 
 
Method A: 
Silane 4S-199 (100 mg, 0.182 mmol, 1.0 eq.) was dissolved in glacial acetic acid (1 ml) and 
ethylacetate (0.5 ml). After cooling to 0 °C peracetic acid (30%, 1.22 ml) was added slowly 
and the reaction mixture was stirred for 3 h at 0 °C. Carefully Hg(OAc)2 (73 mg, 0.228 mmol, 
1.25 eq.) was added and the reaction mixture was stirred for 1 h at 0 °C. Ethylacetate (50 ml) 
and H2O (2 ml) was added and the layers were separated. The organic layer was washed with 
H2O (2 ml), NaHCO3 sat. (2x2 ml) and brine (2x2 ml), dried (Na2SO4) and concentrated in 
vacuo. Chromatography on silica gel (hexanes:ethylacetate 1:2) afforded 57 mg (0.128 mmol, 
70%) product as a colorless oil. 
 
Method B: 
Acetic anhydride (5.4 ml, 57 mmol) was treated with 3 drops of conc. sulfuric acid and cooled 
to 0 °C. To this solution H2O2 (30%, 3.60 ml, 42 mmol) was added carefully and the resulting 
mixture was stirred for 30 min at rt. Silane 4S-199 was dissolved in 0.1 ml THF and 6 ml of 
the above fresh prepared solution was added at 0 °C. Hg(OAc)2 (93 mg, 0.202 mmol, 1.6 eq.) 
was added and the reaction mixture was stirred for 5 h at rt. After diluting the mixture with 
ethylacetate (30 ml) and H2O (5 ml) the layers were separated and the aqueous layer was 
again extracted with ethylacetate (2x15 ml). The combined org. layers were washed (10% 
Na2SO3 (2x 7 ml), sat. NaHCO3 (2x 15 ml) and brine (10 ml)), dried (Na2SO4), filtered and 
concentrated. Chromatography on silica gel (hexanes:ethylacetate 1:2) afforded 36 mg 
(0.083 mmol, 46%) free alcohol 225 along with 9 mg (0.018 mmol, 10%) acetyl protected 
product 226. 
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Rf (hexanes:ethylacetat 1:2, Mostain) = 0.30.- [ ]20Dα = +31.8 (c = 0.425, CHCl3).- 1H NMR 
(600 MHz): δ = 1.39 (s, 3H, Me), 1.77 (dd, J = 13.1, 12.2 Hz, 1H, 5-H), 2.00-2.11 (m, 2H, 7-
H, 9a-H), 2.06 (s, 3H, OAc), 2.17 (dd, J = 15.3, 5.1 Hz, 1H, 7-H), 2.30-2.46 (m, 3H, 3-H, 3a-
H, 5-H), 2.63 (dd, J = 15.3, 5.4 Hz, 1H, 3-H), 2.70-2.77 (m, 1H, 9-H), 3.69 (d, J = 6.5 Hz, 
2H, CH2OH), 3.79 (s, 3H, OMe), 4.06-4.15 (m, 1H, 8-H), 4.21 (dd, J = 11.3, 9.9 Hz, 1H, 9b-
H), 4.36-4.54 (m, 2H, PMB), 4.78-4.86 (m, 1H, 4-H), 6.84-6.89 (m, 2H, PMB), 7.22-7.28 (m, 
2H, PMB).- 13C NMR (75.5 MHz): δ = 21.0 (+, CH3), 21.5 (+, OAc), 35.3 (-, 3-C), 38.2 (-, 7-
C), 44.7 (-, 5-C), 49.1 (+, 9-C), 49.7 (+, 9a-C), 52.2 (+, 3a-C), 55.3 (+, PMB), 58.9 (Cq, 6-C), 
63.6 (-, CH2OH), 69.9 (+, 4-C), 70.7 (Cq, 6a-C), 71.1 (-, PMB), 79.5 (+, 8-C), 81.1 (+, 9b-C), 
113.9 (+, 2xPMB), 129.7 (+, 2x PMB), 130.1 (Cq, PMB), 159.5 (Cq, PMB), 170.1 (Cq, 
OAc), 173.8 (Cq, 2-C).- IR (neat): ~ν = 3515, 2933, 2875, 1784, 1612, 1586, 1514, 1423, 
1373, 1302, 1251, 1174, 1030, 997, 966, 914, 892, 825 cm-1.- MS (EI, 70eV): m/z (%) = 
121.0 (100) [CH2C6H4OMe+], 446.1 (3.8) [M+].- HRMS (EI, 70eV): 446.1945 (C24H30O8: 
calc. 446.1941 [M+]). 
 
OO
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H
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(3aR,4S,6S,6aS,8S,9R,9aS,9bR)-9-(acetoxymethyl)-8-(p-methoxybenzyloxy)-6-methyl-
6,6a-epoxy-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl acetate (226) 
 
Alcohol 225 (35 mg, 78 µmol, 1.0 eq.) was dissolved in abs. CH2Cl2 (2 ml) under a N2-
atmosphere. NEt3 (16 mg, 22 µl, 157 µmol, 2.0 eq.), DMAP (1 mg, 7.84 µmol, 10 mol%) and 
acetic anhydride (16 mg, 157 µmol, 2.0 eq.) were added at rt. The reaction mixture was stirred 
over night. The solvent was removed under reduced pressure and chromatography on silica 
gel (hexanes:ethylacetate 1:1) afforded 38 mg (78 µmol, 99%) product as a white foam. 
 
Rf (hexanes:ethylacetat 1:1, Mostain) = 0.26.- [ ]20Dα = +30.5 (c = 0.475, CHCl3).- 1H NMR 
(300 MHz): δ = 1.39 (s, 3H, CH3), 1.69-1.82 (m, 1H, 5-H), 2.06 (s, 3H, OAc), 2.07 (s, 3H, 
OAc), 2.00-2.12 (m, 2H, 5-H, 9a-H), 2.19 (dd, J = 15.5, 4.5 Hz, 1H, 7-H), 2.29-2.48 (m, 3H, 
3-H, 3a-H, 7-H), 2.64 (dd, J = 14.7, 5.0 Hz, 1H, 3-H), 2.87-2.96 (m, 1H, 9-H), 3.79 (s, 3H, 
OMe), 3.98-4.29 (m, 4H, CH2OAc, 9b-H, 8-H), 4.33-4.54 (m, 2H, PMB), 4.76-4.88 (m, 1H, 
4-H), 6.83-6.90 (m, 2H, PMB), 7.21-7.27 (m, 2H, PMB).- 13C NMR (75.5 MHz): δ = 20.9 (+, 
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CH3), 21.4 (+, 2xOAc), 35.3 (-, 3-C), 38.2 (-, 7-C), 44.8 (-, 5-C), 45.9 (+, 9-C), 50.2 (+, 9a-
C), 52.2 (+, 3a-C), 55.3 (+, OMe), 58.5 (Cq, 6-C), 64.3 (-, CH2OAc), 69.9 (+, 4-C), 70.6 (Cq, 
6a-C), 70.9 (-, PMB), 79.2 (+, 8-C), 80.8 (+, 9b-C), 113.9 (+, 2xPMB), 129.7 (+, 2xPMB), 
129.8 (Cq, PMB), 159.4 (Cq, PMB), 169.9 (Cq, OAc), 170.9 (OAc), 173.6 (Cq, 2-C).- IR 
(neat): ~ν = 2998, 2937, 2876, 1784, 1738, 1612, 1586, 1514, 1462, 1423, 1371, 1302, 1238, 
1173, 1150, 1133, 1077, 1030, 998, 967, 871, 893, 848, 754 cm-1.- MS (EI, 70eV): m/z (%) = 
43.1 (35.4), 121.1 (100), 137.1 (29.3), 488.2 (1.66) [M+].- HRMS (EI, 70eV): 488.2044 
(C26H32O9: calc. 488.2046 [M+]). 
 
OO
H
H
H
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(3aR,4S,6S,6aS,8S,9R,9aS,9bR)-9-(acetoxymethyl)-8-hydroxy-6-methyl-6,6a-epoxy-2-
oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl acetate (227) 
 
Compound 226 (47 mg, 96 µmol, 1.00 eq.) was dissolved in CH2Cl2 (4 ml) and water (0.5 
ml). DDQ (33 mg, 145 µmol, 1.51 eq.) was added in small portions at rt and the solution was 
stirred for 5 h. H2O (2 ml) and CH2Cl2 (5 ml) was added and the layers were separated. The 
aqueous layer was extracted with CH2Cl2 (2x 3 ml), dried (Na2SO4) and concentrated in 
vacuo. Chromatography on silica gel (hexanes:ethylacetate 3:1) afforded 32 mg (87 µmol, 
90%) product as a colorless solid. 
 
Rf (hexanes:ethylacetat 1:3, Mostain) = 0.21.- [ ]20Dα = +12.7 (c = 0.245, CHCl3).- m.p. = 
63 °C.- 1H NMR (600 MHz): δ = 1.41 (s, 3H, CH3), 1.70-1.80 (m, 1H, 5-H), 1.95 (dd, J = 
14.5, 6.3 Hz, 1H, 7-H), 2.07 (s, 3H, OAc), 2.08-2.10 (m, 1H, 9b-H), 2.09 (s, 3H, OAc), 2.16 
(dd, J = 14.5, 6.9 Hz, 1H, 7-H), 2.31-2.40 (m, 2H, 3a-H, 5-H), 2.46 (dd, J = 16.7, 12.7 Hz, 
1H, 3-H), 2.48-2.53 (m, 1H, 9-H), 2.64 (dd, J = 16.7, 6.7 Hz, 1H, 3-H), 4.17-4.26 (m, 3H, 
CH2OAc, 9b-H), 4.27-4.32 (m, 1H, 8-H), 4.82-4.89 (m, 1H, 4-H).-13C NMR (150 MHz): δ = 
20.9 (+, 2x Ac), 21.2 (+, CH3), 35.1 (-, 3-C), 39.8 (-, 7-C), 44.8 (-, 5-C), 49.6 (+, 9a-C), 50.2 
(+, 9-C), 51.9 (+, 3a-C), 58.5 (Cq, 6-C), 64.4 (-, CH2OAc), 69.8 (+, 4-C), 69.9 (Cq, 6a-C), 
81.6 (+, 9b-C), 169.9 (Cq, OAc), 171.3 (Cq, OAc), 173.7 (Cq, 2-C).- IR (KBr): ~ν = 3448, 
2937, 1783, 1735, 1458, 1375, 1238, 1168, 1133, 1093, 1066, 1029, 996, 967, 917, 873, 742, 
669 cm-1.- MS (EI, 70eV): m/z (%) = 350 (60) [M+-H2O], 368.2 (15) [M+].- HRMS (EI, 
70eV): 368.1472 (C18H24O8: calc. 368.1471 [M+]). 
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(3aR,4S,6R,9R,9aS,9bR)-6-hydroxy-9-(acetoxymethyl)-6-methyl-2,8-dioxo-2,3,3a,4,5,6, 
8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl acetate (231) 
 
Alcohol 227 (20 mg, 54 µmol, 1.0 eq.) was dissolved under a N2-atmosphere in abs. CH2Cl2 
(1 ml) and crushed MS (4 Å, 50 mg) was added. PCC (15 mg, 71 µmol, 1.30 eq.) was added 
in portions. The reaction mixture was stirred at rt for 5 h before being filtered over celite and 
concentrated in vacuo. Chromatography on silica gel (hexanes:ethylacetate 1:2) afforded 
16 mg (44 µmol, 80% product as a colorless solid, which can be recrystallized from 
acetonitrile. 
 
Rf (hexanes:ethylacetat 1:2, Mostain) = 0.10.- [ ]20Dα  = -0.8 (c = 0.40, CH3CN).- m.p. 
= 191 °C (decomp).- 1H NMR (600 MHz, CD3CN): δ = 1.51 (s, 3H, CH3), 1.96 (s, 3H, OAc), 
2.01 (s, 3H, OAc), 2.07-2.10 (m, 2H, 5-H), 2.41 (dd, J = 17.2, 12.3 Hz, 1H, 3-H), 2.65 (dd, J 
= 17.2, 8.0 Hz, 1H, 3-H), 2.71-2.75 (m, 1H, 9-H), 3.37-3.41 (m, 1H, 9a-H), 3.46-3.52 (m, 1H, 
3a-H), 3.53 (s, 1H, OH), 4.05 (dd, J = 10.6, 10.6 Hz, 1H, 9b-H), 4.21 (dd, J = 11.2, 5.3 Hz, 
1H, CH2OAc), 4.32 (dd, J = 11.2, 4.0 Hz, 1H, CH2OAc), 4.95-4.99 (m, 1H, 4-H), 6.08 (d, J = 
1.7 Hz, 1H, 7-H).- 13C NMR (150 MHz, CD3CN): δ = 20.9 (+, OAc), 21.4 (+, OAc), 30.8 (+, 
CH3), 36.2 (-, 3-C), 45.2 (+, 3a-C), 45.5 (-, 5-C), 50.2 (+, 9a-C), 51.6 (+, 9-C), 63.6 (-, 
CH2OAc), 72.4 (Cq, 6-C), 73.4 (+, 4-C), 83.2 (+, 9b-C), 130.3 (+, 7-C), 171.1 (Cq, OAc), 
171.7 (Cq,OAc), 175.8 (Cq, 2-C), 182.3 (Cq, 6a-C), 206.8 (Cq, 8-C).- IR (KBr): ~ν = 3475, 
2982, 2939, 1778, 1765, 1726, 1712, 1604, 1456, 1426, 1383, 1311, 1264, 1199, 1158, 1105, 
1076, 1034, 1006, 971, 887 cm-1.- MS (CI, NH3): m/z (%) = 180.1 (73.8), 324.0 (32.1) [M-
HOAc], 384.1 (100.0) [M+NH4+].- HRMS (PI-LSIMS, MeOH/Glycerin): 367.1383 
(C18H22O8: calc. 367.1393 [M+H+]). 
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(3aR,4S,6S,6aS,8S,9R,9aS,9bR)-9-(methylsulfinyloxymethyl)-8-(p-methoxybenzyloxy)-6-
methyl-6,6a-epoxy-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl 
acetate (233) 
 
Under a N2-atmosphere alcohole 225 (17.5 mg, 39 µmol, 1.0 eq.) was dissolved in abs. 
CH2Cl2 (2 ml) and cooled to 0 °C. NEt3 (16 mg, 22 µl, 157 µmol, 4.0 eq.) and MesCl (13 mg, 
9 µl, 118 µmol, 3.0 eq.) were added and the mixture was stirred for 2 h. The reaction mixture 
was diluted with CH2Cl2 (5 ml) and washed with 5% NaHCO3 (2x 1 ml) and brine (1 ml). The 
organic layer was dried (Na2SO4), filtered and concentrated at rt to afford the crude product 
(19 mg, 36 µmol, 92%) as a colorless oil, which was used without further purification. 
 
Rf (hexanes:ethylacetat 1:2, Mostain) = 0.41.- 1H NMR (300 MHz): δ = 1.39 (s, 3H, CH3), 
1.68-1.82 (m, 1H, 5-H), 2.00-2.08 (m, 1H, 9a-H), 2.09-2.23 (m, 2H,7-H), 2.06 (s, 3H, OAc), 
2.28-2.49 (m, 3H, 3-H, 3a-H, 5-H), 2.56-2.69 (m, 1H, 3-H), 2.82-2.91 (m, 1H, 9-H), 3.01 (s, 
3H, Mes), 3.79 (s, 3H, OMe), 4.04-4.14 (m, 1H, 8-H), 4.14-4.24 (m, 1H, 9b-H), 4.28 (dd, J = 
5.5, 2.5 Hz, 2H, CH2OMes), 4.37-4.54 (m, 2H, PMB), 4.75-4.89 (m, 1H, 4-H), 6.80-6.94 (m, 
2H, PMB), 7.19-7.29 (m, 2H, PMB).- IR (neat): ~ν = 3099, 3007, 2937, 2480, 2360, 2339, 
1788, 1732, 1612, 1586, 1514, 1460, 1423, 1357, 1317, 1247, 1174, 1078, 1031, 968, 915, 
895, 823, 801 cm-1.- MS (CI, NH4+): m/z (%) = 542.1 (100) [M+NH4+].- HRMS (EI, 70eV): 
524.1710 (C25H32SO10: calc. 524.1716 [M+H+]). 
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(3aR,4S,6S,6aS,8S,9R,9aS,9bR)-9-(tosyloxymethyl)-8-(p-methoxybenzyloxy)-6-methyl-
6,6a-epoxy-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl acetate (234) 
 
The primary alcohol 225 (34 mg, 76 µmol, 1.0 eq.) was dissolved in abs. CH2Cl2 (2 ml). Dry 
pyridine (50 µl, 610 µmol, 8.0 eq.) and freshly recrystallized TosCl (58 mg, 304 µmol, 4.0 
eq.) were added. The reaction mixture was stirred at rt over night and was diluted with 
CH2Cl2 (10 ml) and extracted with sat. NaHCO3 (2x2 ml) and brine (2 ml), dried (Na2SO4), 
filtered and concentrated. Chromatography on silica gel (hexanes:ethylacetate 1:1) afforded 
30 mg (50 µmol, 66%) product as a white foam along with 6 mg (13 µmol, 18%) unreacted 
starting material 225. 
 
Rf (hexanes:ethylacetate 2:1, Mostain) = 0.12.- [ ]20Dα = +21.3 (c = 0.60, CHCl3).- 1H NMR 
(300 MHz): δ = 1.36 (s, 3H, CH3), 1.63-1.75 (m, 1H, 5-H), 1.90-2.00 (m, 2H, 5-H, 9a-H), 
2.06 (m, 3H, OAc), 2.07-2.17 (m, 1H, 7-H), 2.17-2.27 (m, 1H, 3a-H), 2.27-2.39 (m, 2H, 3-H, 
7-H), 2.43 (s, 3H, Tos), 2.59 (dd, J = 16.5, 6.6 Hz, 1H, 3-H), 2.68-2.78 (m, 1H, 9-H), 3.80 (s, 
3H, OMe), 4.00-4.17 (m, 4H, 8-H, 9b-H, CH2OTos), 4.26-4.42 (m, 2H, PMB), 4.72-4.84 (m, 
1H, 4-H), 6.81-6.91 (m, 2H, PMB), 7.13-7.22 (m, 2H, PMB), 7.32-3.29 (m, 2H, Tos), 7.76-
7.85 (m, 2H, Tos).-13C NMR (75 MHz): δ = 20.9 (+, CH3), 21.3 (+, OAc), 21.7 (+, Tos), 35.0 
(-, 3-C), 37.8 (-, 7-C), 44.5 (-, 5-C), 46.7 (+, 9-C), 48.6 (+, 9a-C), 51.9 (+, 3a-C), 55.3 (+, 
OMe), 58.4 (Cq, 6-C), 69.1 (-, CH2OTos), 69.7 (+, 4-C), 69.8 (Cq, 6a-C), 71.3 (-, PMB), 78.1 
(+, 8-C), 80.9 (+, 9b-C), 113.9 (+, 2xPMB), 128.1 (+, 2xTos), 129.7 (+, 2x PMB), 129.9 (+, 
2xTos), 132.8 (Cq, PMB), 145.0 (Cq, Tos), 159.4 (Cq, PMB), 169.9 (Cq, OAc), 173.4 (Cq, 2-
C), 179.7 (Cq, Tos).- IR (neat): ~ν = 3003, 2933, 1784, 1734, 1613, 1514, 1456, 1423, 1359, 
1301, 1240, 1174, 1095, 1078, 1030, 998, 968, 945, 914, 894, 816, 754, 665 cm-1.- MS (EI, 
70 eV): m/z (%) = 121.0, 136.1, 600.3 (100) [M+].- HRMS (EI, 70eV): 600.2039 
(C31H36O10S: calc. 600.2029 [M +]). 
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(3aR,4S,6S,6aS,8S,9aS,9bR)-9-methylen-8-(p-methoxybenzyloxy)-6-methyl-6,6a-epoxy-2-
oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl acetate (235) 
 
Tosylate 234 (23 mg, 38 µmol, 1.0 eq.) was dissolved in abs. DMF (0.5 ml). NaI (11 mg, 
77 µmol, 2.0 eq.) and DBU (23 µl, 153 µmol, 4.0 eq.) was added and the reaction mixture 
was slowly heated to 100 °C and stirred for 1 h. After cooling to rt the reaction mixture was 
diluted with ethylacetate (10 ml) and washed with H2O (1 ml) and brine (1 ml). After drying 
over Na2SO4 the organic layer was filtered and concentrated. Chromatography on silica gel 
(hexanes:ethylacetate 1:2) afforded 9 mg (21 µmol, 55%) product as a colorless oil. 
 
Rf (hexanes:ethylacetate 1:1, Mostain) = 0.46.- [ ]20Dα = +33.5 (c = 0.20, CHCl3).- 1H NMR 
(400 MHz): δ = 1.39 (s, 3H, CH3), 1.72-1.82 (m, 1H, 5-H), 2.06 (s, 3H, OAc), 2.15 (dd, J = 
16.1, 6.9 Hz, 1H, 7-H), 2.29-2.44 (m, 4H, 3-H, 5-H, 7-H, 3a-H), 2.58-2.67 (m, 2H, 3-H, 9a-
H), 3.79 (s, 3H, OMe), 4.25-4.29 (m, 1H, 8-H), 4.31-4.38 (m, 1H, 9b-H), 4.40 (dd, J = 130.1, 
10.7 Hz, 2H, PMB), 4.78-4.87 (m, 1H, 4-H), 5.43-5.41 (m, 2H, =CH2), 6.81-6.92 (m, 2H, 
PMB), 7.19-7.27 (m, 2H, PMB).- 13C NMR (75 MHz): δ = 20.9 (+, OAc), 21.3 (+, CH3) 35.3 
(-, 3-C), 39.3 (-, 7-C), 44.8 (-, 5-C), 52.4 (+, 3a-C), 53.6 (+, 9a-C), 55.3 (+, OMe), 59.3 (Cq, 
6-C), 69.5 (-, PMB) 69.9 (+, 4-C), 70.7 (Cq, 6a-C), 79.7 (+, 8-C), 80.2 (+, 9b-C), 113.9 (+, 
2xPMB), 117.2 (-, =CH2), 129.9 (+, 2xPMB), 130.1 (Cq, PMB), 145.4 (Cq, PMB) 159.3 (Cq, 
9-C), 169.9 (Cq, OAc), 173.9 (Cq, 2-C).- IR (neat): ~ν = 2996, 2926, 1788, 1734, 1612, 1514, 
1456, 1373, 1302, 1244, 1134, 1084, 1053, 1030, 1000, 968, 916, 825, 756 cm-1.- MS (CI, 
NH3): m/z (%) = 446.2 (100) [M+NH4+].- HRMS (EI, 70eV): 428.1839 (C24H28O7: calc. 
428.1835 [M+]). 
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(3aR,4S,6S,6aS,9R,9aS,9bR)-6-methyl-2-oxo-1´(dimethyl(phenyl)silyl)-2,3,3a,4,5,7,8,9,9a, 
9b-decahydro-1H-cyclopropa[a]azulen [4,5-b]furan-4-yl acetate (243) 
 
Under an argon atmosphere the secondary alcohol 219 (50 mg, 0.112 mmol, 1.0 eq.) was 
dissolved in abs. CH2Cl2 (2 ml) and abs. pyridine (56 µl, 55 mg, 0.692 mmol, 6.0 eq.) was 
added. After cooling to 0 °C Tf2O (30 µl, 45 mg, 0.216 mmol, 2.0 eq.) was added and the 
reaction mixture was allowed to warm to rt over night. The reaction was quenched by diluting 
with CH2Cl2 (5 ml) and addition of sat. NaHCO3 (2 ml). The layers were separated and the 
organic layer was washed with brine (3 ml), dried (Na2SO4), filtered and concentrated. 
Chromatography on silica gel (hexanes:ethylacetate 2:1) afforded 6 mg (13%, 0.014 mmol) 
product as a colorless solid, which was crystallized from CH2Cl2/hexane. 
 
Rf (hexanes:ethylacetat 1:2, Mostain) = 0.69.- [ ]20Dα = -30.89 (c = 0.60, CH3Cl3).- m.p. = 159-
160 °C.- 1H NMR (600 MHz, CDCl3): δ = -0.11 (dd, J = 5.2, 5.2 Hz, 1H, 1´-H), 0.21 (s, 3H, 
SiMe), 0.23 (s, 3H, SiMe), 1.35 (s, 3H, CH3), 1.37 (m, 1H, 8-H), 1.63-1.72 (m, 2H, 5-H, 7-H), 
1.76 (dd, J = 5.2, 5.2 Hz, 1H, 9-H), 2.07 (s, 3H, OAc), 2.20-2.33 (m, 2H, 9a-H, 7-H), 2.36-
2.47 (m, 3H, 3-H, 5-H, 3a-H), 2.59-2.68 (m, 1H, 3-H), 3.77-3.87 (m, 1H, 9b-H), 4.78-4.86 
(m, 1H, 4-H), 7.32.-7.39 (m, 3H, Ph), 7.50-7.57 (m, 2H, Ph).- 13C NMR (150 MHz, CDCl3): δ 
= -3.5 (+, SiMe), -3.3 (+, SiMe), 8.9 (+, 1´-C), 19.7 (+, 8-C), 21.1 (+, OAc), 21.2 (+, CH3), 
22.9 (+, 9-C), 35.2 (-, 3-C), 35.6 (-, 5-C), 44.9 (-, 7-C), 51.8 (+, 9a-C), 52.3 (+, 3a-C), 55.6 
(Cq, 6-C), 70.2 (+, 4-C), 70.8 (Cq, 6a-C), 81.3 (+, 9b-C), 128.0 (+, 2xPh), 129.3 (+, Ph), 
133.9 (+, 2xPh), 138.7 (Cq, Ph), 170.2 (Cq, OAc), 174.3 (Cq, 2-C).- IR (KBr): ~ν = 3000, 
2953, 2925, 2851, 1778, 1734, 1646, 1462, 1426, 1369, 1248, 1236, 1165, 1147, 1116, 1092, 
1027, 991, 940, 896, 871, 832, 806, 779, 733, 698, 679 cm-1.- MS (ES, NH3): m/z (%) = 311.2 
(50), 444.21 (100) [M+NH4+].- HRMS (ES+): 444.2189 (C24H34O5SiN: calc. 444.2206 
[M+NH4+]). 
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(3aR,4S,6S,6aS,8S,9R,9aS,9bR)-9-(tert-butyldimethylsiloxymethyl)-8-(-(p-methoxy-
benzyloxy)-6-methyl-6,6a-epoxy-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-
b]furan-4-yl acetate (246) 
 
Under a nitrogen atmosphere 225 (129 mg, 0.289 mmol, 1.0 eq.) was dissolved in abs. 
CH2Cl2 (2 ml) and NEt3 (102 mg, 142 µl, 1.011 mmol, 3.5 eq.) was added at rt. TBDMSCl 
(131 mg, 0.867 mmol, 3.0 eq.) and DMAP (3.5 mg, 0.029 mmol, 10 mol%) dissolved in abs. 
CH2Cl2 (2 ml) was added and the reaction mixture was stirred over night. The reaction was 
diluted with CH2Cl2 (15 ml) and quenched with sat. NaHCO3 (2 ml). The layers were 
separated and the aqueous layer was again extracted with CH2Cl2 (3 ml). The combined org. 
layers were dried (Na2SO4), filtered and concentrated. Chromatography on silica gel 
(hexanes:ethylacetate 2:1) afforded 131 mg (0.232 mmol, 80%) product as a colorless oil. 
 
Rf (hexanes:ethylacetat 1:2, Mostain) = 0.68.- [ ]20Dα = +22.5 (c = 0.40, CHCl3).- 1H NMR 
(300 MHz): δ = 0.05 (s, 3H, SiMe), 0.06 (s, 3H, SiMe), 0.89 (s, 9H, SitBu), 1.38 (s, 3H, CH3), 
1.75 (dd, J = 12.5, 12.5 Hz, 1H, 5-H), 1.96-2.09 (m, 2H, 7-H, 9a-H), 2.06 (s, 3H, OAc), 2.17 
(dd, J = 15.6, 4.1 Hz, 1H, 7-H), 2.25-2.48 (m, 3H, 3-H, 3a-H, 5-H), 2.62 (dd, J = 15.6, 5.8 
Hz, 1H, 3-H), 2.73-2.85 (m, 1H, 9-H), 3.54 (dd, J = 10.2, 7.7 Hz, 1H, CH2OSi), 3.66 (dd, J = 
10.2, 5.5 Hz, 1H, CH2OSi), 3.79 (s, 3H, OMe), 4.11-4.18 (m, 1H, 8-H), 4.26 (dd, J = 11.4, 
10.0 Hz, 1H, 9b-H), 4.30-4.57 (m, 2H, PMB), 4.76-4.88 (m, 1H, 4-H), 6.82-6.90 (m, 2H, 
PMB), 7.22-7.29 (m, 2H, PMB).- 13C NMR (75.5 MHz): δ = -5.4 (+, SiMe2), 18.3 (Cq, 
SitBu), 21.0 (+, CH3), 21.4 (+, OAc), 25.9 (+, tBu), 35.3 (-, 3-C), 38.0 (-, 7-C), 44.8 (-, 5-C), 
49.0 (+, 9a-C), 49.4 (+, 9-C), 52.4 (+, 3a-C), 55.3 (+, PMB), 58.4 (Cq, 6-C), 62.4 (-, CH2OSi), 
69.9 (Cq, 6a-C), 70.0 (+, 4-C), 70.8 (-, PMB), 78.8 (+, 8-C), 81.0 (+, 9b-C), 113.9 (+, 
2xPMB), 129.7 (+, 2xPMB), 130.3 (Cq, PMB), 159.3 (Cq, PMB), 169.9 (Cq, OAc), 173.9 
(Cq, 2-C).- IR (neat): ~ν = 2954, 2931, 2857, 1788, 1738, 1612, 1586, 1514, 1467, 1423, 1373, 
1302, 1256, 1173, 1112, 1087, 1033, 997, 967, 916, 895, 837, 777, 743, 666 cm-1.- MS 
(LSIMS, MeOH/Glycerin): m/z (%) = 561.4 (22) [MH+], 653.4 (10) [MH++Gly], 1121.5 (15) 
[2M+H+].- HRMS (LSIMS, MeOH/Glycerin): 561.28760 (C30H45O8Si: calc. 561.2884 
[MH+]). 
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(3aR,4S,6S,6aS,8S,9R,9aS,9bR)-9-(tert-butyldimethylsiloxymethyl)-8-hydroxy-6-methyl-
6,6a-epoxy-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl acetate (247) 
 
Compound 246 (131 mg, 0.234 mmol, 1.0 eq.) was dissolved in CH2Cl2 (5 ml) and pH 7 
phosphate-buffer (1 ml) was added. At rt DDQ (66 mg, 0.292 mmol, 1.25 eq.) was added in 
portions and the mixture was stirred for 3 h. After diluting with CH2Cl2 (5 ml) and H2O (2 ml) 
the layers were separated and the aqueous layer was again extracted with CH2Cl2 (3 ml). The 
combined org. layers were dried (Na2SO4), filtered and concentrated. Chromatography on 
silica gel (hexanes:ethylacetate 2:1) afforded 91 mg (0.207 mmol, 88%) product as a colorless 
foam. 
 
Rf (hexanes:ethylacetat 1:2, Mostain) = 0.44.- [ ]20Dα = +12.5 (c = 0.40, CHCl3).- 1H NMR (600 
MHz): δ = 0.09 (s, 6H, SiMe2), 0.91 (s, 9H, SitBu), 1.42 (s, 3H, Me), 1.55-1.64 (bs, 1H, OH), 
1.75 (dd, J = 12.7, 12.7 Hz, 1H, 5-H), 1.81-1.90 (m, 2H, 7-H, 9a-H), 2.06 (s, 3H, OAc), 2.11 
(dd, J = 13.8, 8.9 Hz, 1H, 7-H), 2.26-2.33 (m, 2H, 9-H, 3a-H), 2.32-2.38 (m, 1H, 5-H), 2.46 
(dd, J = 16.9, 12.9 Hz, 1H, 3-H), 2.63 (dd, J = 16.8, 6.7 Hz, 1H, 3-H), 3.59 (dd, J = 9.5, 9.5 
Hz, 1H, CH2OSi), 3.91 (dd, J = 9.7, 4.8 Hz, 1H, CH2OSi), 4.12 (dd, J = 10.9, 10.9 Hz, 1H, 
9b-H), 4.32-4.38 (m, 1H, 8-H), 4.82-4.88 (m, 1H, 4-H).- 13C NMR (75.5 MHz): δ = -5.5 (+, 
SiMe), -5.4 (+, SiMe), 18.2 (Cq, tBu), 20.9 (+, CH3), 21.2 (+, OAc), 25.9 (+, tBu), 35.1 (-, 3-
C), 39.6 (-, 7-C), 45.1 (-, 5-C), 48.6 (+, 9a-C), 51.9 (+, 3a-C), 52.6 (+, 9-C), 58.5 (Cq, 6-C), 
65.4 (-, CH2OSi), 69.7 (Cq, 6a-C), 69.8 (+, 4-C), 74.4 (+, 8-C), 82.3 (+, 9b-C), 169.9 (Cq, 
OAc), 173.6 (Cq, 2-C).- IR (neat): ~ν = 3445, 2955, 2929, 2857, 1789, 1731, 1588, 1456, 
1373, 1257, 1116, 1003, 967, 917, 894, 838, 778, 742, 667 cm-1.- MS (LSIMS, 
MeOH/Glycerin): m/z (%) = 441.4 (30) [MH+], 533.3 (10) [MH++Gly], 881.5 (5) [2M+H+].- 
HRMS (LSIMS, MeOH/Glycerin): 441.2316 (C22H37O7Si: calc. 441.2309 [MH+]). 
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 (3aR,4S,6S,6aS,8S,9R,9aS,9bR)-9-(acetoxymethyl)- 8-(methylsulfinyloxy)-6-methyl-6,6a-
epoxy-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl acetate (248) 
 
Under a N2-atomsphere alcohol 227 (15 mg, 41 µmol, 1.0 eq.) was dissolved in abs. CH2Cl2 
(2 ml) and cooled to 0 °C. NEt3 (16 mg, 23 µl, 163 µmol, 4.0 eq.) and MesCl (14 mg, 9 µl, 
122 µmol, 3.0 eq.) was added via a syringe. The mixture was stirred for 1 h, diluted with 
CH2Cl2 (4 ml). The reaction mixture was washed with NaHCO3 (5%, 2x1 ml), brine (1 ml). 
The organic layer was dried (Na2SO4), filtered and concentrated at rt affording the crude 
product (17 mg, 38 µmol, 94%) as a colorless foam, which was used without further 
purification. 
 
Rf (hexanes:ethylacetat 1:2, Vanillin) = 0.32.- 1H NMR (300 MHz): δ = 1.41 (s, 3H, CH3), 
1.69-1.83 (m, 1H, 5-H), 2.06 (s, 3H, OAc), 2.10 (s, 3H, OAc), 2.08-2.16 (m, 1H, 9b-H), 2.26 
(dd, J = 15.5, 7.0 Hz, 1H, 7-H), 2.33-2.54 (m, 4H, 3-H, 3a-H, 5-H, 7-H), 2.67 (dd, J = 15.9, 
6.3 Hz, 1H, 3-H), 2.81-2.91 (m, 1H, 9-H), 3.06 (s, 3H, Mes), 4.09 (dd, J = 11.5, 9.9 Hz, 1H, 
9b-H), 4.22 (d, J = 5.5 Hz, 2H, CH2OAc), 4.80-4.90 (m, 1H, 4-C), 5.08-5.19 (m, 8-H).- 
IR (neat): ~ν = 3019, 2956, 2937, 2856, 2256, 1784, 1770, 1743, 1731, 1455, 1354, 1241, 
1173, 1091, 1031, 998, 964, 915, 878, 863, 847, 730 cm-1.- MS (CI, NH3): m/z (%) = 464.0 
(100) [M+NH4+].- HRMS (EI, 70eV):447.1322 (C19H27O10S: calc. 447.1325 [M+H+]. 
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11.11 Stereoselective synthesis of Gcn5 inhibitors 
 
Representative procedure for oxidation of lactone aldehyde 210a to carboxylic acid 261: 
 
OO
COOH
 
(-)-(2S,3R)-2-allyl-tetrahydro-5-oxofuran-3-carboxylic acid ((-)-261): 
 
Aldehyde (-)-210a (809 mg, 5.25 mmol, 1.0 eq.) was dissolved in CH3CN (60 ml) and cooled 
to 0 °C. KH2PO4 (430 mg, 3.10 mmol, 0.6 eq., dissolved in 8 ml H2O), NaClO2 (760 mg, 8.40 
mmol, 1.6 eq.) and H2O2 (30% in H2O, 858 µl, 8.40 mmol, 1.6 eq.) was added sequentially 
and the solution was stirred over night to warm to rt. Na2SO3 (1.32 g, 10.50 mmol, 2.0 eq.) 
was added and stirring was continued for 45 min. The mixture was diluted with water (40 ml) 
and pH adjusted to 1-2 using aqueous 1 N KHSO4 solution. The solution was extracted with 
CH2Cl2 (4x50 ml), the combined organic layers were dried (Na2SO4) and concentrated 
affording 702 mg (4.13 mmol, 79%) product as a colorless solid. 
 
 
(-)-(2S,3R)-2-allyl-tetrahydro-5-oxofuran-3-carboxylic acid ((-)-261) 
 
Yield: 79%.- [ ]20Dα = -34.1 (c = 0.512, CHCl3).- m.p. = 72-74 °C.- 1H NMR (300 MHz, 
CDCl3): δ = 2.68-2.45 (m, 2 H, 1'-H), 2.82 (dd, J = 18.1, 9.8 Hz, 1 H, 4-H), 2.95 (dd, J = 
18.1, 8.1 Hz, 1 H, 4-H), 3.20 (ddd, J = 9.8, 8.2, 6.8 Hz, 1 H, 3-H), 4.79-4.70 (m, 1 H, 2-H), 
5.32-5.18 (m, 2 H, 3'-H), 5.89-5.72 (m, 1 H, 2'-H), 7.60-6.00 (bs, 1 H, OH).- 13C NMR (75.5 
MHz, CDCl3): δ = 31.7 (+, 2-C), 38.7 (+, 3-C), 44.0 (-, 1'-C), 80.5 (-, 4-C), 120.3 (+, 2'-C), 
130.9 (-, 3'-C), 174.3 (Cq, CO), 175.8 (Cq, COOH).- IR (KBr): ~ν = 3439, 3085, 2928, 2593, 
1983, 1747, 1643, 1427, 1356, 1234, 1196, 1109, 1059, 975, 918, 862, 670 cm-1.- MS (CI, 
NH3): m/z (%) = 190.1 (48), 189.1 (10), 188.1 (100) [M + NH4+], 172.1 (11), 144.1 (18). 
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(+)-(2R,3S)-2-allyl-tetrahydro-5-oxofuran-3-carboxylic acid ((+)-261): 
 
Yield: 81%.- [ ]20Dα = +29.9 (c = 0.509, CHCl3).- m.p. = 70-72 °C. 
1H NMR and 13 C NMR of (+)-261 identical to (-)-261. 
 
 
Representative procedure for hydrogenation of the allylic double bond: 
 
 
(-)-(2S,3R)-tetrahydro-5-oxo-2-propylfuran-3-carboxylic acid ((-)-262): 
 
Acid (-)-261 (502 mg, 2.95 mmol, 1.0 eq.) was dissolved in ethylacetate (20 ml) and Pd/C 
(5%, 70 mg, 0.0295 mmol, 1 mol%) was added. The apparatus was seal with a septum, 
flushed with hydrogen and a hydrogen filled balloon was set on top. The mixture was stirred 
under this hydrogen atmosphere for 24 h, filtered over celite and concentrated affording 486 
mg (2.82 mmol, 96%) pure product as a colorless solid. 
 
 
(-)-(2S,3R)-tetrahydro-5-oxo-2-propylfuran-3-carboxylic acid ((-)-262): 
 
Yield: 96%.- [ ]20Dα = -50.2 (c = 0.540, CHCl3).- m.p. = 80-81 °C.- 1H NMR (300 MHz, 
CDCl3): δ = 0.98 (t, J = 7.3 Hz, 3 H, 3´-H), 1.61-1.39 (m, 2 H, 2´-H), 1.83-1.71 (m, 2 H, 1´-
H) 2.83 (dd, J = 17.8, 9.9 Hz, 1 H, 4-H), 2.99 (dd, J = 17.8, 8.2 Hz, 1 H, 4-H), 3.16-3.04 (m, 
1 H, 3-H), 4.64 (dt, J = 7.3, 5.3 Hz, 1 H, 2-H), 10.00-8.00 (bs, 1 H, OH).- 13C NMR (75.5 
MHz, CDCl3): δ = 13.7 (-, 2´-C), 18.6 (+, 3´-C), 31.9 (+, 2-C), 37.4 (+, 3-C), 45.4 (-, 1'-C), 
81.6 (-, 4-C), 174.3 (Cq, CO), 176.3 (Cq, COOH).- IR (KBr): ~ν = 3447, 3107, 2960, 2939, 
2875, 1749, 1463, 1431, 1402, 1388, 1236, 1195, 1109, 1064, 1010, 861, 669 cm-1.- MS (EI, 
70 eV): m/z (%) = 129.0 [M-C3H7], 173.0 [M+H+].- HRMS (EI, 70 eV): 173.0814 (C8H12O4: 
calc. 173.0814 [M+H+]). 
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(+)-(2R,3S)-tetrahydro-5-oxo-2-propylfuran-3-carboxylic acid ((+)-262): 
 
Yield: 98%.- [ ]20Dα = +49.2 (c = 0.502, CHCl3).- m.p. = 80-81 °C.  
1H NMR and 13 C NMR of (+)-262 identical to (-)-262. 
 
 
Representative procedure for α-methylenation: 
 
 
(-)-(2S,3R)-tetrahydro-4-methylene-5-oxo-2-propylfuran-3-carboxylic acid ((-)-256c): 
 
Under an argon atmosphere acid (-)-262 (100 mg, 0.587 mmol, 1.0 eq.) was dissolved in 
methoxymagnesiummethylcarbonate solution (11 ml, 22 mmol, 37.5 eq., 2 N in DMF) and 
heated for 3 d to 135 °C. After cooling to 0 °C the mixture was carefully acidified with cold 
2 N HCl and extracted fast with cold CH2Cl2 (4x30 ml). The combined organic layers were 
washed with brine (20 ml), dried (Na2SO4) and concentrated in vacuo strictly at rt. The 
resulting residue was treated under an argon atmosphere with a fresh prepared stock solution 
(2 ml acetic acid, 3 ml 37% formaldehyde in water, 520 µl N-methylanilin and 100 mg 
NaOAc) and stirred at rt for 3.5 h. Brine (10 ml + 1 ml conc. HCl) was added and the mixture 
was extracted with Et2O (3x20 ml). The combined organic layers were washed with brine 
(10 ml + 10 drops of conc. HCl). The aqueous layer was extracted with Et2O (2x20 ml), the 
combined organic layers were dried (Na2SO4) and concentrated. Purification by flash 
chromatography (hexanes:ethylacetate:acetic acid 7:4:1) afforded 57 mg (0.313 mmol, 53%) 
product as a white solid. 
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(-)-(2S,3R)-2-allyl-tetrahydro-4-methylene-5-oxofuran-3-carboxylic acid ((-)-263) 
 
Yield: 53%.- [ ]20Dα = -10.3 (c = 0.518, CHCl3).- m.p. = 56-57 °C.- 1H NMR (300 MHz, 
CDCl3): δ = 2.61-2.49 (m, 2 H, 1'-H), 3.74-3.68 (m, 1 H, 3-H), 4.97-4.87 (m, 1 H, 2-H), 5.28-
5.17 (m, 2 H, 3'-H), 5.84-5.66 (m, 1 H, 2'-H), 6.04 (d, J = 2.5 Hz, 1H, α-CH2), 6.47 (d, J = 
3.0 Hz, 1H, α-CH2), 10.50-9.32 (bs, 1 H, OH).- 13C NMR (75.5 MHz, CDCl3): δ = 39.2 (-, 1´-
C), 48.1 (+, 3-C), 77.4 (+, 2-C), 120.5 (-, 3´-C), 126.4 (-, =CH2), 130.6 (+, 2'-C), 131.9 (Cq, 
4-C), 168.0 (Cq, CO), 174.4 (Cq, COOH).- IR (KBr): ~ν = 3440, 2085, 2564, 1743, 1660, 
1398, 1350, 1255, 1190, 1059, 970, 914, 849, 815, 648 cm-1.- MS (EI, 70 eV): m/z (%) = 
140.9 (100) [M-C3H5], 182.0 [M+].- HRMS (EI, 70 eV): 182.0581 (C9H10O4, calc.: 182.0579 
[M+]). 
 
OO
COOH
 
(+)-(2R,3S)-2-allyl-tetrahydro-4-methylene-5-oxofuran-3-carboxylic acid ((+)-263))  
 
Yield: 56%.- [ ]20Dα = +7.3 (c = 0.479, CHCl3).- m.p. = 56-57 °C. 
1H NMR and 13 C NMR of (+)-263 identical to (-)-263. 
 
 
 
(-)-(2S,3R)-tetrahydro-4-methylene-5-oxo-2-propylfuran-3-carboxylic acid ((-)-265c)) 
 
Yield: 53%.- [ ]20Dα = -5.2 (c = 0.512, CHCl3).- m.p. = 60-61 °C.- 1H NMR (300 MHz, CDCl3): 
δ = 0.90 (t, J = 7.4 Hz, 3 H, 3´-H), 1.51-1.33 (m, 2 H, 2´-H), 1.75-1.59 (m, 2 H, 1´-H), 3.59-
3.53 (m, 1H, 3-H), 4.86-4.71 (m, 1 H, 2-H), 5.96 (d, J = 2.47 Hz, 1H, α-CH2), 6.39 (d, J = 
3.0 Hz, 1H, α-CH2), 11.06-10.75 (bs, 1 H, OH).- 13C NMR (75.5 MHz, CDCl3): δ = 12.6 (+, 
3´-C), 17.1 (-, 2´-C), 36.7 (-, 1´-C), 48.6 (+, 3-C), 77.9 (+, 2-C), 125.0 (-, =CH2), 131.5 (Cq, 
4-C), 167.6 (Cq, CO), 173.3 (Cq, COOH).- IR (KBr): ~ν = 3440, 2964, 1742, 1660, 1394, 
1303, 1254, 1220, 1182, 1098, 1015, 956, 859, 813, 711, 648 cm-1.- MS (CI, NH3): m/z (%) = 
Experimental Part 
 
169
141.0 (100) [M-C3H7], 155.1 (24.4) [M-C2H5], 184.1 [M+].- HRMS (EI, 70 eV): 184.0735 
(C9H12O4: calc. 184.0736 [M+]). 
 
 
(+)-(2R,3S)-tetrahydro-4-methylene-5-oxo-2-propylfuran-3-carboxylic acid ((+)-265c) 
 
Yield: 63%.- [ ]20Dα = +6.1 (c = 0.489, CHCl3).- m.p. = 62-63 °C. 
1H NMR and 13 C NMR of (+)-265c identical to (-)-265c. 
Appendix 
 
170
12. Appendix 
 
12.1 NMR - spectra 
 
1H-NMR spectra     - upper image 
13C-NMR spectra (DEPT 135 integrated)  - lower image 
 
Solvents, if not stated otherwise:  CDCl3 
Appendix 
 
171
((1R,4S)-4-(p-methoxybenzyloxy)cyclopent-2-enyloxy)(tert-butyl)dimethylsilane ((+)-141) 
 
 
 
(ppm)
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180
 
 
Appendix 
 
172
(1R,4S)-4-(p-methoxybenzyloxy)cyclopent-2-enyl acetate ((+)-144) 
 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180
 
Appendix 
 
173
(1R,4S)-4-(p-methoxybenzyloxy)cyclopent-2-enol ((-)-142) 
 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180
 
Appendix 
 
174
(S)-4-(p-methoxybenzyloxy)cyclopent-2-enone ((-)-145) 
 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180200
 
Appendix 
 
175
((3S,4S)-3-((dimethyl(phenyl)silyl)methyl)-4-(p-methoxybenzyloxy)cyclopent-1-enyloxy) 
trimethylsilane (150) 
 
 
(ppm)
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
 
 
(ppm)
020406080100120140160180
 
 
Appendix 
 
176
iso-propoxy(((1S,5S)-5-(p-methoxybenzyloxy)-3-(trimethylsilyloxy)cyclopent-2-enyl) 
methyl)dimethylsilane (151) 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
Appendix 
 
177
1-((((1S,5S)-5-(p-methoxybenzyloxy)-3-((trimethylsilyl)methyl)cyclopent-2-enyl)methyl) 
dimethylsilyl)benzene (152) 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
Appendix 
 
178
(3S,4S)-3-(p-methoxybenzyloxy)-4-((dimethyl(phenyl)silyl)methyl)cyclopentenone (154) 
 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180200
 
Appendix 
 
179
(((3S,4S)-3-((dimethyl(iso-propoxy)silyl)methyl)-4-(p-methoxybenzyloxy)cyclopent-1-
enyl)methyl)trimethylsilane (153) 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
Appendix 
 
180
(3S,4S)-3-((dimethyl(iso-propoxy)silyl)methyl)-4-(p-methoxybenzyloxy)cyclopentenone 
(155) 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180200
 
 
Appendix 
 
181
(1R,2S,3R)-2-((R)-((1´S,2´S,3´S)-2-((dimethyl(phenyl)silyl)methyl)-3-(p-methoxy-
benzyloxy)-5´-methylenecyclopentyl)(hydroxy)methyl)-3-(ethoxycarbonyl)cyclopropyl 
methyl oxalate (171) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
Appendix 
 
182
(2R,3S)-2-((1´S,2´S,3´S)-3´-(p-methoxybenzyloxy)-2´-((dimethyl(phenyl)silyl)methyl)-5´-
methylenecyclopentyl)-tetrahydro-5-oxofuran-3-carbaldehyde (175) 
 
 
(ppm)
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
Appendix 
 
183
(E/Z)-ethyl 2-bromo-3-((2´S,3´R)-2´-((1´´S,2´´S,3´´S)-2´´-((dimethyl(phenyl)silyl) 
methyl)-3´´-(p-methoxybenzyloxy)-5´´-methylenecyclopentyl)-5´-oxo-tetrahydrofuran-3´-
yl)acrylate (183), E/Z = 17:83 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
Appendix 
 
184
(3aR,8S,9S,9aR,9bS,E)-ethyl 9-((dimethyl(phenyl)silyl)methyl)-8-(p-methoxybenzyloxy)-
2-oxo-2,3,3a,6,6a,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-5-carboxylate (184), 
dr = 87:13 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
Appendix 
 
185
(3aR,8S,9S,9aR,9bS,E)-ethyl 9-((dimethyl(phenyl)silyl)methyl)-8-hydroxy-2-oxo-2,3,3a,6, 
6a,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-5-carboxylate (185), dr = 87:13 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180
 
  
Appendix 
 
186
(4R/S,5R)-5-((1S,2S,3S)-2-((dimethyl(phenyl)silyl)methyl)-3-(p-methoxybenzyloxy)-5-
methylenecyclopentyl)-4-(1-hydroxybut-3-enyl)dihydrofuran-2(3H)-one (195), dr = 50:50 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180
 
Appendix 
 
187
(4R/S,5R)-5-((1´S,2´S,3´S)-3´-(p-methoxybenzyloxy)-2´-((dimethyl(phenyl)silyl)methyl)-
5´-methylenecyclopentyl)-dihydro-4-(1´´R/S-hydroxy-3´´-methylbut-3´´-enyl)furan-
2(3H)-one (196), dr = 80:20 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
Appendix 
 
188
(4R/S,5R)-4-(3´-bromo-1´-hydroxybut-3-enyl)-5-((1´´S,2´´S,3´´S)-2´´-((dimethyl(phenyl) 
silyl)methyl)-3´´-(p-methoxybenzyloxy)-5´´-methylenecyclopentyl)-dihydrofuran-2(3H)-
one (197), dr = 78:22 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
OO
H
H
H
OPMB
HO
Br
SiMe2Ph
Appendix 
 
189
(4S,5R)-5-((1´S,2´S,3´S)-3´-(p-methoxybenzyloxy)-2´-((dimethyl(phenyl)silyl)methyl)-5´-
methylenecyclopentyl)-dihydro-4-(1´´R/S-triethylsilanyloxy-3´´-methylbut-3´´-enyl) 
furan-2(3H)-one (198a), dr = 80:20 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
 
 
Appendix 
 
190
1(R/S)-((2R,3R)-2-((1S,2S,3S)-2-((dimethyl(phenyl)silyl)methyl)-3-(p-methoxybenzyl 
oxy)-5-methylenecyclopentyl)-5-oxotetrahydrofuran-3-yl)but-3-enyl acetate (198b), 
dr = 50:50 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180
 
Appendix 
 
191
1-((2´R,3´R)-2´-((1´´S,2´´S,3´´S)-2´´-((dimethyl(phenyl)silyl)methyl)-3´´-(p-methoxy-
benzyloxy)-5´´-methylenecyclopentyl)-5´-oxo-tetrahydrofuran-3´-yl)-3-methylbut-3-enyl 
acetate (198c), dr = 80:20 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
OO
H
H
H
OPMB
AcO
SiMe2Ph
Appendix 
 
192
3-bromo-1(R/S)-((2´R,3´R)-2´-((1´´S,2´´S,3´´S)-2´´-((dimethyl(phenyl)silyl)methyl)-3´´-(p-
methoxybenzyloxy)-5´´-methylenecyclopentyl)-5´-oxo-tetrahydrofuran-3´-yl)but-3-enyl 
acetate (198d), dr = 75:25 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
Appendix 
 
193
(3aR,4S,8S,9S,9aS,9bR)-9-((dimethyl(phenyl)silyl)methyl)-8-(p-methoxybenzyloxy)-2-
oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl acetate (4S-199a) 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
Appendix 
 
194
(3aR,4R,8S,9S,9aS,9bR)-9-((dimethyl(phenyl)silyl)methyl)-8-(p-methoxybenzyloxy)-2-
oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl acetate (4R-199a) 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180
 
Appendix 
 
195
(3aR,8S,9S,9aS,9bR,Z)-9-((dimethyl(phenyl)silyl)methyl)-8-(p-methoxybenzyloxy)-6-
methyl-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl acetate (4S-199b) 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
Appendix 
 
196
(3aR,4R,8S,9S,9aS,9bR,Z)-9-((dimethyl(phenyl)silyl)methyl)-8-(p-methoxybenzyloxy)-6-
methyl-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl acetate (4R-199b) 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
Appendix 
 
197
(3aR,4R/S,8S,9S,9aS,9bR)-9-((dimethyl(phenyl)silyl)methyl)-4-hydroxy-8-(p-methoxy-
benzyloxy)-6-methyl-3,3a,4,5,7,8,9,9a-octahydroazuleno[4,5-b]furan-2(9bH)-one (199c) 
dr = 80:20 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
Appendix 
 
198
1-((2´S,3´S)-2´-allyl-5´-oxo-tetrahydrofuran-3´-yl)but-3-enyl acetate (213a), dr = 73:27 
 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180
 
Appendix 
 
199
1-((2´S,3´R)-2´-allyl-5´-oxo-tetrahydrofuran-3´-yl)-3-methylbut-3-enyl acetate (213b), 
dr = 67:33 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180
 
Appendix 
 
200
((2´S,3´R)-2´-allyl-5´-oxo-tetrahydrofuran-3´-yl)(2-methylenecyclopentyl)methyl acetate 
(213c), dr = 82:18:0:0 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180
 
Appendix 
 
201
1-((2´S,3´S)-2´-(2´´-methylallyl)-5´-oxo-tetrahydrofuran-3´-yl)but-3-enyl acetate (213d), 
dr = 77:23 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180
 
Appendix 
 
202
3-methyl-1-((2´S,3´S)-2´-(2´´-methylallyl)-5´-oxo-tetrahydrofuran-3´-yl)but-3-enyl 
acetate (213e), dr = 70:30 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180
 
Appendix 
 
203
((2´S,3´R)-2´-(2´´-methylallyl)-5´-oxo-tetrahydrofuran-3´-yl)(2-methylenecyclopentyl) 
methyl acetate (213f), dr = 79:21:0:0 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180
 
OO H
H
AcO H
Appendix 
 
204
1-((2´S,3´S)-2´-(2´´-methylenecyclopentyl)-5´-oxo-tetrahydrofuran-3-yl)but-3-enyl 
acetate (213g), dr = 80:20 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180
 
Appendix 
 
205
3-methyl-1-((2´S,3´S)-2´-(2´´-methylenecyclopentyl)-5´-oxo-tetrahydrofuran-3´-yl)but-3-
enyl acetate (213h), dr = 70:30 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180
 
Appendix 
 
206
(2-methylenecyclopentyl)((2´S,3´S)-2´-(2´´-methylenecyclopentyl)-5´-oxo-tetrahydro-
furan-3´-yl)methyl acetate (213i), dr = 99:1:0:0 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180
 
 
Appendix 
 
207
(3aR,8aS,Z)-6-methyl-2-oxo-3,3a,4,5,8,8a-hexahydro-2H-cyclohepta[b]furan-4-yl acetate 
(209b), dr = 68:32 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180
 
Appendix 
 
208
(3aR,9aS,Z)-2-oxo-2,3,3a,4,4a,5,6,7,9,9a-decahydroazuleno[6,5-b]furan-4-yl-acetate 
(209c), dr = 84:16 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180
 
Appendix 
 
209
(3aS,8aS,Z)-7-methyl-2-oxo-3,3a,4,5,8,8a-hexahydro-2H-cyclohepta[b]furan-4-yl acetate 
(209d), dr = 80:20 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180
 
Appendix 
 
210
(3aS,8aS,Z)-6,7-dimethyl-2-oxo-3,3a,4,5,8,8a-hexahydro-2H-cyclohepta[b]furan-4-yl 
acetate (209e), dr = 75:25 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180
 
Appendix 
 
211
(3aR,9aS,Z)-8-methyl-2-oxo-2,3,3a,4,4a,5,6,7,9,9a-decahydroazuleno[6,5-b]furan-4-yl 
acetate (209f), dr = >99:1 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180
 
 
Appendix 
 
212
(3aS,9aR,9bS,Z)-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl acetate 
(209g), dr = 79:21 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180
 
 
Appendix 
 
213
(3aS,9aR,9bS,Z)-6-methyl-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-
yl acetate (209h), dr = 72:28 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180
 
 
Appendix 
 
214
(3aS,4R,5S,9aR,9bS)-6,5-cyclopentanyl-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno 
[4,5-b]furan-4-yl acetate (209i), dr = >99:1 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180
 
Appendix 
 
215
(3aR,4R,8S,9S,9aS,9bR)-9-((dimethyl(phenyl)silyl)methyl)-4-hydroxy-8-(p-methoxy-
benzyloxy)-6-methyl-3,3a,4,5,7,8,9,9a-octahydroazuleno[4,5-b]furan-2(9bH)-one 
(4R-216) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
Appendix 
 
216
(3aS,8S,9S,9aS,9bR,Z)-9-((dimethyl(phenyl)silyl)methyl)-8-(p-methoxybenzyloxy)-6-
methyl-3,3a,7,8,9,9a-hexahydroazuleno[4,5-b]furan-2,4(5H,9bH)-dione (217) 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180200
 
 
Appendix 
 
217
(3aR,4S,8S,9S,9aS,9bR,Z)-9-((dimethyl(phenyl)silyl)methyl)-8-hydroxy-6-methyl-2-oxo-
2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl acetate (218) 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
 
Appendix 
 
218
(3aR,4S,8S,9S,9aS,9bR,Z)-9-((dimethyl(phenyl)silyl)methyl)-8-hydroxy-6,6a-epoxy-6-
methyl-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl acetate (219) 
α:β = 20:80 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
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(3aR,4S,6S,6aS,8S,9R,9aS,9bR)-9-(hydroxymethyl)-8-(p-methoxybenzyloxy)-6-methyl-
6,6a-epoxy-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl acetate (225) 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
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(3aR,4S,6S,6aS,8S,9R,9aS,9bR)-9-(acetoxymethyl)-8-(p-methoxybenzyloxy)-6-methyl-
6,6a-epoxy-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl acetate (226) 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180
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(3aR,4S,6S,6aS,8S,9R,9aS,9bR)-9-(acetoxymethyl)-8-hydroxy-6-methyl-6,6a-epoxy-2-
oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl acetate (227) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180
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(3aR,4S,6R,9R,9aS,9bR)-6-hydroxy-9-(acetoxymethyl)-6-methyl-2,8-dioxo-2,3,3a,4,5, 
6,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl acetate (231) 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180200
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(3aR,4S,6S,6aS,8S,9R,9aS,9bR)-9-(tosyloxymethyl)-8-(p-methoxybenzyloxy)-6-methyl-
6,6a-epoxy-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl acetate (234) 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180
 
 
OO
H
H
H
OPMB
OTs
AcO
O
Appendix 
 
224
(3aR,4S,6S,6aS,8S,9aS,9bR)-9-(methylen)-8-(p-methoxybenzyloxy)-6-methyl-6,6a-epoxy-
2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl acetate (235) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
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(3aR,4S,6S,6aS,9R,9aS,9bR)-6-methyl-2-oxo-1´(dimehtyl(phenyl)silyl)-2,3,3a,4,5,7,8,9,9a, 
9b-decahydro-1H-cyclopropa[a]azulen [4,5-b]furan-4-yl acetate (243) 
 
 
(ppm)
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
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(3aR,4S,6S,6aS,8S,9R,9aS,9bR)-9-(tert-butyldimethylsiloxymethyl)-8-(-(p-methoxybenzyl 
oxy)-6-methyl-6,6a-epoxy-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-
yl acetate (246) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180
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(3aR,4S,6S,6aS,8S,9R,9aS,9bR)-9-(tert-butyldimethylsiloxymethyl)-8-(hydroxy)-6-
methyl-6,6a-epoxy-2-oxo-2,3,3a,4,5,7,8,9,9a,9b-decahydroazuleno[4,5-b]furan-4-yl 
acetate (247) 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
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(-)-(2S,3R)-tetrahydro-5-oxo-2-propylfuran-3-carboxylic acid ((-)-262): 
 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180
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(-)-(2S,3R)-2-allyl-tetrahydro-4-methylene-5-oxofuran-3-carboxylic acid ((-)-263): 
 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
020406080100120140160180
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(-)-(2S,3R)-tetrahydro-4-methylene-5-oxo-2-propylfuran-3-carboxylic acid ((-)-256c): 
 
 
 
(ppm)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.5
 
 
(ppm)
0102030405060708090100110120130140150160170180190
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12.2 X-ray data 
 
  
OO H
H
AcO H
209f  
Table 11. Crystal data and structure refinement for 209f 
Crystal Data  
Empirical formula  C15 H20 O4  
Formula weight  264.31  
Crystal size  0.42 x 0.38 x 0.26 mm  
Crystal description  prism  
Crystal colour  colorless  
Crystal system  Orthorhombic  
Space group  P 21 21 21  
Unit cell dimensions  a = 5.2724(4) A alpha = 90 deg.  
  b = 14.4760(10) A beta = 90 deg.  
  c = 18.2953(17) A gamma = 90 deg.  
Volume  1396.36(19) A3  
Z, Calculated density  4, 1.257 Mg/m3  
Absorption coefficient  0.090 mm-1  
F(000)  568  
Data Collection   
Measurement device type  STOE-IPDS diffractometer  
Measurement method  rotation  
Temperature  123(1) K  
Wavelength  0.71073 A  
Monochromator   graphite  
Theta range for data collection  2.63 to 26.82 deg.  
Index ranges  -6<=h<=6, -18<=k<=18, -23<=l<=23  
Reflections collected / unique  16401 / 2981 [R(int) = 0.0328]  
Reflections greater I>2\s(I)  2850  
Absorption correction  None  
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Refinement   
Refinement method  Full-matrix least-squares on F^2  
Hydrogen treatment   
Data / restraints / parameters  2981 / 0 / 174  
Goodness-of-fit on F2  1.072  
Final R indices [I>2sigma(I)]  R1 = 0.0325, wR2 = 0.0859  
R indices (all data)  R1 = 0.0338, wR2 = 0.0867  
Absolute structure parameter  -0.4(7)  
Largest diff. peak and hole  0.227 and -0.130 e.A-3  
 
 
 
 
Table 12. Atomic coordinates (x104) and equivalent isotropic displacement parameters (A2x103) 
Atom x y z U(eq) 
O(1) -259(2) 1645(1) 6706(1) 30(1) 
O(2) -247(2) 1426(1) 5491(1) 39(1) 
O(3) 5441(2) 4129(1) 6636(1) 25(1) 
O(4) 3133(2) 5383(1) 6322(1) 41(1) 
C(1) 2455(2) 3536(1) 8499(1) 22(1) 
C(2) 2504(2) 4297(1) 9078(1) 29(1) 
C(3) 4991(2) 4817(1) 8943(1) 32(1) 
C(4) 5265(3) 4787(1) 8111(1) 33(1) 
C(5) 4378(2) 3804(1) 7897(1) 24(1) 
C(6) 3405(2) 3781(1) 7108(1) 22(1) 
C(7) 2798(2) 2824(1) 6821(1) 23(1) 
C(8) 547(2) 2382(1) 7210(1) 23(1) 
C(9) 1086(3) 1995(1) 7967(1) 28(1) 
C(10) 1081(2) 2757(1) 8547(1) 24(1) 
C(11) -667(2) 2562(1) 9189(1) 29(1) 
C(12) 1940(3) 2765(1) 6022(1) 32(1) 
C(13) 390(3) 1884(1) 6009(1) 28(1) 
C(14) 5014(2) 4916(1) 6255(1) 25(1) 
C(15) 7157(3) 5116(1) 5741(1) 31(1) 
H(2A) 2475 4034 9566 34 
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H(2B) 1060 4706 9023 34 
H(3A) 4885 5449 9118 38 
H(3B) 6404 4511 9181 38 
H(4A) 7014 4888 7966 39 
H(4B) 4208 5253 7881 39 
H(5) 5837 3387 7933 28 
H(6) 1909 4178 7062 26 
H(7) 4289 2428 6887 27 
H(8) -817 2839 7248 28 
H(9A) 2725 1691 7965 34 
H(9B) -190 1538 8089 34 
H(11A) -526 3052 9540 35 
H(11B) -194 1988 9413 35 
H(11C) -2387 2524 9019 35 
H(12A) 916 3295 5888 38 
H(12B) 3382 2724 5694 38 
H(15A) 7172 4664 5357 37 
H(15B) 8734 5093 6002 37 
H(15C) 6938 5720 5533 37 
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Table 13: Crystal data and structure refinement for 209i. 
Crystal Data   
Empirical formula C17 H22 O4  
Formula weight 290.35  
Crystal size 0.470 x 0.170 x 0.020 mm  
Crystal description flat rod  
Crystal colour colorless  
Crystal system Monoclinic  
Space group P 21  
Unit cell dimensions a = 9.7398(8) A alpha = 90 deg.  
 b = 17.5928(17) A beta = 95.326(8) deg. 
 c = 17.7549(14) A gamma = 90 deg. 
Volume 3029.2(5) A3  
Z, Calculated density 8, 1.273 Mg/m3  
Absorption coefficient 0.729 mm-1  
F(000) 1248  
Data Collection   
Measurement device type Oxford Diffraction Gemini Ultra  
Measurement method omega-scan  
Temperature 150 K  
Wavelength 1.54184 A  
Monochromator  graphite  
Theta range for data collection 2.50 to 51.25 deg.  
Index ranges -9<=h<=8, -17<=k<=17, -17<=l<=17  
Reflections collected / unique 15242 / 6267 [R(int) = 0.0476]  
Reflections greater I>2\s(I) 5063  
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Absorption correction Semi-empirical from equivalents  
Max. and min. transmission 1.13329 and 0.81999  
Refinement   
Refinement method Full-matrix least-squares on F^2  
Hydrogen treatment   
Data / restraints / parameters 6267 / 1 / 761 
Goodness-of-fit on F2 1.085  
Final R indices [I>2sigma(I)] R1 = 0.0649, wR2 = 0.1846  
R indices (all data) R1 = 0.0784, wR2 = 0.1905  
Absolute structure parameter 0.2(3)  
Largest diff. peak and hole 0.323 and -0.243 e.A-3  
 
 
Table 14: Atomic coordinates (x104) and equivalent isotropic displacement parameters (A2x103)
Atom X Y Z U(eq)
O(1) -573(5) 7109(3) 558(3) 47(2)
O(2) -462(6) 6957(3) 1819(3) 66(2)
O(3) 4230(5) 7038(3) 473(3) 53(2)
O(4) 4488(5) 8195(3) 997(3) 63(2)
C(1) 372(7) 7300(4) 3(4) 40(3)
C(2) -168(7) 7014(4) -758(4) 40(2)
C(3) -1636(7) 7312(5) -1008(5) 53(3)
C(4) -1737(9) 7327(5) -1856(5) 71(4)
C(5) -334(7) 7606(4) -2022(4) 49(3)
C(6) 660(8) 7312(4) -1377(4) 48(3)
C(7) 1999(8) 7307(4) -1383(4) 50(3)
C(8) 2802(7) 7642(5) -2016(4) 55(3)
C(9) 4204(8) 7229(5) -1937(5) 68(4)
C(10) 4510(8) 7203(5) -1090(5) 62(3)
C(11) 3128(6) 6998(4) -782(4) 40(3)
C(12) 2992(7) 7286(4) 12(4) 47(3)
C(13) 1728(7) 6954(4) 347(4) 46(3)
C(14) 1641(6) 7100(4) 1190(4) 46(3)
C(15) 112(9) 7046(4) 1257(5) 53(3)
C(16) 4922(8) 7552(5) 926(4) 48(3)
C(17) 6235(8) 7245(5) 1284(5) 64(3)
O(5) -892(5) 5831(3) 6287(3) 52(2)
O(6) -545(5) 5653(3) 7525(3) 64(2)
O(7) 3773(5) 5719(3) 5923(3) 49(2)
O(8) 4647(6) 6894(3) 6069(3) 72(2)
C(18) -32(7) 6034(4) 5674(4) 44(3)
C(19) -780(7) 5761(4) 4919(4) 45(3)
C(20) -2240(8) 6057(5) 4772(4) 54(3)
C(21) -2445(8) 6078(5) 3920(4) 59(3)
C(22) -1135(7) 6392(5) 3659(4) 52(3)
C(23) -17(7) 6058(4) 4255(4) 40(3)
C(24) 1317(8) 6040(4) 4169(4) 48(3)
C(25) 1960(8) 6338(5) 3486(4) 53(3)
C(26) 3328(10) 5980(6) 3510(5) 82(4)
C(27) 3755(8) 5922(5) 4321(4) 57(3)
C(28) 2445(6) 5715(4) 4713(4) 42(3)
C(29) 2522(7) 5998(4) 5519(4) 41(3)
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C(30) 1340(7) 5688(4) 5944(4) 44(3)
C(31) 1425(7) 5835(4) 6778(4) 46(3)
C(32) -95(8) 5763(4) 6933(5) 52(3)
C(33) 4746(8) 6228(5) 6185(4) 50(3)
C(34) 5940(7) 5840(4) 6625(4) 52(3)
O(9) 3642(5) 3596(3) 4294(3) 52(2)
O(10) 3515(5) 3768(3) 3051(3) 67(3)
O(11) 8467(5) 3879(3) 4614(3) 48(2)
O(12) 8801(6) 2779(3) 4022(3) 59(2)
C(35) 4749(7) 3453(4) 4914(4) 41(3)
C(36) 4314(7) 3752(4) 5645(4) 42(3)
C(37) 2884(8) 3436(5) 5835(5) 61(3)
C(38) 2962(7) 3501(5) 6686(4) 59(3)
C(39) 4423(8) 3290(4) 6952(4) 55(3)
C(40) 5285(8) 3533(4) 6318(4) 46(3)
C(41) 6640(8) 3555(4) 6405(4) 47(3)
C(42) 7493(8) 3368(4) 7125(4) 55(3)
C(43) 8987(9) 3624(6) 7041(5) 70(4)
C(44) 9041(8) 3563(5) 6187(4) 57(3)
C(45) 7646(6) 3827(4) 5820(4) 45(3)
C(46) 7375(7) 3546(4) 5024(4) 44(3)
C(47) 5995(7) 3844(4) 4624(4) 39(3)
C(48) 5754(7) 3700(5) 3781(4) 48(3)
C(49) 4181(9) 3698(4) 3643(5) 51(3)
C(50) 9100(8) 3422(5) 4148(5) 52(3)
C(51) 10256(7) 3849(5) 3828(4) 55(3)
O(13) 4634(5) 4984(3) 9272(3) 51(2)
O(14) 4420(6) 5058(3) 8013(3) 67(2)
O(15) 9506(5) 4969(3) 9491(3) 49(2)
O(16) 9486(6) 3794(3) 8962(3) 64(2)
C(52) 5743(7) 4845(4) 9869(4) 45(3)
C(53) 5390(7) 5196(4) 10584(4) 45(3)
C(54) 3977(8) 4968(6) 10808(4) 66(3)
C(55) 4065(8) 5149(5) 11643(4) 67(4)
C(56) 5557(8) 4889(5) 11930(4) 61(3)
C(57) 6381(9) 5001(4) 11265(4) 50(3)
C(58) 7759(8) 4950(4) 11313(4) 44(3)
C(59) 8610(8) 4767(5) 12050(4) 58(3)
C(60) 10097(8) 4923(5) 11899(4) 60(3)
C(61) 10109(8) 4773(5) 11065(4) 56(3)
C(62) 8748(7) 5082(4) 10705(3) 41(3)
C(63) 8356(7) 4778(4) 9914(4) 46(3)
C(64) 7024(7) 5097(4) 9533(4) 43(3)
C(65) 6716(7) 4918(5) 8701(4) 46(3)
C(66) 5119(9) 4984(4) 8585(5) 57(3)
C(67) 10018(8) 4409(5) 9058(4) 51(3)
C(68) 11324(7) 4676(5) 8751(5) 62(3)
H(1) 472 7865 -19 49 
H(2) -165 6445 -761 47 
H(3A) -2343 6970 -827 63 
H(3B) -1767 7828 -803 63 
H(4A) -2471 7679 -2062 86 
H(4B) -1925 6814 -2070 86 
H(5A) -314 8169 -2041 59 
H(5B) -89 7405 -2513 59 
H(8A) 2307 7545 -2519 66 
H(8B) 2929 8197 -1949 66 
H(9A) 4131 6712 -2158 81 
H(9B) 4915 7520 -2179 81 
H(10A) 4846 7702 -893 74 
H(10B) 5217 6813 -943 74 
H(11) 3050 6432 -774 49 
H(12) 2940 7854 10 57 
H(13) 1704 6393 256 55 
H(14A) 2155 6710 1504 56 
H(14B) 2001 7609 1340 56 
H(17A) 6719 7642 1593 76 
H(17B) 6812 7079 892 76 
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H(17C) 6046 6812 1606 76 
H(18) 69 6599 5658 52 
H(19) -792 5193 4909 54 
H(20A) -2908 5710 4982 65 
H(20B) -2331 6570 4991 65 
H(21A) -2624 5561 3715 71 
H(21B) -3237 6407 3749 71 
H(22A) -1132 6955 3669 62 
H(22B) -996 6216 3142 62 
H(25A) 1392 6199 3015 64 
H(25B) 2048 6898 3510 64 
H(26A) 3270 5471 3270 98 
H(26B) 3978 6299 3251 98 
H(27A) 4140 6412 4516 68 
H(27B) 4467 5524 4417 68 
H(28) 2348 5149 4716 51 
H(29) 2513 6566 5526 49 
H(30) 1279 5126 5860 53 
H(31A) 1790 6349 6904 56 
H(31B) 2006 5451 7064 56 
H(34A) 6154 6102 7109 62 
H(34B) 6747 5854 6334 62 
H(34C) 5696 5310 6720 62 
H(35) 4926 2894 4960 50 
H(36) 4260 4319 5616 51 
H(37A) 2117 3745 5592 73 
H(37B) 2760 2901 5671 73 
H(38A) 2754 4026 6841 71 
H(38B) 2303 3148 6896 71 
H(39A) 4504 2735 7041 65 
H(39B) 4730 3559 7428 65 
H(42A) 7466 2815 7223 65 
H(42B) 7129 3636 7555 65 
H(43A) 9150 4152 7221 84 
H(43B) 9666 3282 7318 84 
H(44A) 9788 3888 6023 68 
H(44B) 9219 3031 6043 68 
H(45) 7642 4396 5811 53 
H(46) 7412 2979 5007 53 
H(47) 5929 4402 4718 47 
H(48A) 6146 3206 3644 58 
H(48B) 6161 4109 3490 58 
H(51A) 10301 3704 3298 66 
H(51B) 11131 3723 4119 66 
H(51C) 10088 4397 3860 66 
H(52) 5811 4283 9951 54 
H(53) 5397 5760 10518 54 
H(54A) 3238 5267 10524 79 
H(54B) 3801 4420 10716 79 
H(55A) 3365 4862 11897 80 
H(55B) 3938 5699 11730 80 
H(56A) 5931 5201 12365 74 
H(56B) 5565 4348 12086 74 
H(59A) 8490 4228 12191 70 
H(59B) 8335 5094 12464 70 
H(60A) 10356 5455 12022 72 
H(60B) 10739 4578 12198 72 
H(61A) 10183 4221 10967 67 
H(61B) 10894 5036 10862 67 
H(62) 8861 5645 10657 49 
H(63) 8275 4212 9940 55 
H(64) 7076 5663 9582 51 
H(65A) 7026 4400 8583 55 
H(65B) 7162 5289 8383 55 
H(68A) 11453 4402 8282 75 
H(68B) 12110 4578 9124 75 
H(68C) 11260 5223 8646 75 
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Table 15. Crystal data and structure refinement for 227. 
Crystal Data  
Empirical formula C18 H24 O8 
Formula weight 368.37 
Crystal size 0.32 x 0.18 x 0.04 mm  
Crystal description platelike 
Crystal colour colorless  
Crystal system Monoclinic  
Space group P 21  
Unit cell dimensions a = 10.8348(14) A alpha = 90 deg.  
 b = 7.8686(6) A beta = 111.640(14) deg. 
 c = 11.4418(15) A gamma = 90 deg. 
Volume 906.7(2) A3  
Z, Calculated density 2, 1.349 Mg/m3  
Absorption coefficient 0.106 mm-1  
F(000) 392  
Data Collection   
Measurement device type STOE-IPDS diffractometer  
Measurement method rotation  
Temperature 123(1) K  
Wavelength 0.71073 A  
Monochromator  graphite  
Theta range for data collection 2.02 to 26.87 deg.  
Index ranges -13<=h<=13, -9<=k<=9, -14<=l<=14  
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Reflections collected / unique 10211 / 3875 [R(int) = 0.0489]  
Reflections greater I>2\s(I) 3115  
Absorption correction None  
Refinement   
Refinement method Full-matrix least-squares on F2  
Hydrogen treatment   
Data / restraints / parameters 3875 / 1 / 241  
Goodness-of-fit on F2 0.919  
Final R indices [I>2sigma(I)] R1 = 0.0343, wR2 = 0.0630  
R indices (all data) R1 = 0.0478, wR2 = 0.0658  
Absolute structure parameter -0.2(7)  
Largest diff. peak and hole 0.211 and -0.144 e.A-3  
  
Table 16. Atomic coordinates (x104) and equivalent isotropic displacement parameters (A2x103) 
Atom X Y Z U(eq) 
O(1) -511(1) 9104(2) 4524(1) 24(1) 
O(2) 1737(1) 12982(2) 2957(1) 25(1) 
O(3) 3614(1) 9278(2) 5129(1) 23(1) 
O(4) 5752(1) 8944(2) 5417(1) 43(1) 
O(5) 1480(1) 6922(2) 1624(1) 22(1) 
O(6) 1798(1) 4970(2) 343(1) 28(1) 
O(7) -2666(1) 4719(2) 1409(1) 23(1) 
O(8) -3503(1) 5513(2) -644(1) 32(1) 
C(1) -260(2) 9456(2) 3384(2) 20(1) 
C(2) -86(2) 11320(2) 3114(2) 20(1) 
C(3) 1418(2) 11532(2) 3535(2) 20(1) 
C(4) 1876(2) 9862(2) 3130(2) 20(1) 
C(5) 880(2) 8462(2) 3190(2) 18(1) 
C(6) 355(2) 7507(2) 1949(2) 19(1) 
C(7) -475(2) 5901(2) 1836(2) 20(1) 
C(8) -1880(2) 6286(2) 1756(2) 20(1) 
C(9) -1870(2) 6844(2) 3040(2) 22(1) 
C(10) -1554(2) 8730(2) 3310(2) 20(1) 
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C(11) 3337(2) 9446(3) 3785(2) 22(1) 
C(12) 4889(2) 9034(3) 5849(2) 27(1) 
C(13) 5113(2) 8887(3) 7220(2) 37(1) 
C(14) -315(2) 5082(3) 686(2) 24(1) 
C(15) 1084(2) 5567(3) 831(2) 22(1) 
C(16) -3415(2) 4488(3) 167(2) 23(1) 
C(17) -4102(2) 2798(3) -43(2) 32(1) 
C(18) -2767(2) 9854(3) 2979(2) 28(1) 
H(2A) -452 12075 3599 25 
H(2B) -530 11574 2207 25 
H(2O) 2460(20) 13360(30) 3420(20) 30 
H(3) 1819 11649 4471 24 
H(4) 1728 10002 2219 24 
H(5) 1311 7665 3906 22 
H(6) -179 8320 1283 23 
H(7) -29 5165 2587 24 
H(8) -2286 7191 1115 24 
H(9A) -2749 6603 3081 26 
H(9B) -1202 6164 3702 26 
H(11A) 3550 8372 3450 27 
H(11B) 3887 10364 3637 27 
H(13A) 5436 7743 7517 44 
H(13B) 4276 9092 7340 44 
H(13C) 5773 9729 7697 44 
H(14A) -418 3832 695 29 
H(14B) -971 5542 -105 29 
H(17A) -4714 2712 -920 38 
H(17B) -4602 2690 514 38 
H(17C) -3441 1887 141 38 
H(18A) -3296 9510 3473 33 
H(18B) -3302 9740 2081 33 
H(18C) -2488 11040 3168 33 
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Table 17. Crystal data and structure refinement for 243. 
Crystal Data  
Empirical formula C24 H30 O5 Si 
Formula weight 426.57 
Crystal size 0.32 x 0.18 x 0.04 mm  
Crystal description rectangular 
Crystal colour colorless  
Crystal system Orthorhombic  
Space group P 21 21 21 
Unit cell dimensions a = 6.4369(3) A alpha = 90 deg.  
 b = 11.4236(6) A beta = 90 deg. 
 c = 29.9411(15) A gamma = 90 deg. 
Volume 2201.65(19) A3  
Z, Calculated density 4, 1.287 Mg/m3  
Absorption coefficient 0.139 mm-1  
F(000) 912  
Data Collection   
Measurement device type Bruker SMART  
Measurement method rotation  
Temperature 100 K  
Wavelength 0.71073 A  
Monochromator  graphite  
Index ranges -9<=h<=9, -16<=k<=16, -42<=l<=41  
Reflections collected / unique 25888 / 6680 [R(int) = 0.0788]  
Reflections greater I>2\s(I) 5022 
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Absorption correction None  
Refinement   
Refinement method Full-matrix least-squares on F2  
Hydrogen treatment   
Data / restraints / parameters 6680 / 0 / 275  
Goodness-of-fit on F2 0.956  
Final R indices [I>2sigma(I)] R1 =0.0580, wR2 = 0.1033  
R indices (all data) R1 = 0.0805, wR2 = 0.0658  
Largest diff. peak and hole 0.396 and -0.301 e.A-3  
 
Table 18. Atomic coordinates (x104) and equivalent isotropic displacement parameters (A2) 
Atom X Y Z U(eq) 
Si -0.05639(11) 0.45951(6) 0.46741(2) 0.0148(2) 
O(1) 0.0096(3) 0.41197(16) 0.28152(6) 0.0211(6) 
O(2) 0.4897(3) 0.22341(16) 0.38618(6) 0.0187(6) 
O(3) -0.0658(4) 0.49357(18) 0.21550(6) 0.0331(7) 
O(4) 0.6026(3) 0.22018(17) 0.22612(6) 0.0223(6) 
O(5) 0.4445(4) 0.07714(19) 0.18752(7) 0.0348(7) 
C(1) 0.1445(4) 0.3167(2) 0.29742(8) 0.0144(7) 
C(2) 0.3156(4) 0.3140(2) 0.26212(8) 0.0162(7) 
C(3) 0.1844(4) 0.3330(3) 0.22026(9) 0.0221(8) 
C(4) 0.0289(5) 0.4213(3) 0.23631(9) 0.0250(9) 
C(5) 0.2111(4) 0.3385(2) 0.34517(8) 0.0136(7) 
C(6) 0.2908(4) 0.2215(2) 0.36402(8) 0.0131(7) 
C(7) 0.4668(4) 0.1564(2) 0.34527(8) 0.0167(7) 
C(8) 0.5873(4) 0.2038(2) 0.30561(8) 0.0186(8) 
C(9) 0.4557(4) 0.2076(2) 0.26324(8) 0.0172(7) 
C(10) 0.0318(4) 0.3703(2) 0.37617(8) 0.0143(7) 
C(11) -0.0248(4) 0.2635(2) 0.40325(8) 0.0150(7) 
C(12) 0.1127(4) 0.1632(2) 0.38899(9) 0.0154(7) 
C(13) 0.0827(4) 0.3670(2) 0.42616(8) 0.0138(7) 
C(14) 0.5801(5) 0.1484(2) 0.19072(9) 0.0207(8) 
C(15) 0.7483(5) 0.1696(3) 0.15715(10) 0.0280(9) 
C(16) 0.4805(5) 0.0262(2) 0.35120(9) 0.0229(8) 
C(17) 0.0826(4) 0.4488(2) 0.52208(8) 0.0215(8) 
C(18) -0.3318(4) 0.4112(3) 0.47287(10) 0.0236(8) 
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C(21) -0.0564(5) 0.6167(2) 0.44896(8) 0.0166(7) 
C(22) 0.0972(5) 0.6961(2) 0.46222(9) 0.0220(8) 
C(23) 0.0935(5) 0.8120(3) 0.44753(10) 0.0283(9) 
C(24) -0.0633(6) 0.8506(2) 0.41999(10) 0.0286(9) 
C(25) -0.2167(5) 0.7751(3) 0.40665(10) 0.0301(10) 
C(26) -0.2121(5) 0.6587(3) 0.42092(9) 0.0229(9) 
H(1) 0.06540 0.24140 0.29610 0.0170 
H(2) 0.40440 0.38490 0.26640 0.0190 
H(3A) 0.26900 0.36420 0.19540 0.0270 
H(3B) 0.11590 0.25960 0.21060 0.0270 
H(5) 0.32240 0.39950 0.34640 0.0160 
H(8A) 0.71050 0.15370 0.30030 0.0220 
H(8B) 0.63700 0.28370 0.31260 0.0220 
H(9) 0.37270 0.13410 0.26000 0.0210 
H(10) -0.08070 0.42330 0.36520 0.0170 
H(11) -0.17450 0.24780 0.40990 0.0180 
H(12A) 0.03640 0.10860 0.36930 0.0190 
H(12B) 0.16470 0.11950 0.41530 0.0190 
H(13) 0.23290 0.35380 0.43310 0.0170 
H(15A) 0.87590 0.13030 0.16680 0.0420 
H(15B) 0.77370 0.25390 0.15450 0.0420 
H(15C) 0.70520 0.13850 0.12810 0.0420 
H(16A) 0.62530 0.00390 0.35670 0.0340 
H(16B) 0.43040 -0.01280 0.32410 0.0340 
H(16C) 0.39480 0.00250 0.37670 0.0340 
H(17A) 0.06110 0.37070 0.53480 0.0320 
H(17B) 0.02800 0.50800 0.54260 0.0320 
H(17C) 0.23140 0.46200 0.51740 0.0320 
H(18A) -0.39600 0.40770 0.44320 0.0350 
H(18B) -0.40800 0.46700 0.49160 0.0350 
H(18C) -0.33630 0.33350 0.48670 0.0350 
H(22) 0.20550 0.67070 0.48150 0.0260 
H(23) 0.19980 0.86450 0.45660 0.0340 
H(24) -0.06520 0.92980 0.41020 0.0340 
H(25) -0.32560 0.80180 0.38780 0.0360 
H(26) -0.31820 0.60680 0.41120 0.0270 
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